

APPROVED DRUG PRODUCTS


With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by [DrugPatentWatch.com](https://www.drugpatentwatch.com)

**CUMULATIVE
SUPPLEMENT 8
AUGUST 2012**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

32nd EDITION

Department of Health and Human Services

**Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs**

2012

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

32nd EDITION

Cumulative Supplement 8

August 2012

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content.....	iv
1.3 Applicant Name Changes.....	v
1.4 Levothyroxine Sodium.....	vi
1.5 Availability of the Edition	vii
1.6 Report of Counts for the Prescription Drug Product List	vii
1.7 Cumulative Supplement Legend	viii
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

32nd EDITION

**CUMULATIVE SUPPLEMENT 8
August 2012**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 30th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 32nd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 33rd Edition. The current Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals (20,000 and 50,000 series) appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
ABBOTT LABORATORIES (ABBOTT LABS) (ABBOTT)	ABBVIE INC (ABBVIE) (ABBVIE)
ABBOTT LABORATORIES HOSP PRODUCTS DIV (ABBOTT)	ABBVIE INC (ABBVIE)
ABBOTT LABORATORIES PHARMACEUTICAL (ABBOTT)	ABBVIE INC (ABBVIE)
ABBOTT PRODUCTS (ABBOTT)	ABBVIE INC (ABBVIE)
ALCON UNIVERSAL LTD (ALCON UNIVERSAL)	ALCON PHARMACEUTICALS LTD (ALCON PHARMS LTD)
OVATION PHARMACEUTICALS INC (OVATION PHARMS)	OAK PHARMACEUTICALS INC (OAK PHARMS)

ROSS LABORATORIES DIV ABBOTT
LABORATORIES
(ABBOTT)

ABBVIE INC
(ABBVIE)

SOLVAY PHARMACEUTICALS
(ABBOTT)

ABBVIE INC
(ABBVIE)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB2	76752	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001

LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB3	76752	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2011) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly

data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2011</u>	<u>MAR 2012</u>	<u>JUN 2012</u>	<u>SEPT 2012</u>	<u>DEC 2012</u>
DRUG PRODUCTS LISTED	14480	14711	14834		
SINGLE SOURCE	2451 (16.9%)	2446 (16.6%)	2428 (16.4%)		
MULTISOURCE	11953 (82.5%)	12187 (82.8%)	12328 (83.1%)		
THERAPEUTICALLY EQUIVALENT	11792 (81.4%)	12037 (81.8%)	12187 (82.2%)		
NOT THERAPEUTICALLY EQUIVALENT	161 (1.1%)	150 (1.0%)	141 (1.0%)		
EXCEPTIONS ¹	76 (0.5%)	78 (0.5%)	78 (0.5%)		
NEW MOLECULAR ENTITIES					
APPROVED	6	8	7		
NUMBER OF APPLICANTS	810	826	826		

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

PRESCRIPTION DRUG PRODUCT LIST - 32ND EDITION

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

1-1

ABACAVIR SULFATE

TABLET; ORAL						
ABACAVIR SULFATE						
AB	MYLAN PHARMS INC	EQ 300MG BASE	A091294 001	Jun 18, 2012	Jun	NEWA
ZIAGEN						
AB	+ VIIV HLTHCARE	EQ 300MG BASE	N020977 001	Dec 17, 1998	Jun	CFTG

ACARBOSE

TABLET; ORAL						
ACARBOSE						
AB	EMCURE PHARMS LTD	25MG	A202271 001	Feb 07, 2012	Jan	NEWA
AB		50MG	A202271 002	Feb 07, 2012	Jan	NEWA
AB		100MG	A202271 003	Feb 07, 2012	Jan	NEWA

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL						
BUTAPAP						
+	MIKART	325MG;50MG	A089987 001	Oct 26, 1992	Jun	CRLD
PHRENILIN						
@	VALEANT	325MG;50MG	A087811 001	Jun 19, 1985	Jun	DISC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL						
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE						
>A> AA	LANNETT HOLDINGS INC	325MG;50MG;40MG	A200243 001	Sep 13, 2012	Aug	NEWA

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL						
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE						
	NEXGEN PHARMA INC	300MG;50MG;40MG;30MG	A076560 002	Jul 19, 2012	Jul	NEWA

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL						
ACETAMINOPHEN AND CODEINE PHOSPHATE						
AA	+ PHARM ASSOC	120MG/5ML;12MG/5ML	A087508 001		Jan	CRLD
SUSPENSION; ORAL						
CAPITAL AND CODEINE						
+	VALEANT	120MG/5ML;12MG/5ML	A086024 001		Jan	CTEC
+	VALEANT PHARMS LLC	120MG/5ML;12MG/5ML	A086024 001		Jun	CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL						
HYDROCODONE BITARTRATE AND ACETAMINOPHEN						
	@ NESHER PHARMS	500MG/15ML;7.5MG/15ML	A040366 001	Jan 23, 2002	Jun	DISC
AA	VISTAPHARM	325MG/15ML;7.5MG/15ML	A200343 001	Jan 25, 2012	Jan	NEWA
TABLET; ORAL						
HYDROCODONE BITARTRATE AND ACETAMINOPHEN						
AA	AUROLIFE PHARMA LLC	325MG;5MG	A201013 001	Apr 11, 2012	Mar	NEWA
AA		325MG;7.5MG	A201013 002	Apr 11, 2012	Mar	NEWA
AA		325MG;10MG	A201013 003	Apr 11, 2012	Mar	NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

AA	ACTAVIS TOTOWA	325MG;7.5MG	A040800 001	Apr 03, 2012	Mar	NEWA
AA		325MG;10MG	A040800 002	Apr 03, 2012	Mar	NEWA
AA	ALVOGEN INC	325MG;7.5MG	A202677 001	Jul 26, 2012	Jul	NEWA
AA		325MG;10MG	A202677 002	Jul 26, 2012	Jul	NEWA

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

AB	ALVOGEN INC	325MG;37.5MG	A202076 001	Mar 30, 2012	Mar	NEWA
>A> AB	ZYDUS PHARMS USA INC	325MG;37.5MG	A090460 001	Sep 06, 2012	Aug	NEWA

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

AP	SAGENT STRIDES	EQ 500MG BASE/VIAL	A200880 001	May 09, 2012	Apr	NEWA
AP +	X GEN PHARMS	EQ 500MG BASE/VIAL	A040784 001	Dec 10, 2008	Apr	CRLD
	DIAMOX					
	@ TEVA WOMENS	EQ 500MG BASE/VIAL	N009388 001	Dec 05, 1990	Apr	DISC

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL

ACETYLCYSTEINE

AN	INNOPHARMA INC	20%	A203853 001	Jun 21, 2012	Jun	NEWA
----	----------------	-----	-------------	--------------	-----	------

ACLIDINIUM BROMIDE

POWDER, METERED; INHALATION

TUDORZA PRESSAIR

+	FOREST LABS INC	0.375MG/INH	N202450 001	Jul 23, 2012	Jul	NEWA
---	-----------------	-------------	-------------	--------------	-----	------

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

@	HERITAGE PHARMS INC	200MG	A074889 001	Oct 31, 1997	May	CAHN
---	---------------------	-------	-------------	--------------	-----	------

TABLET; ORAL

ACYCLOVIR

@	HERITAGE PHARMS INC	400MG	A074891 001	Oct 31, 1997	May	CAHN
---	---------------------	-------	-------------	--------------	-----	------

@		800MG	A074891 002	Oct 31, 1997	May	CAHN
---	--	-------	-------------	--------------	-----	------

ADAPALENE

CREAM; TOPICAL

ADAPALENE

AB	FOUGERA PHARMS	0.1%	A090824 001	Jun 30, 2010	Jan	CAHN
----	----------------	------	-------------	--------------	-----	------

GEL; TOPICAL

ADAPALENE

AB	TOLMAR	0.3%	A200298 001	Jun 14, 2012	Jun	NEWA
----	--------	------	-------------	--------------	-----	------

DIFFERIN

AB +	GALDERMA LABS LP	0.3%	N021753 001	Jun 19, 2007	Jun	CFTG
------	------------------	------	-------------	--------------	-----	------

LOTION; TOPICAL

DIFFERIN

+	GALDERMA LABS LP	0.1%	N022502 001	Mar 17, 2010	Apr	CAHN
---	------------------	------	-------------	--------------	-----	------

ADENOSINE

INJECTABLE; INJECTION

ADENOSINE

@ TEVA PARENTERAL

3MG/ML

A078676 001 Jul 31, 2008 Mar DISC

@

3MG/ML

A076564 001 Jun 16, 2004 Jan DISC

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

@ SANDOZ INC

EQ 0.083% BASE;0.017%

A076867 001 Dec 21, 2006 Apr DISC

ALCLOMETASONE DIPROPIONATE

CREAM; TOPICAL

ALCLOMETASONE DIPROPIONATE

AB

FOUGERA PHARMS

0.05%

A076973 001 Jul 12, 2005 Jan CAHN

OINTMENT; TOPICAL

ALCLOMETASONE DIPROPIONATE

AB

FOUGERA PHARMS

0.05%

A076884 001 Jul 18, 2005 Jan CAHN

ALENDRONATE SODIUM

TABLET, EFFERVESCENT; ORAL

BINOSTO

+ MISSION PHARMA

EQ 70MG BASE

N202344 001 Mar 12, 2012 Mar NEWA

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALFUZOSIN HYDROCHLORIDE

>A>

AB

AUROBINDO PHARMA LTD

10MG

A079060 001 Aug 30, 2012 Aug NEWA

AB

INVAGEN PHARMS

10MG

A090284 001 Jan 17, 2012 Jan NEWA

AB

WOCKHARDT LTD

10MG

A090221 001 Aug 10, 2012 Jul NEWA

ALGLUCERASE

INJECTABLE; INJECTION

CEREDASE

@ GENZYME

80 UNITS/ML

N020057 003 Apr 05, 1991 Mar DISC

ALPRAZOLAM

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

@ SANDOZ INC

0.5MG

A077777 001 Jun 30, 2006 Mar DISC

@

1MG

A077777 002 Jun 30, 2006 Mar DISC

@

2MG

A077777 003 Jun 30, 2006 Mar DISC

@

3MG

A077777 004 Jun 30, 2006 Mar DISC

@ VINTAGE PHARMS

0.5MG

A078442 001 Oct 15, 2007 Jul DISC

@

1MG

A078442 002 Oct 15, 2007 Jul DISC

@

2MG

A078442 003 Oct 15, 2007 Jul DISC

@

3MG

A078442 004 Oct 15, 2007 Jul DISC

TABLET, ORALLY DISINTEGRATING; ORAL

NIRAVAM

AB

UCB INC

0.25MG

N021726 001 Jan 19, 2005 Jan CAHN

AB

0.5MG

N021726 002 Jan 19, 2005 Jan CAHN

AB

+

1MG

N021726 003 Jan 19, 2005 Jan CAHN

AB

2MG

N021726 004 Jan 19, 2005 Jan CAHN

ALVIMOPAN

CAPSULE; ORAL

ENTEREG

+ CUBIST PHARMS 12MG N021775 001 May 20, 2008 Feb CAHN

AMCINONIDE

CREAM; TOPICAL

AMCINONIDE

AB + FOUGERA PHARMS 0.1% A076065 001 May 15, 2003 Jan CAHN

LOTION; TOPICAL

AMCINONIDE

+ FOUGERA PHARMS 0.1% A076329 001 Nov 06, 2002 Jan CAHN

OINTMENT; TOPICAL

AMCINONIDE

AB + FOUGERA PHARMS 0.1% A076096 001 Nov 19, 2002 Jan CAHN

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

@ HOSPIRA

EQ 50MG BASE/ML

A063263 001 Nov 30, 1994 Jun DISC

AMINO ACIDS

INJECTABLE; INJECTION

AMINO ACIDS

B BRAUN

15%(300GM/2000ML)

A091112 002 Apr 13, 2012 Mar NEWA

15%(150GM/1000ML)

A091112 001 Apr 13, 2012 Mar NEWA

CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER

BAXTER HLTHCARE

15% (15GM/100ML)

A020512 001 Aug 30, 1996 Jun CAHN

NOVAMINE 15%

@ HOSPIRA INC

15% (75GM/500ML)

N017957 004 Nov 28, 1986 Mar CPOT

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AMICAR

@ CLOVER PHARMS

250MG/ML

N015229 002 Mar CAHN

SYRUP; ORAL

AMICAR

AA + CLOVER PHARMS 1.25GM/5ML N015230 002 Mar CAHN

TABLET; ORAL

AMICAR

AB CLOVER PHARMS 500MG N015197 001 Mar CAHN

+

1GM

N015197 002 Jun 24, 2004 Mar CAHN

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

@ BEDFORD

50MG/ML

A076018 001 Oct 15, 2002 Jun DISC

@ BEDFORD LABS

50MG/ML

A076299 001 Oct 24, 2002 Jun DISC

@ TEVA PARENTERAL

50MG/ML

A076163 001 Sep 05, 2003 Jan DISC

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

AB MURTY PHARMS 200MG A077069 001 Apr 08, 2005 May CAHN

AB 400MG A077069 002 Apr 08, 2005 May CAHN

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB	CARACO	10MG	A040816 002	Jun 27, 2008	Apr	NEWA
AB		50MG	A040816 003	Jun 27, 2008	Apr	NEWA
AB		75MG	A040816 004	Jun 27, 2008	Apr	NEWA
AB		100MG	A040816 005	Jun 27, 2008	Apr	NEWA
AB		150MG	A040816 006	Jun 27, 2008	Apr	NEWA

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

	MYLAN PHARMS INC	EQ 12.5MG BASE;5MG	A071297 002	Dec 10, 1986	Feb	CTEC
+		EQ 25MG BASE;10MG	A071297 001	Dec 10, 1986	Feb	CRLD
	LIMBITROL					
	@ VALEANT PHARM INTL	EQ 12.5MG BASE;5MG	N016949 001		Feb	DISC
	LIMBITROL DS					
	@ VALEANT PHARM INTL	EQ 25MG BASE;10MG	N016949 002		Feb	DISC

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

AB	MACLEODS PHARMS LTD	EQ 5MG BASE	A201380 001	Apr 13, 2012	Mar	NEWA
AB		EQ 10MG BASE	A201380 002	Apr 13, 2012	Mar	NEWA

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

>A>	AB	AUROBINDO PHARMA LTD	EQ 2.5MG BASE;10MG	A202239 001	Sep 05, 2012	Aug	NEWA
>A>	AB		EQ 5MG BASE;10MG	A202239 002	Sep 05, 2012	Aug	NEWA
>A>	AB		EQ 5MG BASE;20MG	A202239 003	Sep 05, 2012	Aug	NEWA
>A>	AB		EQ 5MG BASE;40MG	A202239 004	Sep 05, 2012	Aug	NEWA
>A>	AB		EQ 10MG BASE;20MG	A202239 005	Sep 05, 2012	Aug	NEWA
>A>	AB		EQ 10MG BASE;40MG	A202239 006	Sep 05, 2012	Aug	NEWA

AMOXICILLIN

TABLET, FOR SUSPENSION; ORAL

DISPERMOX

	@ RANBAXY LABS LTD	600MG	A065159 001	Dec 04, 2003	Apr	DISC
--	--------------------	-------	-------------	--------------	-----	------

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	SANDOZ INC	200MG/5ML;EQ 28.5MG BASE/5ML	A065098 001	Dec 16, 2002	Jul	CAHN
AB		400MG/5ML;EQ 57MG BASE/5ML	A065098 002	Dec 16, 2002	Jul	CAHN
AB		600MG/5ML;EQ 42.9MG BASE/5ML	A065358 001	Aug 13, 2007	Jul	CAHN

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	AUROBINDO PHARMA LTD	250MG;EQ 125MG BASE	A091569 001	Jan 20, 2012	Jan	NEWA
AB		500MG;EQ 125MG BASE	A091569 002	Jan 20, 2012	Jan	NEWA
AB		875MG;EQ 125MG BASE	A091568 001	Jan 20, 2012	Jan	NEWA
AB	SANDOZ INC	500MG;EQ 125MG BASE	A065117 001	Nov 27, 2002	Jul	CAHN
AB		875MG;EQ 125MG BASE	A065093 001	Nov 21, 2002	Jul	CAHN

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

AB	ADDERALL XR 10								
	SHIRE	2.5MG;2.5MG;2.5MG;2.5MG	N021303 001	Oct 11, 2001	Jun	CFTG			
AB	ADDERALL XR 15								
	SHIRE	3.75MG;3.75MG;3.75MG;3.75MG	N021303 006	May 22, 2002	Jun	CFTG			
AB	ADDERALL XR 20								
	SHIRE	5MG;5MG;5MG;5MG	N021303 002	Oct 11, 2001	Jun	CFTG			
AB	ADDERALL XR 25								
	SHIRE	6.25MG;6.25MG;6.25MG;6.25MG	N021303 004	May 22, 2002	Jun	CFTG			
AB	ADDERALL XR 30								
+	SHIRE	7.5MG;7.5MG;7.5MG;7.5MG	N021303 003	Oct 11, 2001	Jun	CFTG			
AB	ADDERALL XR 5								
	SHIRE	1.25MG;1.25MG;1.25MG;1.25MG	N021303 005	May 22, 2002	Jun	CFTG			
AB	DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE								
	ACTAVIS ELIZABETH	1.25MG;1.25MG;1.25MG;1.25MG	A077302 001	Jun 22, 2012	Jun	NEWA			
AB		2.5MG;2.5MG;2.5MG;2.5MG	A077302 002	Jun 22, 2012	Jun	NEWA			
AB		3.75MG;3.75MG;3.75MG;3.75MG	A077302 003	Jun 22, 2012	Jun	NEWA			
AB		5MG;5MG;5MG;5MG	A077302 004	Jun 22, 2012	Jun	NEWA			
AB		6.25MG;6.25MG;6.25MG;6.25MG	A077302 005	Jun 22, 2012	Jun	NEWA			
AB		7.5MG;7.5MG;7.5MG;7.5MG	A077302 006	Jun 22, 2012	Jun	NEWA			

AMPHETAMINE SULFATE

TABLET; ORAL

AMPHETAMINE SULFATE

	INDEPENDENCE PHARMS	5MG	A200166 001	Aug 09, 2012	Jul	NEWA			
+		10MG	A200166 002	Aug 09, 2012	Jul	NEWA			

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX; INJECTION

AMPHOTEC

+	ALKOPHARMA USA	50MG/VIAL	N050729 001	Nov 22, 1996	May	CAHN			
+		100MG/VIAL	N050729 002	Nov 22, 1996	May	CAHN			

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

>D>	AP	ACIC FINE CHEMS	EQ 250MG BASE/VIAL	A090354 001	Dec 28, 2009	Aug	CAHN		
>D>	AP		EQ 500MG BASE/VIAL	A090354 002	Dec 28, 2009	Aug	CAHN		
>D>	AP		EQ 1GM BASE/VIAL	A090354 003	Dec 28, 2009	Aug	CAHN		
>D>	AP		EQ 2GM BASE/VIAL	A090354 004	Dec 28, 2009	Aug	CAHN		
>A>	AP	ANTIBIOTICE	EQ 250MG BASE/VIAL	A090354 001	Dec 28, 2009	Aug	CAHN		
>A>	AP		EQ 500MG BASE/VIAL	A090354 002	Dec 28, 2009	Aug	CAHN		
>A>	AP		EQ 1GM BASE/VIAL	A090354 003	Dec 28, 2009	Aug	CAHN		
>A>	AP		EQ 2GM BASE/VIAL	A090354 004	Dec 28, 2009	Aug	CAHN		

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

AGRYLIN

AB	SHIRE LLC	EQ 0.5MG BASE	N020333 001	Mar 14, 1997	Jan	CAHN			
	ANAGRELIDE HYDROCHLORIDE								
	@ SANDOZ INC	EQ 0.5MG BASE	A076683 001	Apr 18, 2005	Mar	DISC			
	@	EQ 1MG BASE	A076683 002	Apr 18, 2005	Mar	DISC			

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

AB	APOTEX INC	1MG	A200654 001	May 11, 2012	Apr	NEWA
AB	IMPAX LABS INC	1MG	A091242 001	May 31, 2012	May	NEWA

APROTININ

INJECTABLE; INJECTION

TRASYLOL

@ BAYER HLTHCARE	10,000KIU/ML	N020304 001	Dec 29, 1993	May	DISC
------------------	--------------	-------------	--------------	-----	------

ARGATROBAN

INJECTABLE; INJECTION

ACOVA

AP	+ PFIZER	250MG/2.5ML (100MG/ML)	N020883 001	Jun 30, 2000	Jan	CTNA
----	----------	------------------------	-------------	--------------	-----	------

ARGATROBAN

AP	HIKMA PHARM CO LTD	250MG/2.5ML (100MG/ML)	N203049 001	Jan 05, 2012	Jan	NEWA
----	--------------------	------------------------	-------------	--------------	-----	------

ARMODAFINIL

TABLET; ORAL

ARMODAFINIL

AB	MYLAN PHARMS INC	50MG	A200043 001	Jun 01, 2012	May	NEWA
----	------------------	------	-------------	--------------	-----	------

AB		150MG	A200043 002	Jun 01, 2012	May	NEWA
----	--	-------	-------------	--------------	-----	------

AB		250MG	A200043 003	Jun 01, 2012	May	NEWA
----	--	-------	-------------	--------------	-----	------

>A>	WATSON LABS INC	100MG	A200156 002	Aug 29, 2012	Aug	NEWA
-----	-----------------	-------	-------------	--------------	-----	------

>A>		200MG	A200156 004	Aug 29, 2012	Aug	NEWA
-----	--	-------	-------------	--------------	-----	------

NUVIGIL

AB	CEPHALON	50MG	N021875 001	Jun 15, 2007	May	CFTG
----	----------	------	-------------	--------------	-----	------

AB		150MG	N021875 003	Jun 15, 2007	May	CFTG
----	--	-------	-------------	--------------	-----	------

AB	+	250MG	N021875 004	Jun 15, 2007	May	CFTG
----	---	-------	-------------	--------------	-----	------

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

AA	NOVEL LABS INC	4.7GM;100GM;1.015GM;5.9GM;2.691GM ;7.5GM	A090145 001	Jan 25, 2012	Jan	NEWA
----	----------------	---	-------------	--------------	-----	------

MOVIPREP

AA	+ SALIX PHARMS	4.7GM;100GM;1.015GM;5.9GM;2.691GM ;7.5GM	N021881 001	Aug 02, 2006	Jan	CFTG
----	----------------	---	-------------	--------------	-----	------

ASENAPINE MALEATE

TABLET; SUBLINGUAL

SAPHRIS

ORGANON SUB MERCK EQ 5MG BASE

N022117 001	Aug 13, 2009	Jul	CAHN
-------------	--------------	-----	------

+ EQ 10MG BASE

N022117 002	Aug 13, 2009	Jul	CAHN
-------------	--------------	-----	------

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN

AB	PROSAM LABS	325MG;200MG	A040252 001	Dec 10, 1997	Feb	CAHN
----	-------------	-------------	-------------	--------------	-----	------

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

AB	PROSAM LABS	325MG;200MG;16MG	A040283 001	Dec 29, 1998	Feb	CAHN
----	-------------	------------------	-------------	--------------	-----	------

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

ATOMOXETINE HYDROCHLORIDE

@ ZYDUS PHARMS USA INC 18MG

A079017 001 Sep 17, 2010 Jun DISC

@ 25MG

A079017 002 Sep 17, 2010 Jun DISC

@ 40MG

A079017 003 Sep 17, 2010 Jun DISC

@ 60MG

A079017 004 Sep 17, 2010 Jun DISC

@ 80MG

A079017 005 Sep 17, 2010 Jun DISC

@ 100MG

A079017 006 Sep 17, 2010 Jun DISC

STRATTERA

LILLY 10MG

N021411 002 Nov 26, 2002 Jun CTEC

18MG

N021411 003 Nov 26, 2002 Jun CTEC

25MG

N021411 004 Nov 26, 2002 Jun CTEC

40MG

N021411 005 Nov 26, 2002 Jun CTEC

+ 60MG

N021411 006 Nov 26, 2002 Jun CTEC

80MG

N021411 007 Feb 14, 2005 Jun CTEC

100MG

N021411 008 Feb 14, 2005 Jun CTEC

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

AB	APOTEX INC	EQ 10MG BASE	A090548 001	May 29, 2012	May	NEWA
----	------------	--------------	-------------	--------------	-----	------

AB		EQ 20MG BASE	A090548 002	May 29, 2012	May	NEWA
----	--	--------------	-------------	--------------	-----	------

AB		EQ 40MG BASE	A090548 003	May 29, 2012	May	NEWA
----	--	--------------	-------------	--------------	-----	------

AB		EQ 80MG BASE	A090548 004	May 29, 2012	May	NEWA
----	--	--------------	-------------	--------------	-----	------

AB	DR REDDYS LABS LTD	EQ 10MG BASE	A091650 001	Jul 17, 2012	Jul	NEWA
----	--------------------	--------------	-------------	--------------	-----	------

AB		EQ 20MG BASE	A091650 002	Jul 17, 2012	Jul	NEWA
----	--	--------------	-------------	--------------	-----	------

AB		EQ 40MG BASE	A091650 003	Jul 17, 2012	Jul	NEWA
----	--	--------------	-------------	--------------	-----	------

AB		EQ 80MG BASE	A202357 001	Jul 17, 2012	Jul	NEWA
----	--	--------------	-------------	--------------	-----	------

AB	MYLAN PHARMS INC	EQ 10MG BASE	A091226 001	May 29, 2012	May	NEWA
----	------------------	--------------	-------------	--------------	-----	------

AB		EQ 20MG BASE	A091226 002	May 29, 2012	May	NEWA
----	--	--------------	-------------	--------------	-----	------

AB		EQ 40MG BASE	A091226 003	May 29, 2012	May	NEWA
----	--	--------------	-------------	--------------	-----	------

AB		EQ 80MG BASE	A091226 004	May 29, 2012	May	NEWA
----	--	--------------	-------------	--------------	-----	------

AB	SANDOZ INC	EQ 10MG BASE	A077575 001	May 29, 2012	May	NEWA
----	------------	--------------	-------------	--------------	-----	------

AB		EQ 20MG BASE	A077575 002	May 29, 2012	May	NEWA
----	--	--------------	-------------	--------------	-----	------

AB		EQ 40MG BASE	A077575 003	May 29, 2012	May	NEWA
----	--	--------------	-------------	--------------	-----	------

AB		EQ 80MG BASE	A077575 004	May 29, 2012	May	NEWA
----	--	--------------	-------------	--------------	-----	------

AB	TEVA PHARMS	EQ 10MG BASE	A078773 001	May 29, 2012	May	NEWA
----	-------------	--------------	-------------	--------------	-----	------

AB		EQ 20MG BASE	A078773 002	May 29, 2012	May	NEWA
----	--	--------------	-------------	--------------	-----	------

AB		EQ 40MG BASE	A078773 003	May 29, 2012	May	NEWA
----	--	--------------	-------------	--------------	-----	------

AB		EQ 80MG BASE	A078773 004	May 29, 2012	May	NEWA
----	--	--------------	-------------	--------------	-----	------

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

AP	+	BEDFORD	10MG/ML	A074901 001	Jul 18, 1997	Feb	CTEC
----	---	---------	---------	-------------	--------------	-----	------

AP		SAGENT PHARMS	10MG/ML	A091489 001	Feb 17, 2012	Feb	NEWA
----	--	---------------	---------	-------------	--------------	-----	------

ATRACURIUM BESYLATE PRESERVATIVE FREE

AP	+	BEDFORD	10MG/ML	A074900 001	Jul 18, 1997	Feb	CTEC
----	---	---------	---------	-------------	--------------	-----	------

AP		SAGENT PHARMS	10MG/ML	A091488 001	Feb 17, 2012	Feb	NEWA
----	--	---------------	---------	-------------	--------------	-----	------

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

SOLUTION; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

AA	+	ROXANE	0.025MG/5ML;2.5MG/5ML	A087708 001	May 03, 1982	Apr	CRLD
		LOMOTIL					
		@ GD SEARLE LLC	0.025MG/5ML;2.5MG/5ML	N012699 001		Apr	DISC

AVANAFIL

TABLET; ORAL

STENDRA

VIVUS

+

50MG
100MG
200MG

N202276 001	Apr 27, 2012	Apr	NEWA
N202276 002	Apr 27, 2012	Apr	NEWA
N202276 003	Apr 27, 2012	Apr	NEWA

AXITINIB

TABLET; ORAL

INLYTA

PFIZER

+

1MG
5MG

N202324 001	Jan 27, 2012	Jan	NEWA
N202324 002	Jan 27, 2012	Jan	NEWA

AZELAIC ACID

GEL; TOPICAL

FINACEA

+

BAYER HLTHCARE 15%

N021470 001	Dec 24, 2002	Jun	CAHN
-------------	--------------	-----	------

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AZELASTINE HYDROCHLORIDE

AT		ALCON PHARMA	0.05%	A202305 001	May 31, 2012	May	NEWA
----	--	--------------	-------	-------------	--------------	-----	------

SPRAY, METERED; NASAL

ASTEPRO

>D>	+	MEDA PHARMS	EQ 0.1876MG BASE/SPRAY	N022371 001	Aug 31, 2009	Aug	CFTG
>A>	AB	+	EQ 0.1876MG BASE/SPRAY	N022371 001	Aug 31, 2009	Aug	CFTG

AZELASTINE HYDROCHLORIDE

>A>	AB	APOTEX INC	EQ 0.1876MG BASE/SPRAY	A201846 001	Aug 31, 2012	Aug	NEWA
AB		SUN PHARMA GLOBAL	EQ 0.125MG BASE/SPRAY	A090423 001	May 23, 2012	May	NEWA

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

SPRAY, METERED; NASAL

DYMISTA

+	MEDA PHARMS	EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY	N202236 001	May 01, 2012	May	NEWA
---	-------------	---------------------------------------	-------------	--------------	-----	------

AZILSARTAN KAMEDOXOMIL

TABLET; ORAL

EDARBI

TAKEDA PHARMS USA

+

EQ 40MG MEDOXOMIL
EQ 80MG MEDOXOMIL

N200796 001	Feb 25, 2011	Apr	CAHN
N200796 002	Feb 25, 2011	Apr	CAHN

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET; ORAL

EDARBYCLOR

TAKEDA PHARMS USA

+

EQ 40MG MEDOXOMIL;12.5MG
EQ 40MG MEDOXOMIL;25MG

N202331 001	Dec 20, 2011	Apr	CAHN
N202331 002	Dec 20, 2011	Apr	CAHN

AZITHROMYCIN

INJECTABLE; INJECTION

AZITHROMYCIN

@ PLIVA HRVATSKA DOO	EQ 500MG BASE/VIAL	A065265 001	Jan 18, 2007	Jul	DISC
@ TEVA PARENTERAL	EQ 500MG BASE/VIAL	N050809 001	Dec 19, 2006	Jun	DISC
@	EQ 2.5GM BASE/VIAL	N050809 002	Dec 19, 2006	Jun	DISC

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE

AT	AKORN	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A065213 001	Jul 25, 2012	Jul	NEWA	
AT	+	BAUSCH AND LOMB	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A064068 001	Oct 30, 1995	Jul	CTEC

BACLOFEN

INJECTABLE; INTRATHECAL

GABLOFEN

	CNS THERAPS INC	1MG/ML	N022462 004	Jun 22, 2012	Jun	NEWA
--	-----------------	--------	-------------	--------------	-----	------

TABLET; ORAL

BACLOFEN

AB	PROSAM LABS	10MG	A077089 001	Oct 31, 2007	Feb	CAHN
AB		20MG	A077088 001	Oct 31, 2007	Feb	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

KEMSTRO

@	UCB INC	10MG	N021589 001	Oct 30, 2003	Jan	CAHN
@		20MG	N021589 002	Oct 30, 2003	Jan	CAHN

BALSALAZIDE DISODIUM

TABLET; ORAL

GIAZO

+	SALIX PHARMS	1.1GM	N022205 001	Feb 03, 2012	Feb	NEWA
---	--------------	-------	-------------	--------------	-----	------

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; NASAL

QNASL

+	TEVA BRANDED PHARM	0.08MG/ACTIVATION	N202813 001	Mar 23, 2012	Mar	NEWA
---	--------------------	-------------------	-------------	--------------	-----	------

BENZONATATE

CAPSULE; ORAL

BENZONATATE

@	NESHER PHARMS	100MG	A040795 001	Oct 31, 2007	Jun	DISC
@		200MG	A040795 002	Oct 31, 2007	Jun	DISC

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

BENZACLIN

AB	VALEANT INTL	5%;EQ 1% BASE	N050756 001	Dec 21, 2000	Apr	CAHN	
BT	+	5%;EQ 1% BASE	N050756 002	Apr 20, 2007	Apr	CAHN	
AB		CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE					
	PERRIGO ISRAEL	5%;1.2%	A090979 001	Jun 26, 2012	Jun	NEWA	
	DUAC						
AB	+	STIEFEL	5%;1.2%	N050741 001	Aug 26, 2002	Jun	CFTG

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

BENZAMYCIN

AB	+	VALEANT INTL	5%;3%	N050557 001	Oct 26, 1984	Jan	CAHN
		BENZAMYCIN PAK					
	+	VALEANT INTL	5%;3%	N050769 001	Nov 27, 2000	Jun	CAHN

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

AA		EMCURE PHARMS LTD	50MG	A202061 001	Jan 27, 2012	Jan	NEWA
----	--	-------------------	------	-------------	--------------	-----	------

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

AP		APP PHARMS LLC	1MG/ML	A090233 001	Jul 28, 2009	May	CAHN
----	--	----------------	--------	-------------	--------------	-----	------

COGENTIN

AP	+	OAK PHARMS AKORN	1MG/ML	N012015 001		Feb	CAHN
----	---	------------------	--------	-------------	--	-----	------

TABLET; ORAL

BENZTROPINE MESYLATE

		@ LANNETT HOLDINGS INC	0.5MG	A088877 001	Apr 11, 1985	Jan	DISC
		@	1MG	A088894 001	Apr 11, 1985	Jan	DISC
		@	2MG	A088895 001	Apr 11, 1985	Jan	DISC
AA		PROSAM LABS	0.5MG	A040699 001	Feb 14, 2008	Feb	CMFD
AA			1MG	A040705 001	Feb 14, 2008	Feb	CMFD
AA			2MG	A040706 001	Feb 14, 2008	Feb	CMFD
AA	+	USL PHARMA	0.5MG	A040103 001	Dec 12, 1996	Jan	CRLD
AA	+		1MG	A040103 002	Dec 12, 1996	Jan	CRLD
AA	+		2MG	A040103 003	Dec 12, 1996	Jan	CRLD

BETAMETHASONE

SYRUP; ORAL

CELESTONE

		@ SCHERING	0.6MG/5ML	N014215 002		May	DISC
--	--	------------	-----------	-------------	--	-----	------

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	+	FOUGERA PHARMS	EQ 0.05% BASE	N019137 001	Jun 26, 1984	Jan	CAHN
----	---	----------------	---------------	-------------	--------------	-----	------

CREAM, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	EQ 0.05% BASE	A076215 001	Dec 09, 2003	Jan	CAHN
----	--	----------------	---------------	-------------	--------------	-----	------

GEL, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	+	FOUGERA PHARMS	EQ 0.05% BASE	A075276 001	May 13, 2003	Jan	CAHN
----	---	----------------	---------------	-------------	--------------	-----	------

LOTION, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	EQ 0.05% BASE	A077111 001	May 21, 2007	Jan	CAHN
----	--	----------------	---------------	-------------	--------------	-----	------

OINTMENT, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	EQ 0.05% BASE	A075373 001	Jun 22, 1999	Jan	CAHN
----	--	----------------	---------------	-------------	--------------	-----	------

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL							
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE							
AB	FOUGERA PHARMS	EQ 0.05% BASE;1%	A075502	001	Jun 05, 2001	Jan	CAHN
LOTION; TOPICAL							
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE							
AB	FOUGERA PHARMS	EQ 0.05% BASE;1%	A076516	001	Jun 16, 2005	Jan	CAHN
LOTRISONE							
AB	+ SCHERING CORP	EQ 0.05% BASE;1%	N020010	001	Dec 08, 2000	Feb	CAHN

BETAMETHASONE VALERATE

AEROSOL, FOAM; TOPICAL							
LUXIQ							
	+ STIEFEL	EQ 0.12% BASE	N020934	001	Feb 28, 1999	Jan	CAHN

BISOPROLOL FUMARATE

TABLET; ORAL							
ZEBETA							
AB	TEVA WOMENS	5MG	N019982	002	Jul 31, 1992	Jan	CAHN
AB	+	10MG	N019982	001	Jul 31, 1992	Jan	CAHN

BOCEPREVIR

CAPSULE; ORAL							
VICTRELIS							
	+ MERCK SHARP DOHME	200MG	N202258	001	May 13, 2011	Mar	CAHN

BORTEZOMIB

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS							
VELCADE							
	+ MILLENNIUM PHARMS	3.5MG/VIAL	N021602	001	May 13, 2003	Jan	CDFR

BOSENTAN

TABLET; ORAL							
TRACLEER							
	ACTELION PHARMS LTD	62.5MG	N021290	001	Nov 20, 2001	May	CAHN
	+	125MG	N021290	002	Nov 20, 2001	May	CAHN

BUDESONIDE

POWDER, METERED; INHALATION							
PULMICORT							
	@ ASTRAZENECA	0.16MG/INH	N020441	002	Jun 24, 1997	Jun	DISC
SUSPENSION; INHALATION							
BUDESONIDE							
AN	WATSON LABS INC	0.25MG/2ML	A078404	001	Jul 31, 2012	Jul	NEWA
AN		0.5MG/2ML	A078404	002	Jul 31, 2012	Jul	NEWA

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

AEROSOL, METERED; INHALATION							
SYMBICORT							
	+ ASTRAZENECA	0.08MG/INH;0.0045MG/INH	N021929	001	Jul 21, 2006	Jan	CDFR
	+	0.16MG/INH;0.0045MG/INH	N021929	002	Jul 21, 2006	Jan	CDFR

BUPIVACAINE

INJECTABLE, LIPOSOMAL; INJECTION

EXPAREL

@ PACIRA PHARMS INC 133MG/10ML (13.3MG/ML)

N022496 001 Oct 28, 2011 Jul DISC

BUPRENORPHINE HYDROCHLORIDE

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

>D>	AB	ROXANE	EQ 8MG BASE	A078633 002	Oct 08, 2009	Aug	CRLD
>A>	AB	+	EQ 8MG BASE	A078633 002	Oct 08, 2009	Aug	CRLD
>D>		SUBUTEX					
>D>	AB	RECKITT BENCKISER	EQ 2MG BASE	N020732 002	Oct 08, 2002	Aug	DISC
>A>		@	EQ 2MG BASE	N020732 002	Oct 08, 2002	Aug	DISC
>D>	AB	+	EQ 8MG BASE	N020732 003	Oct 08, 2002	Aug	DISC
>A>		@	EQ 8MG BASE	N020732 003	Oct 08, 2002	Aug	DISC

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM; SUBLINGUAL

SUBOXONE

>A>		RECKITT BENCKISER	EQ 2MG BASE;EQ 0.5MG BASE	N022410 001	Aug 30, 2010	Apr	CAIN
			EQ 4MG BASE;EQ 1MG BASE	N022410 003	Aug 10, 2012	Aug	NEWA
>A>		+	EQ 8MG BASE;EQ 2MG BASE	N022410 002	Aug 30, 2010	Apr	CAIN
			EQ 12MG BASE;EQ 3MG BASE	N022410 004	Aug 10, 2012	Aug	NEWA

TABLET; SUBLINGUAL

SUBOXONE

		RECKITT BENCKISER	EQ 2MG BASE;EQ 0.5MG BASE	N020733 001	Oct 08, 2002	Apr	CPOT
		+	EQ 8MG BASE;EQ 2MG BASE	N020733 002	Oct 08, 2002	Apr	CPOT

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

>A>	AB1	WOCKHARDT LTD	100MG	A201331 001	Aug 30, 2012	Aug	NEWA
>A>	AB1		150MG	A201331 002	Aug 30, 2012	Aug	NEWA
>A>	AB1		200MG	A201331 003	Aug 30, 2012	Aug	NEWA
		FORFIVO XL					
		+	EDGEMONT PHARMS LLC 450MG	N022497 001	Nov 10, 2011	Mar	CAHN

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

		@ APOTEX	5MG	A075521 001	Apr 05, 2002	Mar	DISC
		@	10MG	A075521 002	Apr 05, 2002	Mar	DISC
		@	15MG	A075521 003	Apr 05, 2002	Mar	DISC
		@ EGIS	5MG	A075119 001	Mar 14, 2002	Mar	DISC
		@	10MG	A075119 002	Mar 14, 2002	Mar	DISC
		@	15MG	A075119 003	Jan 23, 2003	Mar	DISC
		@ NESHER PHARMS	5MG	A075572 001	Feb 27, 2002	Jun	DISC
		@	10MG	A075572 002	Feb 27, 2002	Jun	DISC
		@	15MG	A075572 003	Feb 27, 2002	Jun	DISC
		@ PROSAM LABS	5MG	A075388 001	May 09, 2002	Mar	DISC
AB			5MG	A075388 001	May 09, 2002	Feb	CMFD
		@	10MG	A075388 002	May 09, 2002	Mar	DISC
AB			10MG	A075388 002	May 09, 2002	Feb	CMFD
		@	15MG	A075388 003	May 09, 2002	Mar	DISC
AB			15MG	A075388 003	May 09, 2002	Feb	CMFD

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

AB	PROSAM LABS	30MG	A078302 001	Dec 17, 2007	Feb	CMFD
----	-------------	------	-------------	--------------	-----	------

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

BUTOCONAZOLE NITRATE

@ PERRIGO ISRAEL 2%

A200923 001	May 18, 2012	Apr	NEWA
-------------	--------------	-----	------

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS

CAFCIT

AP	+ BEDFORD LABS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793 001	Sep 21, 1999	Jan	CAHN
----	----------------	------------------------------------	-------------	--------------	-----	------

CAFFEINE CITRATE

>A>	AP	SAGENT PHARMS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A090827 001	Aug 29, 2012	Aug	NEWA
-----	----	---------------	------------------------------------	-------------	--------------	-----	------

SOLUTION; ORAL

CAFCIT

AA	+ BEDFORD LABS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793 002	Apr 12, 2000	Jan	CAHN
----	----------------	------------------------------------	-------------	--------------	-----	------

CAFFEINE CITRATE

>A>	AA	SAGENT PHARMS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A091102 001	Aug 29, 2012	Aug	NEWA
-----	----	---------------	------------------------------------	-------------	--------------	-----	------

CALCIPOTRIENE

CREAM; TOPICAL

CALCIPOTRIENE

AB	TOLMAR	0.005%	A200935 001	May 30, 2012	May	NEWA
----	--------	--------	-------------	--------------	-----	------

DOVONEX

AB	+ LEO PHARMA AS	0.005%	N020554 001	Jul 22, 1996	May	CFTG
----	-----------------	--------	-------------	--------------	-----	------

SOLUTION; TOPICAL

CALCIPOTRIENE

AT	FOUGERA PHARMS	0.005%	A078305 001	May 06, 2008	Jan	CAHN
----	----------------	--------	-------------	--------------	-----	------

CALCIUM ACETATE

CAPSULE; ORAL

CALCIUM ACETATE

AB	PADDOCK LLC	EQ 169MG CALCIUM	A091312 001	Jun 01, 2012	May	NEWA
----	-------------	------------------	-------------	--------------	-----	------

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

AB	SUN PHARMA GLOBAL	25MG;200MG;100MG	A079085 001	May 10, 2012	Apr	NEWA
----	-------------------	------------------	-------------	--------------	-----	------

AB		37.5MG;200MG;150MG	A079085 002	May 10, 2012	Apr	NEWA
----	--	--------------------	-------------	--------------	-----	------

STALEVO 100

AB	ORION PHARMA	25MG;200MG;100MG	N021485 002	Jun 11, 2003	Apr	CFTG
----	--------------	------------------	-------------	--------------	-----	------

STALEVO 150

AB	ORION PHARMA	37.5MG;200MG;150MG	N021485 003	Jun 11, 2003	Apr	CFTG
----	--------------	--------------------	-------------	--------------	-----	------

CARBIDOPA; LEVODOPA

TABLET, ORALLY DISINTEGRATING; ORAL

PARCOPA

AB	UCB INC	10MG;100MG	A076699 001	Aug 27, 2004	Jan	CAHN
----	---------	------------	-------------	--------------	-----	------

AB		25MG;100MG	A076699 002	Aug 27, 2004	Jan	CAHN
----	--	------------	-------------	--------------	-----	------

AB	+	25MG;250MG	A076699 003	Aug 27, 2004	Jan	CAHN
----	---	------------	-------------	--------------	-----	------

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

AP	CIPLA LTD	50MG/VIAL	A077383 001	Jan 27, 2006	Mar	CAHN
AP		150MG/VIAL	A077383 002	Jan 27, 2006	Mar	CAHN
AP		450MG/VIAL	A077383 003	Jan 27, 2006	Mar	CAHN
AP	ONCO THERAPIES LTD	50MG/VIAL	A091510 001	May 29, 2012	May	NEWA
AP		150MG/VIAL	A091510 002	May 29, 2012	May	NEWA
AP		450MG/VIAL	A091510 003	May 29, 2012	May	NEWA

PARAPLATIN

@ CORDEN PHARMA

@

@

50MG/VIAL

150MG/VIAL

450MG/VIAL

N019880 001 Mar 03, 1989 Feb CAHN

N019880 002 Mar 03, 1989 Feb CAHN

N019880 003 Mar 03, 1989 Feb CAHN

INJECTABLE; IV (INFUSION)

CARBOPLATIN

AP	ACTAVIS TOTOWA	50MG/5ML (10MG/ML)	A078732 001	Feb 06, 2012	Jan	NEWA
AP		150MG/15ML (10MG/ML)	A078732 002	Feb 06, 2012	Jan	NEWA
AP		450MG/45ML (10MG/ML)	A078732 003	Feb 06, 2012	Jan	NEWA
AP		600MG/60ML (10MG/ML)	A078732 004	Feb 06, 2012	Jan	NEWA
AP	CIPLA LTD	50MG/5ML (10MG/ML)	A077861 001	Jan 18, 2007	Mar	CAHN
AP		150MG/15ML (10MG/ML)	A077861 002	Jan 18, 2007	Mar	CAHN
AP		450MG/45ML (10MG/ML)	A077861 003	Jan 18, 2007	Mar	CAHN
AP		600MG/60ML (10MG/ML)	A077861 004	Jan 18, 2007	Mar	CAHN

CARFILZOMIB

POWDER; INTRAVENOUS

KYPROLIS

+ ONYX PHARMS

60MG/VIAL

N202714 001 Jul 20, 2012 Jul NEWA

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

AA	PROSAM LABS	350MG	A040188 001	Mar 07, 1997	Feb	CAHN
----	-------------	-------	-------------	--------------	-----	------

CEFACLOR

CAPSULE; ORAL

CEFACLOR

@ RANBAXY

@

EQ 250MG BASE

EQ 500MG BASE

A064156 001 Aug 28, 1997 Apr DISC

A064156 002 Aug 28, 1997 Apr DISC

FOR SUSPENSION; ORAL

CEFACLOR

@ RANBAXY

AB	+	EQ 125MG BASE/5ML	A064166 001	Oct 02, 1997	Apr	DISC
		EQ 125MG BASE/5ML	A064166 001	Oct 02, 1997	Feb	CTEC
	@	EQ 187MG BASE/5ML	A064165 001	Oct 02, 1997	Apr	DISC
AB	+	EQ 187MG BASE/5ML	A064165 001	Oct 02, 1997	Feb	CTEC
	@	EQ 250MG BASE/5ML	A064164 001	Oct 02, 1997	Apr	DISC
AB	+	EQ 250MG BASE/5ML	A064164 001	Oct 02, 1997	Feb	CTEC
	@	EQ 375MG BASE/5ML	A064155 001	Oct 02, 1997	Apr	DISC
AB	+	EQ 375MG BASE/5ML	A064155 001	Oct 02, 1997	Feb	CTEC
AB		EQ 125MG BASE/5ML	A065412 001	Feb 17, 2012	Feb	NEWA
AB		EQ 187MG BASE/5ML	A065412 002	Feb 17, 2012	Feb	NEWA
AB		EQ 250MG BASE/5ML	A065412 003	Feb 17, 2012	Feb	NEWA
AB		EQ 375MG BASE/5ML	A065412 004	Feb 17, 2012	Feb	NEWA

TABLET, CHEWABLE; ORAL

RANICLOR

@ RANBAXY LABS LTD

EQ 125MG BASE

A065092 001 Dec 22, 2003 Apr DISC

@

EQ 187MG BASE

A065092 002 Dec 22, 2003 Apr DISC

@

EQ 250MG BASE

A065092 003 Dec 22, 2003 Apr DISC

@

EQ 375MG BASE

A065092 004 Dec 22, 2003 Apr DISC

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

CEFADROXIL

@ RANBAXY LABS LTD

EQ 500MG BASE

A065015 001 Jun 22, 1999 Apr DISC

TABLET; ORAL

CEFADROXIL

>D>

+ IVAX SUB TEVA PHARMS

EQ 1GM BASE

A062774 001 Apr 08, 1987 Aug CAHN

@ RANBAXY

EQ 1GM BASE

A065018 001 Apr 23, 1999 Apr DISC

>A>

+ TEVA PHARMS

EQ 1GM BASE

A062774 001 Apr 08, 1987 Aug CAHN

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN AND DEXTROSE

B BRAUN

EQ 2GM BASE/VIAL

N050779 003 Jan 13, 2012 May NEWA

CEFDITOREN PIVOXIL

TABLET; ORAL

SPECTRACEF

VANSER PHARMA

200MG

N021222 001 Aug 29, 2001 Mar CAHN

+

400MG

N021222 002 Jul 21, 2008 Mar CAHN

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

AP HOSPIRA INC

EQ 1GM BASE/VIAL

A202268 001 Jul 30, 2012 Jul NEWA

AP

EQ 2GM BASE/VIAL

A202268 002 Jul 30, 2012 Jul NEWA

CEFIXIME

CAPSULE; ORAL

SUPRAX

+ LUPIN LTD

400MG

N203195 001 Jun 01, 2012 Jun NEWA

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CLAFORAN

AP + SANOFI AVENTIS US

EQ 1GM BASE/VIAL

A062659 001 Jan 13, 1987 Mar CRLD

AP

+

EQ 2GM BASE/VIAL

A062659 002 Jan 13, 1987 Mar CRLD

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

AP ANTIBIOTICOS BRASIL

EQ 1GM BASE/VIAL

A065467 001 Aug 31, 2011 Jul CAIN

AP

EQ 2GM BASE/VIAL

A065467 002 Aug 31, 2011 Jul CAIN

AP

EQ 10GM BASE/VIAL

A065464 001 Aug 31, 2011 Jul CAIN

CEFPROZIL

FOR SUSPENSION; ORAL

CEFPROZIL

AB APOTEX INC

125MG/5ML

A065351 001 Feb 29, 2012 Feb NEWA

FOR SUSPENSION; ORAL

CEFPROZIL

AB	APOTEX INC	250MG/5ML	A065351 002	Feb 29, 2012	Feb	NEWA
	@ RANBAXY LABS LTD	125MG/5ML	A065202 001	Jun 30, 2006	Apr	DISC
	@	250MG/5ML	A065202 002	Jun 30, 2006	Apr	DISC

TABLET; ORAL

CEFPROZIL

@ RANBAXY LABS LTD

250MG

A065198 001 Dec 13, 2006 Apr DISC

@

500MG

A065198 002 Dec 13, 2006 Apr DISC

CEFZIL

@ CORDEN PHARMA

250MG

N050664 001 Dec 23, 1991 Feb CAHN

@

500MG

N050664 002 Dec 23, 1991 Feb CAHN

CEFTAZIDIME

INJECTABLE; INJECTION

FORTAZ

AP	+	COVIS PHARMA	500MG/VIAL	N050578 001	Jul 19, 1985	Apr	CAHN
AP	+		1GM/VIAL	N050578 002	Jul 19, 1985	Apr	CAHN
AP	+		2GM/VIAL	N050578 003	Jul 19, 1985	Apr	CAHN
AP	+		6GM/VIAL	N050578 004	Jul 19, 1985	Apr	CAHN

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION

FORTAZ IN PLASTIC CONTAINER

@ COVIS PHARMA

EQ 10MG BASE/ML

N050634 001 Apr 28, 1989 Apr CAHN

+

EQ 20MG BASE/ML

N050634 002 Apr 28, 1989 Apr CAHN

+

EQ 40MG BASE/ML

N050634 003 Apr 28, 1989 Apr CAHN

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION

CEFTRIAXONE

>A>	AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A202563 001	Aug 20, 2012	Aug	NEWA
>A>	AP		EQ 2GM BASE/VIAL	A202563 002	Aug 20, 2012	Aug	NEWA
	AP	+	SANDOZ INC	EQ 1GM BASE/VIAL	A065204 001	May 03, 2005	Mar
	AP	+		EQ 2GM BASE/VIAL	A065204 002	May 03, 2005	Mar

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

@ RANBAXY LABS LTD

EQ 125MG BASE

A065043 003 Feb 15, 2002 Apr DISC

@

EQ 250MG BASE

A065043 002 Feb 15, 2002 Apr DISC

@

EQ 500MG BASE

A065043 001 Feb 15, 2002 Apr DISC

CEFUROXIME SODIUM

INJECTABLE; IM-IV

ZINACEF

AB	+	COVIS PHARMA	EQ 750MG BASE/VIAL	N050558 002	Oct 19, 1983	Apr	CAHN
----	---	--------------	--------------------	-------------	--------------	-----	------

INJECTABLE; INJECTION

ZINACEF

AP	+	COVIS PHARMA	EQ 1.5GM BASE/VIAL	N050558 003	Oct 19, 1983	Apr	CAHN
----	---	--------------	--------------------	-------------	--------------	-----	------

AP	+		EQ 7.5GM BASE/VIAL	N050558 004	Oct 23, 1986	Apr	CAHN
----	---	--	--------------------	-------------	--------------	-----	------

ZINACEF IN PLASTIC CONTAINER

+ COVIS PHARMA

EQ 15MG BASE/ML

N050643 001 Apr 28, 1989 Apr CAHN

+

EQ 30MG BASE/ML

N050643 002 Apr 28, 1989 Apr CAHN

CEPHALEXIN

FOR SUSPENSION; ORAL

KEFLEX

@ SHIONOGI INC	EQ 100MG BASE/ML	N050406 003		Jul	CAHN
@	EQ 125MG BASE/5ML	N050406 001		Jul	CAHN
@	EQ 250MG BASE/5ML	N050406 002		Jul	CAHN

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

AA	@ RANBAXY LABS LTD	5MG/5ML	A077472 001	Jun 18, 2008	Jul	DISC
	SILARX	5MG/5ML	A078876 001	May 11, 2012	Apr	NEWA

CHLORAMBUCIL

TABLET; ORAL

LEUKERAN

+	ASPEN GLOBAL INC	2MG	N010669 002		May	CAHN
---	------------------	-----	-------------	--	-----	------

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX

AB	CORNERSTONE THERAP	EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML	A091671 001	Jun 29, 2012	Jun	NEWA
----	--------------------	---	-------------	--------------	-----	------

CICLESONIDE

AEROSOL, METERED; INHALATION

ALVESCO

	NYCOMED GMBH	0.08MG/INH	N021658 002	Jan 10, 2008	May	CAHN
+		0.16MG/INH	N021658 003	Jan 10, 2008	May	CAHN

AEROSOL, METERED; NASAL

ZETONNA

+	NYCOMED GMBH	0.037MG/INH	N202129 001	Jan 20, 2012	Jan	NEWA
---	--------------	-------------	-------------	--------------	-----	------

SPRAY, METERED; NASAL

OMNARIS

+	NYCOMED GMBH	0.05MG/INH	N022004 001	Oct 20, 2006	May	CAHN
---	--------------	------------	-------------	--------------	-----	------

CICLOPIROX

CREAM; TOPICAL

CICLOPIROX

AB	FOUGERA PHARMS	0.77%	A076435 001	Dec 29, 2004	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

GEL; TOPICAL

CICLOPIROX

AB	FOUGERA PHARMS	0.77%	A077896 001	Jun 10, 2008	Jan	CAHN
AB	GLENMARK GENERICS	0.77%	A091595 001	Feb 29, 2012	Feb	NEWA

SHAMPOO; TOPICAL

CICLOPIROX

AT	FOUGERA PHARMS	1%	A090146 001	May 25, 2010	Jan	CAHN
----	----------------	----	-------------	--------------	-----	------

SOLUTION; TOPICAL

CICLOPIROX

AT	MYLAN PHARMS INC	8%	A078567 001	Sep 18, 2007	Feb	CAHN
----	------------------	----	-------------	--------------	-----	------

SUSPENSION; TOPICAL

CICLOPIROX

AB	FOUGERA PHARMS	0.77%	A076422 001	Aug 06, 2004	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

CIDOFOVIR

INJECTABLE; INJECTION

CIDOFOVIR

AP	EMCURE PHARMS LTD	EQ 75MG BASE/ML	A202501 001	Jul 26, 2012	Jul	NEWA
AP	MYLAN LLC	EQ 75MG BASE/ML	A201276 001	Jun 27, 2012	Jun	NEWA
VISTIDE						
AP	+ GILEAD SCIENCES INC	EQ 75MG BASE/ML	N020638 001	Jun 26, 1996	Jun	CFTG

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HYDROCHLORIDE

@	HOSPIRA	EQ 300MG BASE/2ML	A074344 001	Jan 31, 1995	Jun	DISC
@		EQ 300MG BASE/2ML	A074345 001	Jan 31, 1995	Jun	DISC

CIPROFLOXACIN

INJECTABLE; INJECTION

CIPROFLOXACIN

@	TEVA PARENTERAL	200MG/20ML (10MG/ML)	A077782 001	Aug 28, 2006	Mar	DISC
@		400MG/40ML (10MG/ML)	A077782 002	Aug 28, 2006	Jan	DISC

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

@	BAXTER HLTHCARE	200MG/100ML	A077888 001	Mar 18, 2008	Jun	DISC
@		400MG/200ML	A077888 002	Mar 18, 2008	Jun	DISC

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

@	PLIVA	EQ 100MG BASE	A076426 001	Jun 15, 2005	Jan	DISC
@		EQ 250MG BASE	A076426 002	Jun 15, 2005	Jan	DISC
@		EQ 500MG BASE	A076426 003	Jun 15, 2005	Jan	DISC
@		EQ 750MG BASE	A076426 004	Jun 15, 2005	Jan	DISC

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPROFLOXACIN EXTENDED RELEASE

AB	DR REDDYS LABS LTD	212.6MG;EQ 287.5MG BASE	A077701 002	Oct 31, 2007	Apr	NEWA
----	--------------------	-------------------------	-------------	--------------	-----	------

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

CISATRACURIUM BESYLATE

AP	SANDOZ INC	EQ 2MG BASE/ML	A200159 001	Feb 03, 2012	Jan	NEWA
CISATRACURIUM BESYLATE PRESERVATIVE FREE						
AP	SANDOZ INC	EQ 2MG BASE/ML	A200154 001	Feb 03, 2012	Jan	NEWA
AP		EQ 10MG BASE/ML	A200154 002	Feb 03, 2012	Jan	NEWA
NIMBEX						
AP	+ ABBOTT	EQ 2MG BASE/ML	N020551 001	Dec 15, 1995	Jan	CFTG
NIMBEX PRESERVATIVE FREE						
AP	+ ABBOTT	EQ 2MG BASE/ML	N020551 003	Dec 15, 1995	Jan	CFTG
AP	+	EQ 10MG BASE/ML	N020551 002	Dec 15, 1995	Jan	CFTG

CISPLATIN

INJECTABLE; INJECTION

CISPLATIN

AP	ONCO THERAPIES LTD	1MG/ML	A091062 001	Apr 18, 2012	Apr	NEWA
	@ TEVA PARENTERAL	1MG/ML	A074814 001	May 16, 2000	Mar	DISC

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

>D>	AB	IVAX SUB TEVA PHARMS	EQ 10MG BASE	A077048 001	Nov 16, 2004	Aug	CAHN
>D>	AB		EQ 20MG BASE	A077048 002	Nov 16, 2004	Aug	CAHN
>D>	AB		EQ 40MG BASE	A077048 003	Nov 16, 2004	Aug	CAHN
>D>	AB	SANDOZ	EQ 10MG BASE	A077035 001	Oct 28, 2004	Aug	DISC
>A>	@		EQ 10MG BASE	A077035 001	Oct 28, 2004	Aug	DISC
>D>	AB		EQ 20MG BASE	A077035 002	Oct 28, 2004	Aug	DISC
>A>	@		EQ 20MG BASE	A077035 002	Oct 28, 2004	Aug	DISC
>D>	AB		EQ 40MG BASE	A077035 003	Oct 28, 2004	Aug	DISC
>A>	@		EQ 40MG BASE	A077035 003	Oct 28, 2004	Aug	DISC
>A>	AB	TEVA PHARMS	EQ 10MG BASE	A077048 001	Nov 16, 2004	Aug	CAHN
>A>	AB		EQ 20MG BASE	A077048 002	Nov 16, 2004	Aug	CAHN
>A>	AB		EQ 40MG BASE	A077048 003	Nov 16, 2004	Aug	CAHN

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

FOR SOLUTION; ORAL

PREPOPIK

+	FERRING PHARMS AS	12GM/PACKET;3.5GM/PACKET;10MG/PAC	N202535 001	Jul 16, 2012	Jul	NEWA
		KET				

CLARITHROMYCIN

TABLET; ORAL

CLARITHROMYCIN

AB	AUROBINDO	250MG	A065489 001	Jul 25, 2012	Jul	NEWA
AB		500MG	A065489 002	Jul 25, 2012	Jul	NEWA

TABLET, EXTENDED RELEASE; ORAL

CLARITHROMYCIN

>D>	AB	SANDOZ	500MG	A065250 001	Aug 25, 2005	Aug	DISC
>A>	@		500MG	A065250 001	Aug 25, 2005	Aug	DISC

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

>A>	AA	LYNE	EQ 75MG BASE/5ML	A201821 001	Aug 28, 2012	Aug	NEWA
-----	----	------	------------------	-------------	--------------	-----	------

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL

CLINDAMYCIN PHOSPHATE

AB	FOUGERA PHARMS	EQ 2% BASE	A065139 001	Dec 27, 2004	Jan	CAHN
----	----------------	------------	-------------	--------------	-----	------

GEL; TOPICAL

CLINDAMYCIN PHOSPHATE

AB	FOUGERA PHARMS	EQ 1% BASE	A064160 001	Jan 28, 2000	Jan	CAHN
----	----------------	------------	-------------	--------------	-----	------

INJECTABLE; INJECTION

CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	PHARMACIA AND UPJOHN	EQ 6MG BASE/ML	N050639 001	Aug 30, 1989	May	CFTG
AP	+		EQ 12MG BASE/ML	N050639 002	Aug 30, 1989	May	CFTG
AP	+		EQ 18MG BASE/ML	N050639 003	Apr 10, 1991	May	CFTG

CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER

AP		SANDOZ INC	EQ 6MG BASE/ML	A201692 001	May 31, 2012	May	NEWA
AP			EQ 12MG BASE/ML	A201692 002	May 31, 2012	May	NEWA
AP			EQ 18MG BASE/ML	A201692 003	May 31, 2012	May	NEWA

LOTION; TOPICAL									
CLINDAMYCIN PHOSPHATE									
AB	FOUGERA PHARMS	EQ 1% BASE		A065067	001	Jan 31, 2002	Jan	CAHN	
SOLUTION; TOPICAL									
CLINDAMYCIN PHOSPHATE									
AT	FOUGERA PHARMS	EQ 1% BASE		A065254	001	Feb 14, 2006	Jan	CAHN	
<u>CLINDAMYCIN PHOSPHATE; TRETINOIN</u>									
GEL; TOPICAL									
VELTIN									
BX	+ STIEFEL GSK	1.2%;0.025%		N050803	001	Jul 16, 2010	May	CRLD	
<u>CLOBAZAM</u>									
TABLET; ORAL									
ONFI									
	LUNDBECK LLC	5MG		N202067	001	Oct 21, 2011	Mar	CAHN	
		10MG		N202067	002	Oct 21, 2011	Mar	CAHN	
	+	20MG		N202067	003	Oct 21, 2011	Mar	CAHN	
<u>CLOBETASOL PROPIONATE</u>									
AEROSOL, FOAM; TOPICAL									
CLOBETASOL PROPIONATE									
AB1	PERRIGO ISRAEL	0.05%		A077763	001	Mar 10, 2008	Jul	CTEC	
AB2		0.05%		A201402	001	Aug 14, 2012	Jul	NEWA	
OLUX									
AB1	+ STIEFEL LABS INC	0.05%		N021142	001	May 26, 2000	Jul	CTEC	
OLUX E									
AB2	+ STIEFEL LABS INC	0.05%		N022013	001	Jan 12, 2007	Jul	CFTG	
CREAM; TOPICAL									
CLOBETASOL PROPIONATE									
>D>	@ COREPHARMA	0.05%		A075338	001	Feb 09, 2001	Aug	CAHN	
	@ G AND W LABS INC	0.05%		A074139	001	Aug 03, 1994	Jun	CAHN	
>A>	@ RENAISSANCE PHARMA	0.05%		A075338	001	Feb 09, 2001	Aug	CAHN	
CLOBETASOL PROPIONATE (EMOLLIENT)									
>D>	@ COREPHARMA	0.05%		A075733	001	Aug 22, 2001	Aug	CAHN	
AB2	FOUGERA PHARMS	0.05%		A075430	001	May 26, 1999	Jan	CAHN	
>A>	@ RENAISSANCE PHARMA	0.05%		A075733	001	Aug 22, 2001	Aug	CAHN	
TEMOVATE									
AB1	+ FOUGERA PHARMS	0.05%		N019322	001	Dec 27, 1985	Jan	CAHN	
GEL; TOPICAL									
CLOBETASOL PROPIONATE									
AB	FOUGERA PHARMS	0.05%		A075368	001	Feb 15, 2000	Jan	CAHN	
TEMOVATE									
AB	+ FOUGERA PHARMS	0.05%		N020337	001	Apr 29, 1994	Jan	CAHN	
LOTION; TOPICAL									
CLOBETASOL PROPIONATE									
AB	TARO	0.05%		A200302	001	Jul 02, 2012	Jun	NEWA	
OINTMENT; TOPICAL									
CLOBETASOL PROPIONATE									
>D>	@ COREPHARMA	0.05%		A075057	001	Aug 12, 1998	Aug	CAHN	
AB	FOUGERA PHARMS	0.05%		A074407	001	Feb 23, 1996	Jan	CAHN	
>A>	@ RENAISSANCE PHARMA	0.05%		A075057	001	Aug 12, 1998	Aug	CAHN	
TEMOVATE									
AB	+ FOUGERA PHARMS	0.05%		N019323	001	Dec 27, 1985	Jan	CAHN	

SHAMPOO; TOPICAL					
CLOBETASOL PROPIONATE					
AB	PERRIGO ISRAEL	0.05%	A090974 001	Aug 09, 2012	Jul NEWA
SOLUTION; TOPICAL					
CLOBETASOL PROPIONATE					
AT	FOUGERA PHARMS	0.05%	A075391 001	Feb 08, 1999	Jan CAHN
	@ G AND W LABS INC	0.05%	A074331 001	Dec 15, 1995	Jun CAHN
TEMOVATE					
AT	+ FOUGERA PHARMS	0.05%	N019966 001	Feb 22, 1990	Jan CAHN
<u>CLONIDINE HYDROCHLORIDE</u>					
INJECTABLE; INJECTION					
DURACLON					
AP	MYLAN INSTITUTIONAL	1 MG/10 ML (0.1 MG/ML)	N020615 001	Oct 02, 1996	Feb CAHN
AP	+	5 MG/10 ML (0.5 MG/ML)	N020615 002	Apr 27, 1999	Feb CAHN
TABLET, EXTENDED RELEASE; ORAL					
KAPVAY					
	SHIONOGI INC	0.2MG	N022331 004	Sep 28, 2010	May CMFD
<u>CLOPIDOGREL BISULFATE</u>					
TABLET; ORAL					
CLOPIDOGREL BISULFATE					
AB	APOTEX INC	EQ 75MG BASE	A076274 001	May 17, 2012	Apr NEWA
AB	AUROBINDO PHARMA LTD	EQ 75MG BASE	A090540 001	May 17, 2012	Apr NEWA
AB	DR REDDYS LABS INC	EQ 75MG BASE	A076273 001	Jan 14, 2008	Mar CMFD
AB	DR REDDYS LABS LTD	EQ 300MG BASE	A091023 001	May 17, 2012	Apr NEWA
AB	GATE PHARMS	EQ 300MG BASE	A091216 001	May 17, 2012	Apr NEWA
AB	MYLAN PHARMS INC	EQ 75MG BASE	A077665 001	May 17, 2012	Apr NEWA
AB		EQ 300MG BASE	A077665 002	May 17, 2012	Apr NEWA
AB	ROXANE	EQ 75MG BASE	A078004 001	May 17, 2012	Apr NEWA
AB	SUN PHARMA GLOBAL	EQ 75MG BASE	A090494 001	May 17, 2012	Apr NEWA
AB	TEVA	EQ 75MG BASE	A076999 001	May 17, 2012	Apr NEWA
AB	TEVA PHARMS	EQ 300MG BASE	A090625 001	May 17, 2012	Apr NEWA
AB	TORRENT PHARMS LTD	EQ 75MG BASE	A090844 001	May 17, 2012	Apr NEWA
AB	WOCKHARDT LTD	EQ 75MG BASE	A202266 001	Aug 14, 2012	Jul NEWA
PLAVIX					
AB	SANOFI AVENTIS US	EQ 75MG BASE	N020839 001	Nov 17, 1997	Mar CTEC
AB	+	EQ 300MG BASE	N020839 002	Sep 20, 2007	Apr CTEC
<u>CLORAZEPATE DIPOTASSIUM</u>					
CAPSULE; ORAL					
TRANXENE					
	@ LUNDBECK LLC	3.75MG	N017105 001		Mar CAHN
	@	7.5MG	N017105 002		Mar CAHN
	@	15MG	N017105 003		Mar CAHN
TABLET; ORAL					
TRANXENE					
AB	LUNDBECK LLC	3.75MG	N017105 006		Mar CAHN
AB		7.5MG	N017105 007		Mar CAHN
AB	+	15MG	N017105 008		Mar CAHN
TRANXENE SD					
	@ LUNDBECK LLC	11.25MG	N017105 005		Mar CAHN
	@	22.5MG	N017105 004		Mar CAHN

CLOTRIMAZOLECREAM; TOPICAL
CLOTRIMAZOLE

AB	FOUGERA PHARMS	1%	A078338 001	Sep 02, 2008	Jan	CAHN
----	----------------	----	-------------	--------------	-----	------

CLOZAPINETABLET, ORALLY DISINTEGRATING; ORAL
FAZACLO ODT

	JAZZ	12.5MG	N021590 004	May 30, 2007	Apr	CAHN
		25MG	N021590 001	Feb 10, 2004	Apr	CAHN
	@	50MG	N021590 003	Jun 03, 2005	Apr	CAHN
+		100MG	N021590 002	Feb 10, 2004	Apr	CAHN
		150MG	N021590 005	Jul 09, 2010	Apr	CAHN
		200MG	N021590 006	Jul 09, 2010	Apr	CAHN
	JAZZ PHARMS III	12.5MG	N021590 004	May 30, 2007	Jun	CAHN
		25MG	N021590 001	Feb 10, 2004	Jun	CAHN
	@	50MG	N021590 003	Jun 03, 2005	Jun	CAHN
+		100MG	N021590 002	Feb 10, 2004	Jun	CAHN
		150MG	N021590 005	Jul 09, 2010	Jun	CAHN
		200MG	N021590 006	Jul 09, 2010	Jun	CAHN

>A> COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

>A> TABLET; ORAL

>A> STRIBILD

>A>	+	GILEAD SCIENCES INC	150MG;150MG;200MG;300MG	N203100 001	Aug 27, 2012	Aug	NEWA
-----	---	---------------------	-------------------------	-------------	--------------	-----	------

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

AA	TRIS PHARMA INC	10MG/5ML;6.25MG/5ML	A200386 001	Jun 29, 2012	Jun	NEWA
----	-----------------	---------------------	-------------	--------------	-----	------

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE

PARAGARD T 380A

+	TEVA WOMENS	309MG/COPPER	N018680 001	Nov 15, 1984	May	CAHN
---	-------------	--------------	-------------	--------------	-----	------

COSYNTROPIN

INJECTABLE; INJECTION

COSYNTROPIN

AP	INNOPHARMA INC	0.25MG/VIAL	A202147 001	Jun 29, 2012	Jun	NEWA
----	----------------	-------------	-------------	--------------	-----	------

CROMOLYN SODIUM

AEROSOL, METERED; INHALATION

INTAL

@ KING PFIZER 0.8MG/INH

N018887 001	Dec 05, 1985	Jun	DISC
-------------	--------------	-----	------

CONCENTRATE; ORAL

GASTROCROM

AA	+	JAZZ PHARMS COMMERCL	100MG/5ML	N020479 001	Feb 29, 1996	Mar	CAHN
----	---	----------------------	-----------	-------------	--------------	-----	------

AA	+	JAZZ PHARMS INTL	100MG/5ML	N020479 001	Feb 29, 1996	Jun	CAHN
----	---	------------------	-----------	-------------	--------------	-----	------

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB	+	MYLAN PHARMS INC	10MG	A073144 001	May 30, 1991	Jul	CRLD
----	---	------------------	------	-------------	--------------	-----	------

AB		PROSAM LABS	5MG	A077291 001	Feb 03, 2006	Feb	CAHN
----	--	-------------	-----	-------------	--------------	-----	------

TABLET; ORAL									
CYCLOBENZAPRINE HYDROCHLORIDE									
AB		PROSAM LABS	10MG	A077209	001	Oct 04, 2005	Feb	CAHN	
FLEXERIL									
	@	JANSSEN RES AND DEV	5MG	N017821	001		Jul	DISC	
	@		10MG	N017821	002		Jul	DISC	
<u>CYCLOPHOSPHAMIDE</u>									
INJECTABLE; INJECTION									
CYTOXAN									
AP	+	BAXTER HLTHCARE	500MG/VIAL	N012142	003		Apr	CRLD	
AP	+		1GM/VIAL	N012142	004	Aug 30, 1982	Apr	CRLD	
AP	+		2GM/VIAL	N012142	005	Aug 30, 1982	Apr	CRLD	
<u>CYCLOSPORINE</u>									
CAPSULE; ORAL									
CYCLOSPORINE									
AB1		WATSON LABS INC	25MG	A065044	002	Dec 20, 2000	May	CAHN	
AB1			100MG	A065044	001	Dec 20, 2000	May	CAHN	
<u>CYTARABINE</u>									
INJECTABLE; INJECTION									
CYTARABINE									
AP		ONCO THERAPIES LTD	100MG/ML	A201784	001	Jan 30, 2012	Jan	NEWA	
<u>DACTINOMYCIN</u>									
INJECTABLE; INJECTION									
COSMEGEN									
AP	+	LUNDBECK LLC	0.5MG/VIAL	N050682	001		Mar	CAHN	
<u>DANTROLENE SODIUM</u>									
CAPSULE; ORAL									
DANTROLENE SODIUM									
	@	MIKAH PHARMA	25MG	A076686	001	Oct 24, 2005	Jul	CAHN	
	@		50MG	A076686	002	Oct 24, 2005	Jul	CAHN	
	@		100MG	A076686	003	Oct 24, 2005	Jul	CAHN	
<u>DAPIPRAZOLE HYDROCHLORIDE</u>									
SOLUTION/DROPS; OPHTHALMIC									
DAPIPRAZOLE HYDROCHLORIDE									
	@	FERA PHARMS	0.5%	N019849	001	Dec 31, 1990	Jul	CTNA	
<u>DARUNAVIR ETHANOLATE</u>									
SUSPENSION; ORAL									
PREZISTA									
+		JANSSEN PRODS	EQ 100MG BASE/ML	N202895	001	Dec 16, 2011	Feb	CAHN	
TABLET; ORAL									
PREZISTA									
		JANSSEN PRODS	EQ 75MG BASE	N021976	004	Dec 18, 2008	Feb	CAHN	
			EQ 150MG BASE	N021976	005	Dec 18, 2008	Feb	CAHN	
	@		EQ 300MG BASE	N021976	001	Jun 23, 2006	Feb	CAHN	
			EQ 400MG BASE	N021976	003	Oct 21, 2008	Feb	CAHN	
+			EQ 600MG BASE	N021976	002	Feb 25, 2008	Feb	CAHN	

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

DECELOMYCIN

@ COREPHARMA 150MG

N050261 002 Jul DISC

@ 300MG

N050261 003 Jul DISC

DEMECLOCYCLINE HYDROCHLORIDE

AB + AMNEAL PHARM 300MG

A065425 002 Feb 27, 2008 Jul CRLD

DESFLURANE

LIQUID; INHALATION

SUPRANE

+ BAXTER HLTHCARE 99.9%

N020118 001 Sep 18, 1992 Jul CAHN

DESLOMATADINE

TABLET; ORAL

DESLOMATADINE

AB BELCHER PHARMS 5MG

A078355 001 Apr 19, 2012 Apr NEWA

AB MYLAN PHARMS INC 5MG

A078351 001 Feb 10, 2012 Jan NEWA

DESMOPRESSIN ACETATE

SOLUTION; NASAL

DDAVP

AB + SANOFI AVENTIS US 0.01%

N017922 001 Mar CFTG

DESMOPRESSIN ACETATE

AB SUN PHARM INDS 0.01%

A077212 001 Apr 12, 2012 Mar NEWA

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

MIRCETTE

AB + TEVA BRANDED PHARM 0.15MG,N/A;0.02MG,0.01MG

N020713 001 Apr 22, 1998 Jun CAHN

VIORELE

AB GLENMARK GENERICS .15MG,N/A; 0.02MG,0.01MG

A091346 001 Apr 02, 2012 Mar NEWA

DESONIDE

LOTION; TOPICAL

DESONIDE

AB FOUGERA PHARMS 0.05%

A075860 001 Mar 19, 2002 Jan CAHN

OINTMENT; TOPICAL

DESONIDE

AB FOUGERA PHARMS 0.05%

A075751 001 Mar 12, 2001 Jan CAHN

DESOXIMETASONE

CREAM; TOPICAL

DESOXIMETASONE

AB FOUGERA PHARMS 0.25%

A078369 001 Jun 29, 2010 Jan CAHN

TOPICORT

+ TARO 0.05%

A073210 001 Nov 30, 1990 Apr CTNA

+ 0.25%

A073193 001 Nov 30, 1990 Apr CTNA

@ TARO PHARMS NORTH 0.25%

N017856 001 Apr DISC

TOPICORT LP

@ TARO PHARMS NORTH 0.05%

N018309 001 Apr DISC

GEL; TOPICAL

TOPICORT

AB + TARO 0.05%

A074904 001 Jul 14, 1998 Apr CTNA

@ TARO PHARMS NORTH 0.05%

N018586 001 Mar 29, 1982 Apr DISC

OINTMENT; TOPICAL						
DESOXIMETASONE						
AB	+	TARO	0.25%	A074286 001	Jun 07, 1996 Mar	CRLD
TOPICORT						
	+	TARO	0.25%	A074286 001	Jun 07, 1996 Apr	CTNA
		@ TARO PHARMS NORTH	0.25%	N018763 001	Sep 30, 1983 Mar	DISC
<u>DEXAMETHASONE SODIUM PHOSPHATE</u>						
INJECTABLE; INJECTION						
DEXAMETHASONE SODIUM PHOSPHATE						
AP	+	APP PHARMS LLC	EQ 10MG PHOSPHATE/ML	A040572 001	Apr 22, 2005 Feb	CRLD
<u>DEXRAZOXANE HYDROCHLORIDE</u>						
INJECTABLE; INJECTION						
TOTECT						
	+	APRICUS PHARMS	EQ 500MG BASE/VIAL	N022025 001	Sep 06, 2007 Jun	CAHN
<u>DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE</u>						
SYRUP; ORAL						
PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE						
AA		TRIS PHARMA INC	15MG/5ML;6.25MG/5ML	A091687 001	Jun 28, 2012 Jun	NEWA
<u>DIAZEPAM</u>						
INJECTABLE; INJECTION						
DIAZEPAM						
		@ HIKMA MAPLE	5MG/ML	A071310 001	Jul 17, 1987 Jul	CAHN
		@	5MG/ML	A071308 001	Jul 17, 1987 Jul	CAHN
		@	5MG/ML	A070312 001	Dec 16, 1985 Jul	CAHN
		@	5MG/ML	A071309 001	Jul 17, 1987 Jul	CAHN
		@	5MG/ML	A070313 001	Dec 16, 1985 Jul	CAHN
		@	5MG/ML	A070311 001	Dec 16, 1985 Jul	CAHN
		@ HOSPIRA	5MG/ML	A071584 001	Oct 13, 1987 Apr	DISC
<u>DICLOFENAC POTASSIUM</u>						
CAPSULE; ORAL						
ZIPSOR						
	+	DEPOMED INC	25MG	N022202 001	Jun 16, 2009 Jun	CAHN
<u>DICLOFENAC SODIUM; MISOPROSTOL</u>						
TABLET, DELAYED RELEASE; ORAL						
ARTHROTEC						
AB		GD SEARLE LLC	50MG;0.2MG	N020607 001	Dec 24, 1997 Jun	CFTG
AB	+		75MG;0.2MG	N020607 002	Dec 24, 1997 Jun	CFTG
DICLOFENAC SODIUM AND MISOPROSTOL						
AB		WATSON LABS INC	50MG;0.2MG	A201089 001	Jul 09, 2012 Jun	NEWA
AB			75MG;0.2MG	A201089 002	Jul 09, 2012 Jun	NEWA
<u>DIDANOSINE</u>						
TABLET, CHEWABLE; ORAL						
DIDANOSINE						
		AUROBINDO	100MG	A077275 001	Aug 14, 2012 Jul	NEWA
			150MG	A077275 002	Aug 14, 2012 Jul	NEWA
			200MG	A077275 003	Aug 14, 2012 Jul	NEWA

DIFLORASONE DIACETATE

CREAM; TOPICAL

DIFLORASONE DIACETATE

BX	+	FOUGERA PHARMS	0.05%	A076263	001	Dec 20, 2002	Jan	CAHN
AB1	+		0.05%	A075187	001	Mar 30, 1998	Jan	CAHN

OINTMENT; TOPICAL

DIFLORASONE DIACETATE

AB		FOUGERA PHARMS	0.05%	A075374	001	Apr 27, 1999	Jan	CAHN
----	--	----------------	-------	---------	-----	--------------	-----	------

DIFLUNISAL

TABLET; ORAL

DIFLUNISAL

AB		EMCURE PHARMS USA	500MG	A202845	001	Mar 08, 2012	Feb	NEWA
AB	+	TEVA	500MG	A073673	001	Jul 31, 1992	Feb	CTEC

DIGOXIN

INJECTABLE; INJECTION

DIGOXIN

AP		HIKMA MAPLE	0.25MG/ML	A083391	001		Jul	CAHN
		@ HOSPIRA	0.25MG/ML	A040093	001	May 16, 1996	Jun	DISC

TABLET; ORAL

DIGOXIN

		@ MYLAN PHARMS INC	0.125MG	A040282	001	Dec 23, 1999	Jul	CAHN
		@	0.25MG	A040282	002	Dec 23, 1999	Jul	CAHN

DILTIAZEM HYDROCHLORIDE

INJECTABLE; INJECTION

DILTIAZEM HYDROCHLORIDE

AP		HIKMA FARMACEUTICA	5MG/ML	A202651	001	Aug 09, 2012	Jul	NEWA
AP		HIKMA MAPLE	5MG/ML	A078538	001	Dec 17, 2008	Jul	CAHN
		@ TEVA PARENTERAL	5MG/ML	A074894	001	Aug 26, 1997	Jan	DISC

DINOPROSTONEINSERT, EXTENDED RELEASE; VAGINAL
CERVIDIL

+	FERRING CONTROLLED	10MG	N020411	001	Mar 30, 1995	Jul	CAHN
---	--------------------	------	---------	-----	--------------	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

BENADRYL

		@ MCNEIL CONS	50MG/ML	N006146	002		Mar	DISC
--	--	---------------	---------	---------	-----	--	-----	------

BENADRYL PRESERVATIVE FREE

		@ MCNEIL CONS	50MG/ML	N009486	001		Mar	DISC
--	--	---------------	---------	---------	-----	--	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE

AP	+	BAXTER HLTHCARE	50MG/ML	A080817	002		Apr	CRLD
		@ HIKMA MAPLE	50MG/ML	A083183	001		Jul	CAHN
AP	+		50MG/ML	A080817	002		Jul	CAHN

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

AP		HIKMA MAPLE	5MG/ML	A074521	001	Oct 18, 1996	Jul	CAHN
		@ TEVA PARENTERAL	5MG/ML	A074952	001	Nov 26, 1997	Jan	DISC

TABLET; ORAL

DIPYRIDAMOLE

AB	PROSAM LABS	25MG	A040542 001	Apr 21, 2006	Feb	CAHN
AB		50MG	A040542 002	Apr 21, 2006	Feb	CAHN
AB		75MG	A040542 003	Apr 21, 2006	Feb	CAHN

DISOPYRAMIDE PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL

DISOPYRAMIDE PHOSPHATE

@ NESHER PHARMS	EQ 150MG BASE	A071200 001	Dec 15, 1987	Jun	DISC
-----------------	---------------	-------------	--------------	-----	------

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE; ORAL

DIVALPROEX SODIUM

AB	DR REDDYS LABS LTD	EQ 250MG VALPROIC ACID	A090161 001	Mar 15, 2012	Feb	NEWA
AB	REDDYS	EQ 500MG VALPROIC ACID	A090070 001	Mar 12, 2012	Feb	NEWA

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

AP	ACCORD HLTHCARE	20MG/ML (20MG/ML)	N201195 003	Apr 20, 2012	Apr	NEWA
AP		20MG/0.5ML (40MG/ML)	N201195 001	Jun 08, 2011	Jan	CTEC
AP		80MG/4ML (20MG/ML)	N201195 004	Apr 20, 2012	Apr	NEWA
AP		80MG/2ML (40MG/ML)	N201195 002	Jun 08, 2011	Jan	CTEC
		160MG/8ML (20MG/ML)	N201195 005	Apr 20, 2012	Apr	NEWA
AP	APOTEX INC	20MG/0.5ML (40MG/ML)	N022312 001	Jan 11, 2012	Jan	NEWA
AP		80MG/2ML (40MG/ML)	N022312 002	Jan 11, 2012	Jan	NEWA
	TAXOTERE					
AP	+ SANOFI AVENTIS US	20MG/ML (20MG/ML)	N020449 003	Aug 03, 2010	Apr	CTEC
AP	+	80MG/4ML (20MG/ML)	N020449 004	Aug 02, 2010	Apr	CTEC

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

	AB	INDICUS PHARMA	5MG	A201634 001	Jun 13, 2012	Jul	NEWA
	AB		10MG	A201634 002	Jun 13, 2012	Jul	NEWA
>A>	AB	MACLEODS PHARMS LTD	5MG	A201146 001	Aug 17, 2012	Aug	NEWA
>A>	AB		10MG	A201146 002	Aug 17, 2012	Aug	NEWA
	AB	PRINSTON INC	5MG	A200292 001	May 31, 2011	Jun	CAHN
	AB		10MG	A200292 002	May 31, 2011	Jun	CAHN

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

COSOPT PF

+ MERCK SHARP DOHME	EQ 2% BASE;EQ 0.5% BASE	N202667 001	Feb 01, 2012	Feb	NEWA
---------------------	-------------------------	-------------	--------------	-----	------

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

@ NESHER PHARMS	EQ 1MG BASE	A075609 001	Oct 18, 2000	Feb	DISC
@	EQ 2MG BASE	A075609 002	Oct 18, 2000	Feb	DISC
@	EQ 4MG BASE	A075609 003	Oct 18, 2000	Feb	DISC
@	EQ 8MG BASE	A075609 004	Oct 18, 2000	Feb	DISC

DOXEPIN HYDROCHLORIDE

CREAM; TOPICAL

ZONALON

+	FOUGERA PHARMS	5%	N020126 001	Apr 01, 1994	Jan	CAHN
---	----------------	----	-------------	--------------	-----	------

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

AP	ONCO THERAPIES LTD	2MG/ML	A200901 001	Feb 14, 2012	Jan	NEWA
AP	SANDOZ INC	2MG/ML	A200146 001	Jul 18, 2012	Jul	NEWA
AP	SUN PHARM INDS	2MG/ML	A091418 001	Feb 15, 2012	Jan	NEWA

INJECTABLE, LIPOSOMAL; INJECTION

DOXIL

+	JANSSEN R AND D	20MG/10ML (2MG/ML)	N050718 001	Nov 17, 1995	Jan	CAHN
+		50MG/25ML (2MG/ML)	N050718 002	Jun 13, 2000	Jan	CAHN

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

AB	MYLAN PHARMS INC	EQ 150MG BASE	A202778 001	Jun 08, 2012	May	NEWA
	@ SANDOZ INC	EQ 50MG BASE	A065032 001	Jun 30, 2000	Mar	DISC
	@	EQ 100MG BASE	A065032 002	Jun 30, 2000	Mar	DISC

MONODOX

AB	AQUA PHARMS	EQ 50MG BASE	N050641 002	Feb 10, 1992	Jul	CAHN
AB		EQ 75MG BASE	N050641 003	Oct 18, 2006	Jul	CAHN
AB	+	EQ 100MG BASE	N050641 001	Dec 29, 1989	Jul	CAHN

TABLET; ORAL

DOXYCYCLINE

	@ SANDOZ INC	EQ 50MG BASE	A065353 001	Nov 27, 2006	Mar	DISC
	@	EQ 75MG BASE	A065353 002	Nov 27, 2006	Mar	DISC
	@	EQ 100MG BASE	A065353 003	Nov 27, 2006	Mar	DISC

DOXYCYCLINE HYCLATE

INJECTABLE; INJECTION

DOXYCYCLINE

	@ HIKMA MAPLE	EQ 100MG BASE/VIAL	A062450 001	Oct 27, 1983	Jul	CAHN
	@	EQ 200MG BASE/VIAL	A062450 002	Oct 27, 1983	Jul	CAHN
>A> AP	PFIZER	EQ 100MG BASE/VIAL	A091406 001	Aug 21, 2012	Aug	NEWA
	DOXYCYCLINE HYCLATE					
	@ HIKMA MAPLE	EQ 100MG BASE/VIAL	A062992 001	Feb 16, 1989	Jul	CAHN
	@	EQ 200MG BASE/VIAL	A062992 002	Feb 16, 1989	Jul	CAHN

TABLET; ORAL

DOXYCYCLINE HYCLATE

AB	LARKEN LABS	EQ 20MG BASE	A065287 001	Feb 28, 2006	Apr	CMFD
----	-------------	--------------	-------------	--------------	-----	------

TABLET, DELAYED RELEASE; ORAL

DORYX

AB	+	MAYNE PHARMA	EQ 150MG BASE	N050795 003	Jun 20, 2008	Jan	CTEC
		DOXYCYCLINE HYCLATE					
AB		MYLAN PHARMS INC	EQ 150MG BASE	A091052 001	Feb 08, 2012	Jan	NEWA

DROSPIRENONE; ESTRADIOL

TABLET; ORAL

ANGELIQ

	BAYER HLTHCARE	0.25MG;0.5MG	N021355 001	Feb 29, 2012	Feb	NEWA
--	----------------	--------------	-------------	--------------	-----	------

ECONAZOLE NITRATE

CREAM; TOPICAL

ECONAZOLE NITRATE

AB	+	FOUGERA PHARMS	1%	A076075 001	Nov 26, 2002	Jan	CAHN
----	---	----------------	----	-------------	--------------	-----	------

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

COMPLERA

+	GILEAD SCIENCES INC	200MG;EQ 25MG BASE;300MG	N202123 001	Aug 10, 2011	Apr	CAIN
---	---------------------	--------------------------	-------------	--------------	-----	------

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

@	SANDOZ INC	2.5MG	A075621 001	Aug 22, 2000	Feb	DISC
@		2.5MG	A075496 001	Aug 22, 2000	Jan	DISC
@		5MG	A075621 002	Aug 22, 2000	Feb	DISC
@		5MG	A075496 002	Aug 22, 2000	Jan	DISC
@		10MG	A075621 003	Aug 22, 2000	Feb	DISC
@		10MG	A075459 001	Aug 22, 2000	Jan	DISC
@		20MG	A075621 004	Aug 22, 2000	Feb	DISC
@		20MG	A075459 002	Aug 22, 2000	Jan	DISC

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

@	SANDOZ INC	5MG;12.5MG	A076116 001	Sep 19, 2001	Mar	DISC
@		10MG;25MG	A076116 002	Sep 19, 2001	Mar	DISC

ENFLURANE

LIQUID; INHALATION

ETHRANE

AN	+	BAXTER HLTHCARE	99.9%	N017087 001		Jul	CAHN
----	---	-----------------	-------	-------------	--	-----	------

ENTACAPONE

TABLET; ORAL

COMTAN

AB	+	ORION PHARMA	200MG	N020796 001	Oct 19, 1999	Jul	CFTG
	+		200MG	N020796 001	Oct 19, 1999	May	CAHN

ENTACAPONE

AB		SUN PHARMA GLOBAL	200MG	A090690 001	Jul 16, 2012	Jul	NEWA
AB		WOCKHARDT LTD	200MG	A078941 001	Aug 16, 2012	Jul	NEWA

>A> ENZALUTAMIDE

>A> CAPSULE; ORAL

>A> XTANDI

>A>	+	MEDIVATION	40MG	N203415 001	Aug 31, 2012	Aug	NEWA
-----	---	------------	------	-------------	--------------	-----	------

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

EPINASTINE HYDROCHLORIDE

AT		LUITPOLD	0.05%	A090951 001	Oct 31, 2011	Mar	CAHN
----	--	----------	-------	-------------	--------------	-----	------

EPINEPHRINE

INJECTABLE; IM-SC

ADRENALINE

BX	+	COREPHARMA	EQ 0.15MG/DELIVERY	N020800 003	Nov 25, 2009	Mar	CAHN
BX	+		EQ 0.3MG/DELIVERY	N020800 004	Nov 25, 2009	Mar	CAHN
>A>		AUVI-Q					
>A>	BX	+	INTELLIJECT	EQ 0.15MG/DELIVERY	N201739 002	Aug 10, 2012	Aug NEWA
>A>	BX		EQ 0.3MG/DELIVERY	N201739 001	Aug 10, 2012	Aug	NEWA
		TWINJECT 0.15					
BX	+	COREPHARMA	EQ 0.15MG/DELIVERY	N020800 002	May 28, 2004	Mar	CAHN
		TWINJECT 0.3					
BX	+	COREPHARMA	EQ 0.3MG/DELIVERY	N020800 001	May 30, 2003	Mar	CAHN

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

OCTOCAINE

AP	+	SEPTODONT	0.01MG/ML;2%	A084048 001		May	CRLD
		XYLOCAINE DENTAL WITH EPINEPHRINE					
		@ DENTSPLY PHARM	0.01MG/ML;2%	N021381 001		May	DISC
		@	0.02MG/ML;2%	N021381 002		May	DISC

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE

AP		CIPLA LTD	200MG/100ML (2MG/ML)	A065361 002	Oct 22, 2007	Mar	CAHN
AP			50MG/25ML (2MG/ML)	A065361 001	Oct 22, 2007	Mar	CAHN
AP		HISUN PHARM HANGZHOU	50MG/25ML (2MG/ML)	A090075 001	Mar 25, 2010	Mar	CAHN
AP			200MG/100ML (2MG/ML)	A090075 002	Mar 25, 2010	Mar	CAHN
AP		ONCO THERAPIES LTD	50MG/25ML (2MG/ML)	A091599 001	Mar 12, 2012	Mar	NEWA
AP			200MG/100ML (2MG/ML)	A091599 002	Mar 12, 2012	Mar	NEWA

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION

VELETRI

		ACTELION PHARMS LTD	EQ 0.5MG BASE/VIAL	N022260 002	Jun 28, 2012	Jun	NEWA
	+		EQ 1.5MG BASE/VIAL	N022260 001	Jun 27, 2008	May	CAHN

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

ERYC

AB		WARNER CHILCOTT LLC	250MG	A062338 001		Jun	CAHN
----	--	---------------------	-------	-------------	--	-----	------

GEL; TOPICAL

E-GLADES

>D>		@ COREPHARMA	2%	A065009 001	Mar 18, 2002	Aug	CAHN
		@	2%	A065009 001	Mar 18, 2002	Jul	DISC
>A>		@ RENAISSANCE PHARMA	2%	A065009 001	Mar 18, 2002	Aug	CAHN

ERYTHROMYCIN

AT		FOUGERA PHARMS	2%	A064184 001	Sep 30, 1997	Jan	CAHN
----	--	----------------	----	-------------	--------------	-----	------

SOLUTION; TOPICAL

C-SOLVE-2

AT		FOUGERA PHARMS	2%	A062468 001	Jul 03, 1985	Jan	CMFD
----	--	----------------	----	-------------	--------------	-----	------

ERYTHROMYCIN

>D>		@ COREPHARMA	2%	A064127 001	Feb 14, 1997	Aug	CAHN
>A>		@ RENAISSANCE PHARMA	2%	A064127 001	Feb 14, 1997	Aug	CAHN

SWAB; TOPICAL

ERYCETTE

@ JOHNSON AND JOHNSON

2%

N050594 001 Feb 15, 1985 Apr CAHN

ERYTHROMYCIN

AT + FOUGERA PHARMS 2%

A065320 001 Jul 25, 2006 Jan CAHN

ESCITALOPRAM OXALATE

SOLUTION; ORAL

ESCITALOPRAM OXALATE

AA AMNEAL PHARMS EQ 5MG BASE/5ML A202227 001 Mar 14, 2012 Feb NEWA

AA AUROBINDO PHARMA LTD EQ 5MG BASE/5ML A079062 001 Apr 02, 2012 Mar NEWA

AA HETERO LABS LTD III EQ 5MG BASE/5ML A202221 001 Jun 12, 2012 May NEWA

AA TARO EQ 5MG BASE/5ML A079121 001 May 03, 2012 Apr NEWA

LEXAPRO

AA + FOREST LABS EQ 5MG BASE/5ML N021365 001 Nov 27, 2002 Feb CFTG

TABLET; ORAL

ESCITALOPRAM OXALATE

>A> AB ACCORD HLTHCARE EQ 5MG BASE A202389 001 Sep 11, 2012 Aug NEWA

>A> AB EQ 10MG BASE A202389 002 Sep 11, 2012 Aug NEWA

>A> AB EQ 20MG BASE A202389 003 Sep 11, 2012 Aug NEWA

>A> AB APOTEX INC EQ 5MG BASE A078777 001 Sep 11, 2012 Aug NEWA

>A> AB EQ 10MG BASE A078777 002 Sep 11, 2012 Aug NEWA

>A> AB EQ 20MG BASE A078777 003 Sep 11, 2012 Aug NEWA

>A> AB AUROBINDO PHARMA LTD EQ 5MG BASE A090432 001 Sep 11, 2012 Aug NEWA

>A> AB EQ 10MG BASE A090432 002 Sep 11, 2012 Aug NEWA

>A> AB EQ 20MG BASE A090432 003 Sep 11, 2012 Aug NEWA

>A> AB HIKMA PHARMS EQ 5MG BASE A078766 001 Sep 11, 2012 Aug NEWA

>A> AB EQ 10MG BASE A078766 002 Sep 11, 2012 Aug NEWA

>A> AB EQ 20MG BASE A078766 003 Sep 11, 2012 Aug NEWA

>A> AB INVAGEN PHARMS EQ 5MG BASE A078604 001 Sep 11, 2012 Aug NEWA

>A> AB EQ 10MG BASE A078604 002 Sep 11, 2012 Aug NEWA

>A> AB EQ 20MG BASE A078604 003 Sep 11, 2012 Aug NEWA

AB IVAX SUB TEVA PHARMS EQ 5MG BASE A076765 001 Mar 14, 2012 Feb NEWA

AB EQ 10MG BASE A076765 002 Mar 14, 2012 Feb NEWA

AB EQ 20MG BASE A076765 003 Mar 14, 2012 Feb NEWA

>A> AB JUBILANT ORGANOSYS EQ 5MG BASE A202280 001 Sep 12, 2012 Aug NEWA

>A> AB EQ 10MG BASE A202280 002 Sep 12, 2012 Aug NEWA

>A> AB EQ 20MG BASE A202280 003 Sep 12, 2012 Aug NEWA

>A> AB LUPIN LTD EQ 5MG BASE A078169 001 Sep 11, 2012 Aug NEWA

>A> AB EQ 10MG BASE A078169 002 Sep 11, 2012 Aug NEWA

>A> AB EQ 20MG BASE A078169 003 Sep 11, 2012 Aug NEWA

>A> AB MACLEODS PHARMS LTD EQ 5MG BASE A202210 001 Sep 11, 2012 Aug NEWA

>A> AB EQ 10MG BASE A202210 002 Sep 11, 2012 Aug NEWA

>A> AB EQ 20MG BASE A202210 003 Sep 11, 2012 Aug NEWA

>A> AB STI PHARMA LLC EQ 5MG BASE A077512 001 Sep 12, 2012 Aug NEWA

>A> AB EQ 10MG BASE A077512 002 Sep 12, 2012 Aug NEWA

>A> AB EQ 20MG BASE A077512 003 Sep 12, 2012 Aug NEWA

>A> AB TORRENT PHARMS LTD EQ 5MG BASE A090939 001 Sep 11, 2012 Aug NEWA

>A> AB EQ 10MG BASE A090939 002 Sep 11, 2012 Aug NEWA

>A> AB EQ 20MG BASE A090939 003 Sep 11, 2012 Aug NEWA

>A> AB ZYDUS PHARMS USA INC EQ 5MG BASE A077734 001 Sep 11, 2012 Aug NEWA

>A> AB EQ 10MG BASE A077734 002 Sep 11, 2012 Aug NEWA

>A> AB EQ 20MG BASE A077734 003 Sep 11, 2012 Aug NEWA

LEXAPRO

AB FOREST LABS EQ 5MG BASE N021323 001 Aug 14, 2002 Feb CFTG

AB EQ 10MG BASE N021323 002 Aug 14, 2002 Feb CFTG

TABLET; ORAL									
LEXAPRO									
AB	+	FOREST LABS	EQ 20MG BASE	N021323	003	Aug 14,	2002	Feb	CFTG
<u>ESMOLOL HYDROCHLORIDE</u>									
INJECTABLE; INJECTION									
BREVIBLOC									
AP	+	BAXTER HLTHCARE	10MG/ML	N019386	006	Feb 25,	2003	Jun	CAHN
		@	10MG/ML	N019386	003	Aug 15,	1988	Jun	CAHN
		@	20MG/ML	N019386	007	May 28,	2003	Jun	CAHN
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER									
+		BAXTER HLTHCARE	2GM/100ML	N019386	005	Jan 27,	2003	Jun	CAHN
BREVIBLOC IN PLASTIC CONTAINER									
+		BAXTER HLTHCARE	1GM/100ML	N019386	004	Feb 16,	2001	Jun	CAHN
<u>ESOMEPRAZOLE MAGNESIUM</u>									
FOR SUSPENSION, DELAYED RELEASE; ORAL									
NEXIUM									
		ASTRAZENECA	EQ 2.5MG BASE/PACKET	N021957	003	Dec 15,	2011	Jun	NEWA
			EQ 5MG BASE/PACKET	N021957	004	Dec 15,	2011	Jun	NEWA
<u>ESTRADIOL</u>									
CREAM; VAGINAL									
ESTRACE									
+		WARNER CHILCOTT US	0.01%	A086069	001	Jan 31,	1984	Jun	CAHN
GEL, METERED; TRANSDERMAL									
ELESTRIN									
+		JAZZ PHARMS COMMERCL	0.06% (0.87GM/ACTIVATION)	N021813	001	Dec 15,	2006	Jun	CAHN
<u>ESTRADIOL ACETATE</u>									
INSERT, EXTENDED RELEASE; VAGINAL									
FEMRING									
		WARNER IRELAND	EQ 0.05MG BASE/24HR	N021367	001	Mar 20,	2003	May	CAHN
+			EQ 0.1MG BASE/24HR	N021367	002	Mar 20,	2003	May	CAHN
TABLET; ORAL									
FEMTRACE									
		WARNER CHILCOTT LLC	0.45MG	N021633	001	Aug 20,	2004	Jun	CAHN
			0.9MG	N021633	002	Aug 20,	2004	Jun	CAHN
+			1.8MG	N021633	003	Aug 20,	2004	Jun	CAHN
<u>ESTRADIOL; NORETHINDRONE ACETATE</u>									
TABLET; ORAL									
ESTRADIOL AND NORETHINDRONE ACETATE									
AB		TEVA PHARMS USA	0.5MG;0.1MG	A200747	001	Mar 08,	2012	Feb	NEWA
<u>ESTROGENS, CONJUGATED SYNTHETIC A</u>									
TABLET; ORAL									
CENESTIN									
		TEVA BRANDED PHARM	0.3MG	N020992	001	Jun 21,	2002	Jun	CAHN
			0.45MG	N020992	005	Feb 05,	2004	Jun	CAHN
			0.625MG	N020992	002	Mar 24,	1999	Jun	CAHN
			0.9MG	N020992	003	Mar 24,	1999	Jun	CAHN
+			1.25MG	N020992	004	Mar 13,	2000	Jun	CAHN

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL									
LEVONORGESTREL AND ETHINYL ESTRADIOL									
	+	WATSON LABS	0.02MG;0.09MG	A079218	001	Jun 06, 2011	May	CRLD	
LOSEASONIQUE									
AB		TEVA BRANDED PHARM	0.02MG,0.01MG;0.1MG,N/A	N022262	001	Oct 24, 2008	Jun	CAHN	
LYBREL									
		@ WYETH PHARMS INC	0.02MG;0.09MG	N021864	001	May 22, 2007	May	DISC	
PREVEN EMERGENCY CONTRACEPTIVE KIT									
		@ TEVA BRANDED PHARM	0.05MG;0.25MG	N020946	001	Sep 01, 1998	Jun	CAHN	
SEASONALE									
AB	+	TEVA BRANDED PHARM	0.03MG;0.15MG	N021544	001	Sep 05, 2003	Jul	CAHN	
SEASONIQUE									
AB	+	TEVA BRANDED PHARM	0.03MG,0.01MG;0.15MG,N/A	N021840	001	May 25, 2006	Jun	CAHN	
TABLET; ORAL-21									
NORDETTE-21									
		@ TEVA BRANDED PHARM	0.03MG;0.15MG	N018668	001	May 10, 1982	Jun	CAHN	
TABLET; ORAL-28									
FALMINA									
AB1		NOVAST LABS LTD	0.02MG;0.1MG	A090721	001	Mar 28, 2012	Mar	NEWA	
MARLISSA									
AB		GLENMARK GENERICS	0.03MG;0.15MG	A091452	001	Feb 29, 2012	Feb	NEWA	
MYZILRA									
AB		VINTAGE PHARMS	0.03MG,0.04MG,0.03MG;0.05MG,0.075 MG,0.125MG	A077502	001	Nov 23, 2011	May	CDFR	
NORDETTE-28									
AB	+	TEVA BRANDED PHARM	0.03MG;0.15MG	N018782	001	Jul 21, 1982	Jun	CAHN	

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE; TRANSDERMAL									
ORTHO EVRA									
	+	JANSSEN PHARMS	0.75MG;6MG	N021180	001	Nov 20, 2001	Jun	CPOT	

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28									
ALYACEN 1/35									
AB		GLENMARK GENERICS	0.035MG;1MG	A091634	001	Jan 19, 2012	Jan	NEWA	
ALYACEN 7/7/7									
AB		GLENMARK GENERICS	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A091636	001	Jan 19, 2012	Jan	NEWA	
OVCON-35									
AB	+	WARNER CHILCOTT LLC	0.035MG;0.4MG	N017716	001		Jun	CAHN	
OVCON-50									
	+	WARNER CHILCOTT LLC	0.05MG;1MG	N017576	001		Jun	CAHN	
WERA									
AB		NOVAST LABS LTD	0.035MG;0.5MG	A091204	001	Mar 27, 2012	Mar	NEWA	
TABLET, CHEWABLE; ORAL									
FEMCON FE									
AB	+	WARNER CHILCOTT LLC	0.035MG;0.4MG	N021490	001	Nov 14, 2003	Jun	CAHN	

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL									
FEMHRT									
		WARNER CHILCOTT LLC	0.0025MG;0.5MG	N021065	001	Jan 14, 2005	Jun	CAHN	
AB	+		0.005MG;1MG	N021065	002	Oct 15, 1999	Jun	CAHN	

TABLET; ORAL

LO LOESTRIN FE

	+	WARNER CHILCOTT LLC	0.01MG,0.01MG;1MG,N/A	N022501 001	Oct 21, 2010	Jun	CAHN
--	---	---------------------	-----------------------	-------------	--------------	-----	------

TABLET; ORAL-21

ESTROSTEP 21

	@	WARNER CHILCOTT LLC	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N020130 001	Oct 09, 1996	Jun	CAHN
--	---	---------------------	-----------------------------------	-------------	--------------	-----	------

LOESTRIN 21 1.5/30

AB		WARNER CHILCOTT LLC	0.03MG;1.5MG	N017875 001		Jun	CAHN
----	--	---------------------	--------------	-------------	--	-----	------

LOESTRIN 21 1/20

AB		WARNER CHILCOTT LLC	0.02MG;1MG	N017876 001		Jun	CAHN
----	--	---------------------	------------	-------------	--	-----	------

TABLET; ORAL-28

ESTROSTEP FE

AB	+	WARNER CHILCOTT LLC	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N020130 002	Oct 09, 1996	Jun	CAHN
----	---	---------------------	-----------------------------------	-------------	--------------	-----	------

LOESTRIN FE 1.5/30

AB	+	WARNER CHILCOTT LLC	0.03MG;1.5MG	N017355 001		Jun	CAHN
----	---	---------------------	--------------	-------------	--	-----	------

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

MONO-LINYAH

AB		NOVAST LABS LTD	0.035MG;0.25MG	A090523 001	May 23, 2012	May	NEWA
----	--	-----------------	----------------	-------------	--------------	-----	------

NORGESTIMATE AND ETHINYL ESTRADIOL

AB		GLENMARK GENERICS	0.035MG;0.25MG	A200538 001	Apr 05, 2012	Mar	NEWA
----	--	-------------------	----------------	-------------	--------------	-----	------

AB		LUPIN PHARMS	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A200541 001	Jun 25, 2012	Jun	NEWA
----	--	--------------	---	-------------	--------------	-----	------

TRI-LINYAH

AB		NOVAST LABS LTD	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A090524 001	May 30, 2012	May	NEWA
----	--	-----------------	---	-------------	--------------	-----	------

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-28

ELINEST

AB		NOVAST LABS LTD	0.03MG;0.3MG	A091105 001	Mar 28, 2012	Mar	NEWA
----	--	-----------------	--------------	-------------	--------------	-----	------

ETHOTOIN

TABLET; ORAL

PEGANONE

>D>	+	LUNDBECK INC	250MG	N010841 001		Aug	CAHN
-----	---	--------------	-------	-------------	--	-----	------

>D>	@		500MG	N010841 003		Aug	CAHN
-----	---	--	-------	-------------	--	-----	------

>A>	+	LUNDBECK LLC	250MG	N010841 001		Aug	CAHN
-----	---	--------------	-------	-------------	--	-----	------

>A>	@		500MG	N010841 003		Aug	CAHN
-----	---	--	-------	-------------	--	-----	------

ETODOLAC

TABLET; ORAL

ETODOLAC

AB		PROSAM LABS	400MG	A074819 001	Feb 28, 1997	Feb	CMFD
----	--	-------------	-------	-------------	--------------	-----	------

AB			500MG	A074819 002	Apr 28, 1998	Feb	CMFD
----	--	--	-------	-------------	--------------	-----	------

ETOMIDATE

INJECTABLE; INJECTION

ETOMIDATE

AP		MYLAN INSTITUTIONAL	2MG/ML	A091297 001	Jun 20, 2012	Jun	NEWA
----	--	---------------------	--------	-------------	--------------	-----	------

ETOPOSIDE

CAPSULE; ORAL

VEPESID

	@	CORDEN PHARMA	50MG	N019557 001	Dec 30, 1986	Feb	CAHN
--	---	---------------	------	-------------	--------------	-----	------

CAPSULE; ORAL

VEPESID

@ CORDEN PHARMA

100MG

N019557 002 Dec 30, 1986 Feb CAHN

INJECTABLE; INJECTION

ETOPOSIDE

AP + APP PHARMS LLC

20MG/ML

A074983 001 Sep 30, 1998 Mar CRLD

AP BEDFORD

20MG/ML

A074290 001 Jul 17, 1995 Mar CRLD

VEPESID

@ CORDEN PHARMA

20MG/ML

N018768 001 Nov 10, 1983 Feb CAHN

ETRAVIRINE

TABLET; ORAL

INTELENCE

JANSSEN R AND D

25MG

N022187 003 Mar 26, 2012 Mar NEWA

100MG

N022187 001 Jan 18, 2008 Feb CAHN

+

200MG

N022187 002 Dec 22, 2010 Feb CAHN

EVEROLIMUS

TABLET; ORAL

AFINITOR

NOVARTIS

7.5MG

N022334 004 Mar 30, 2012 Apr NEWA

>A> TABLET, FOR SUSPENSION; ORAL

>A> AFINITOR DISPERZ

>A> NOVARTIS PHARM

2MG

N203985 001 Aug 29, 2012 Aug NEWA

>A> 3MG

N203985 002 Aug 29, 2012 Aug NEWA

>A> + 5MG

N203985 003 Aug 29, 2012 Aug NEWA

EXENATIDE SYNTHETIC

FOR SUSPENSION, EXTENDED RELEASE; SUBCUTANEOUS

BYDUREON

+ AMYLIN

2MG/VIAL

N022200 001 Jan 27, 2012 Jan NEWA

EZETIMIBE

TABLET; ORAL

ZETIA

+ MSD INTL GMBH

10MG

N021445 001 Oct 25, 2002 Feb CAHN

+ MSP SINGAPORE

10MG

N021445 001 Oct 25, 2002 Jan CAHN

EZETIMIBE; SIMVASTATIN

TABLET; ORAL

VYTORIN

MSD INTL

10MG;10MG

N021687 001 Jul 23, 2004 Jan CAHN

10MG;20MG

N021687 002 Jul 23, 2004 Jan CAHN

10MG;40MG

N021687 003 Jul 23, 2004 Jan CAHN

+ 10MG;80MG

N021687 004 Jul 23, 2004 Jan CAHN

EZOABINE

TABLET; ORAL

POTIGA

GLAXOSMITHKLINE

50MG

N022345 001 Jun 10, 2011 May CAHN

200MG

N022345 002 Jun 10, 2011 May CAHN

300MG

N022345 003 Jun 10, 2011 May CAHN

+ 400MG

N022345 004 Jun 10, 2011 May CAHN

FAMCICLOVIR

TABLET; ORAL

FAMCICLOVIR

AB	MACLEODS PHARMS LTD	125MG	A201022 001	Jan 12, 2012	Jan	NEWA
AB		250MG	A201022 002	Jan 12, 2012	Jan	NEWA
AB		500MG	A201022 003	Jan 12, 2012	Jan	NEWA

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE

AP	+	HIKMA MAPLE	10MG/ML	A075799 001	Apr 30, 2002	Jul	CAHN
AP	+		10MG/ML	A075488 001	Apr 16, 2001	Jul	CAHN
		FAMOTIDINE PRESERVATIVE FREE					
AP	+	HIKMA MAPLE	10MG/ML	A075486 001	Apr 16, 2001	Jul	CAHN
AP	+		10MG/ML	A075789 001	Apr 30, 2002	Jul	CAHN

TABLET; ORAL

PEPCID

AB		MARATHON PHARMS	20MG	N019462 001	Oct 15, 1986	Jan	CAHN
AB	+		40MG	N019462 002	Oct 15, 1986	Jan	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

FLUXID

@ UCB INC

@

20MG

40MG

N021712 001 Sep 24, 2004 Jan CAHN

N021712 002 Sep 24, 2004 Jan CAHN

FEBUXOSTAT

TABLET; ORAL

ULORIC

TAKEDA PHARMS USA

+

40MG

80MG

N021856 001 Feb 13, 2009 Apr CAHN

N021856 002 Feb 13, 2009 Apr CAHN

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

FELODIPINE

AB		WOCKHARDT LTD	2.5MG	A091484 001	Aug 15, 2012	Jul	NEWA
AB			5MG	A091484 002	Aug 15, 2012	Jul	NEWA
AB			10MG	A091484 003	Aug 15, 2012	Jul	NEWA

FENOFIBRATE

CAPSULE; ORAL

ANTARA (MICRONIZED)

AB		LUPIN ATLANTIS	43MG	N021695 001	Nov 30, 2004	Feb	CFTG
AB	+		130MG	N021695 003	Nov 30, 2004	Feb	CFTG

FENOFIBRATE (MICRONIZED)

AB		DR REDDYS LABS SA	43MG	A090859 001	Mar 01, 2012	Feb	NEWA
AB			130MG	A090859 002	Mar 01, 2012	Feb	NEWA

TABLET; ORAL

FENOFIBRATE

AB		IMPAX LABS	160MG	A076509 002	Mar 26, 2008	May	CRLD
AB	+		160MG	A076509 002	Mar 26, 2008	Mar	CRLD
AB		TEVA	54MG	A076433 001	May 13, 2005	May	CMFD
		@	54MG	A076433 001	May 13, 2005	Mar	DISC
AB	+		160MG	A076433 002	May 13, 2005	May	CMFD
		@	160MG	A076433 002	May 13, 2005	Mar	DISC
AB		VALEANT INTL	48MG	A090715 001	Apr 05, 2012	Mar	NEWA
AB			145MG	A090715 002	Apr 05, 2012	Mar	NEWA

FENOPROFEN CALCIUM

CAPSULE; ORAL

NALFON

>D>	+	PEDINOL	EQ 200MG BASE	N017604 003		Aug	CAHN
>D>		@	EQ 300MG BASE	N017604 002		Aug	CAHN
>D>			EQ 400MG BASE	N017604 004	Jul 21, 2009	Aug	CAHN
>A>	+	XSPIRE	EQ 200MG BASE	N017604 003		Aug	CAHN
>A>		@	EQ 300MG BASE	N017604 002		Aug	CAHN
>A>			EQ 400MG BASE	N017604 004	Jul 21, 2009	Aug	CAHN

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

FENTANYL-100

AB		AVEVA	100MCG/HR	A077449 004	Oct 20, 2008	Jun	CAHN
----	--	-------	-----------	-------------	--------------	-----	------

FENTANYL-25

AB		AVEVA	25MCG/HR	A077449 001	Oct 20, 2008	Jun	CAHN
----	--	-------	----------	-------------	--------------	-----	------

FENTANYL-50

AB		AVEVA	50MCG/HR	A077449 002	Oct 20, 2008	Jun	CAHN
----	--	-------	----------	-------------	--------------	-----	------

FENTANYL-75

AB		AVEVA	75MCG/HR	A077449 003	Oct 20, 2008	Jun	CAHN
----	--	-------	----------	-------------	--------------	-----	------

SPRAY; SUBLINGUAL

SUBSYS

INSYS THERAP

			0.1MG	N202788 001	Jan 04, 2012	Mar	CPOT
			0.1MCG	N202788 001	Jan 04, 2012	Jan	NEWA
			0.2MG	N202788 002	Jan 04, 2012	Mar	CPOT
			0.2MCG	N202788 002	Jan 04, 2012	Jan	NEWA
+			0.4MG	N202788 003	Jan 04, 2012	Mar	CPOT
+			0.4MCG	N202788 003	Jan 04, 2012	Jan	NEWA
			0.6MG	N202788 004	Jan 04, 2012	Mar	CPOT
			0.6MCG	N202788 004	Jan 04, 2012	Jan	NEWA
			0.8MG	N202788 005	Jan 04, 2012	Mar	CPOT
			0.8MCG	N202788 005	Jan 04, 2012	Jan	NEWA

FENTANYL CITRATE

SPRAY, METERED; NASAL

LAZANDA

ARCHIMEDES

			EQ 0.1MG BASE	N022569 001	Jun 30, 2011	Jan	CPOT
--	--	--	---------------	-------------	--------------	-----	------

+			EQ 0.4MG BASE	N022569 002	Jun 30, 2011	Jan	CPOT
---	--	--	---------------	-------------	--------------	-----	------

TROCHE/LOZENGE; TRANSMUCOSAL

FENTANYL CITRATE

AB		PAR PHARM	EQ 0.2MG BASE	A077312 001	Oct 30, 2009	Feb	CAHN
AB			EQ 0.4MG BASE	A077312 002	Oct 30, 2009	Feb	CAHN
AB			EQ 0.6MG BASE	A077312 003	Oct 30, 2009	Feb	CAHN
AB			EQ 0.8MG BASE	A077312 004	Oct 30, 2009	Feb	CAHN
AB			EQ 1.2MG BASE	A077312 005	Oct 30, 2009	Feb	CAHN
AB			EQ 1.6MG BASE	A077312 006	Oct 30, 2009	Feb	CAHN

FERUMOXIDES

INJECTABLE; INJECTION

FERIDEX I.V.

@ AMAG PHARMS INC

EQ 11.2MG IRON/ML	N020416 001	Aug 30, 1996	Jun	DISC
-------------------	-------------	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE

SUSPENSION; ORAL

ALLEGRA

AB	+	SANOFI AVENTIS US	30MG/5ML	N021963 001	Oct 16, 2006	Jul	CFTG
FEXOFENADINE HYDROCHLORIDE							
AB		ACTAVIS MID ATLANTIC	30MG/5ML	A201311 001	Jul 25, 2012	Jul	NEWA

FLORBETAPIR F-18

SOLUTION; INTRAVENOUS

AMYVID

+	AVID RADIOPHARMS INC	10-50ML (13.5-51MCI/ML)	N202008 003	Apr 06, 2012	Jun	CPOT
+		10-30ML (13.5-51MCI/ML)	N202008 002	Apr 06, 2012	Apr	NEWA
+		10-50ML (13.5-51MCI/ML)	N202008 003	Apr 06, 2012	Apr	NEWA
+		10ML (13.5-51MCI/ML)	N202008 001	Apr 06, 2012	Apr	NEWA

FLUCONAZOLE

INJECTABLE; INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

>A>	AP	AGILA SPECLTS	200MG/100ML (2MG/ML)	A076888 001	Mar 25, 2005	Aug	CAHN
>A>	AP		400MG/200ML (2MG/ML)	A076888 002	Mar 25, 2005	Aug	CAHN
>D>	AP	APOTEX INC	200MG/100ML (2MG/ML)	A076888 001	Mar 25, 2005	Aug	CAHN
>D>	AP		400MG/200ML (2MG/ML)	A076888 002	Mar 25, 2005	Aug	CAHN
	AP	HIKMA FARMACEUTICA	200MG/100ML (2MG/ML)	A078764 001	Jan 30, 2012	Jan	NEWA
	AP		400MG/200ML (2MG/ML)	A078764 002	Jan 30, 2012	Jan	NEWA

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>A>		@ AGILA SPECLTS	200MG/100ML (2MG/ML)	A076889 001	Mar 25, 2005	Aug	CAHN
>A>		@	400MG/200ML (2MG/ML)	A076889 002	Mar 25, 2005	Aug	CAHN
>D>		@ APOTEX INC	200MG/100ML (2MG/ML)	A076889 001	Mar 25, 2005	Aug	CAHN
>D>		@	400MG/200ML (2MG/ML)	A076889 002	Mar 25, 2005	Aug	CAHN
	AP	HIKMA FARMACEUTICA	200MG/100ML (2MG/ML)	A078698 001	Jan 30, 2012	Jan	NEWA
	AP		400MG/200ML (2MG/ML)	A078698 002	Jan 30, 2012	Jan	NEWA

TABLET; ORAL

FLUCONAZOLE

AB		HARRIS PHARM	50MG	A078423 001	Mar 07, 2011	Jul	CAHN
AB			100MG	A078423 002	Mar 07, 2011	Jul	CAHN
AB			150MG	A078423 003	Mar 07, 2011	Jul	CAHN
AB			200MG	A078423 004	Mar 07, 2011	Jul	CAHN
		@ PLIVA	50MG	A076424 001	Jul 29, 2004	Feb	DISC
		@	100MG	A076424 002	Jul 29, 2004	Feb	DISC
		@	150MG	A076424 003	Jul 29, 2004	Feb	DISC
		@	200MG	A076424 004	Jul 29, 2004	Feb	DISC
		@ RANBAXY LABS LTD	50MG	A076386 001	Jul 29, 2004	Apr	DISC
		@	100MG	A076386 002	Jul 29, 2004	Apr	DISC
		@	150MG	A076386 003	Jul 29, 2004	Apr	DISC
		@	200MG	A076386 004	Jul 29, 2004	Apr	DISC

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARA

@	GENZYME CORP	50MG/VIAL	N020038 001	Apr 18, 1991	Mar	DISC
---	--------------	-----------	-------------	--------------	-----	------

FLUDARABINE PHOSPHATE

AP	+	HOSPIRA	50MG/VIAL	A077790 001	Apr 06, 2007	Mar	CRLD
----	---	---------	-----------	-------------	--------------	-----	------

TABLET; ORAL

OFORTA

@	SANOFI AVENTIS US	10MG	N022273 001	Dec 18, 2008	May	DISC
---	-------------------	------	-------------	--------------	-----	------

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

	AP	HIKMA MAPLE	0.5MG/5ML (0.1MG/ML)	A076787	002	Oct 12, 2004	Jul	CAHN
	AP		1MG/10ML (0.1MG/ML)	A076787	001	Oct 12, 2004	Jul	CAHN
>A>	AP	SAGENT PHARMS	0.5MG/5ML (0.1MG/ML)	A090584	001	Aug 28, 2012	Aug	NEWA
>A>	AP		1MG/10ML (0.1MG/ML)	A090584	002	Aug 28, 2012	Aug	NEWA
		@ TEVA PARENTERAL	0.5MG/5ML (0.1MG/ML)	A076589	002	Oct 12, 2004	Jan	DISC
		@	1MG/10ML (0.1MG/ML)	A076589	001	Oct 12, 2004	Jan	DISC

FLUNISOLIDE

AEROSOL, METERED; INHALATION

AEROSPAN HFA

+	ACTON PHARMS	EQ 78MG BASE/INH	N021247	001	Jan 27, 2006	Jul	CPOT
---	--------------	------------------	---------	-----	--------------	-----	------

SPRAY, METERED; NASAL

FLUNISOLIDE

>D>	AB	HH AND P	0.025MG/SPRAY	A077704	001	Aug 03, 2006	Aug	CAHN
>A>	AB	HI TECH PHARMA CO	0.025MG/SPRAY	A077704	001	Aug 03, 2006	Aug	CAHN

FLUOCINOLONE ACETONIDE

OIL/DROPS; OTIC

FLUOCINOLONE ACETONIDE

AT	IDENTI PHARMS INC	0.01%	A091306	001	Oct 17, 2011	Jan	CPOT
----	-------------------	-------	---------	-----	--------------	-----	------

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDE EMULSIFIED BASE

AB2	FOUGERA PHARMS	0.05%	A076586	001	Jun 23, 2004	Jan	CAHN
	@ G AND W LABS INC	0.05%	A074204	001	Jun 13, 1995	May	CAHN

OINTMENT; TOPICAL

FLUOCINONIDE

AB	FOUGERA PHARMS	0.05%	A074905	001	Aug 26, 1997	Jan	CAHN
----	----------------	-------	---------	-----	--------------	-----	------

FLUOROURACIL

CREAM; TOPICAL

CARAC

+	VALEANT INTL	0.5%	N020985	001	Oct 27, 2000	Jul	CAHN
---	--------------	------	---------	-----	--------------	-----	------

FLUOROPLEX

+	AQUA PHARMS	1%	N016988	001		Jan	CAHN
---	-------------	----	---------	-----	--	-----	------

INJECTABLE; INJECTION

FLUOROURACIL

AP	ONCO THERAPIES LTD	500MG/10ML (50MG/ML)	A202668	001	Jul 17, 2012	Jul	NEWA
AP		1GM/20ML (50MG/ML)	A202668	002	Jul 17, 2012	Jul	NEWA
AP		2.5GM/50ML (50MG/ML)	A202669	001	Jul 17, 2012	Jul	NEWA
AP		5GM/100ML (50MG/ML)	A202669	002	Jul 17, 2012	Jul	NEWA

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

PROZAC

AB1	ELI LILLY AND CO	EQ 10MG BASE	N018936	006	Dec 23, 1992	Apr	CAHN
AB1		EQ 20MG BASE	N018936	001	Dec 29, 1987	Apr	CAHN
AB	+	EQ 40MG BASE	N018936	003	Jun 15, 1999	Apr	CAHN
	@	EQ 60MG BASE	N018936	004	Jun 15, 1999	Apr	CAHN

SARAFEM

AB2	ELI LILLY AND CO	EQ 10MG BASE	N018936	007	Jul 06, 2000	Apr	CAHN
-----	------------------	--------------	---------	-----	--------------	-----	------

CAPSULE; ORAL

SARAFEM

AB2	+	ELI LILLY AND CO	EQ 20MG BASE	N018936 008	Jul 06, 2000	Apr	CAHN
-----	---	------------------	--------------	-------------	--------------	-----	------

TABLET; ORAL

SARAFEM

		WARNER CHILCOTT LLC	EQ 10MG BASE	N021860 001	May 19, 2006	Jun	CAHN
--	--	---------------------	--------------	-------------	--------------	-----	------

			EQ 15MG BASE	N021860 002	May 19, 2006	Jun	CAHN
--	--	--	--------------	-------------	--------------	-----	------

+			EQ 20MG BASE	N021860 003	May 19, 2006	Jun	CAHN
---	--	--	--------------	-------------	--------------	-----	------

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE; ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

AB		TEVA PHARMS	EQ 25MG BASE;EQ 6MG BASE	A077528 001	Jun 19, 2012	Jun	NEWA
----	--	-------------	--------------------------	-------------	--------------	-----	------

AB			EQ 25MG BASE;EQ 12MG BASE	A077528 002	Jun 19, 2012	Jun	NEWA
----	--	--	---------------------------	-------------	--------------	-----	------

AB			EQ 50MG BASE;EQ 6MG BASE	A077528 003	Jun 19, 2012	Jun	NEWA
----	--	--	--------------------------	-------------	--------------	-----	------

AB			EQ 50MG BASE;EQ 12MG BASE	A077528 004	Jun 19, 2012	Jun	NEWA
----	--	--	---------------------------	-------------	--------------	-----	------

SYMBYAX

AB		LILLY	EQ 25MG BASE;EQ 6MG BASE	N021520 002	Dec 24, 2003	Jun	CFTG
----	--	-------	--------------------------	-------------	--------------	-----	------

AB			EQ 25MG BASE;EQ 12MG BASE	N021520 004	Dec 24, 2003	Jun	CFTG
----	--	--	---------------------------	-------------	--------------	-----	------

AB	+		EQ 50MG BASE;EQ 6MG BASE	N021520 003	Dec 24, 2003	Jun	CFTG
----	---	--	--------------------------	-------------	--------------	-----	------

AB			EQ 50MG BASE;EQ 12MG BASE	N021520 005	Dec 24, 2003	Jun	CFTG
----	--	--	---------------------------	-------------	--------------	-----	------

FLURANDRENOLIDE

CREAM; TOPICAL

CORDRAN SP

>D>		AQUA PHARMS	0.025%	N012806 003		Aug	CRLD
-----	--	-------------	--------	-------------	--	-----	------

>A>	+		0.025%	N012806 003		Aug	CRLD
-----	---	--	--------	-------------	--	-----	------

			0.025%	N012806 003		Jul	CAHN
--	--	--	--------	-------------	--	-----	------

>D>			0.05%	N012806 002		Aug	CRLD
-----	--	--	-------	-------------	--	-----	------

>A>	+		0.05%	N012806 002		Aug	CRLD
-----	---	--	-------	-------------	--	-----	------

			0.05%	N012806 002		Jul	CAHN
--	--	--	-------	-------------	--	-----	------

		WATSON PHARMS	0.05%	N012806 002		Apr	CMFD
--	--	---------------	-------	-------------	--	-----	------

LOTION; TOPICAL

CORDRAN

+		AQUA PHARMS	0.05%	N013790 001		Jul	CAHN
---	--	-------------	-------	-------------	--	-----	------

OINTMENT; TOPICAL

CORDRAN

@		AQUA PHARMS	0.025%	N012806 004		Jul	CAHN
---	--	-------------	--------	-------------	--	-----	------

@			0.05%	N012806 001		Jul	CAHN
---	--	--	-------	-------------	--	-----	------

FLUTAMIDE

CAPSULE; ORAL

FLUTAMIDE

AB	+	IVAX SUB TEVA PHARMS	125MG	A075780 001	Sep 19, 2001	Mar	CRLD
----	---	----------------------	-------	-------------	--------------	-----	------

AB		SANDOZ INC	125MG	A075818 001	Sep 18, 2001	Mar	CRLD
----	--	------------	-------	-------------	--------------	-----	------

FLUTICASONE PROPIONATE

CREAM; TOPICAL

CUTIVATE

AB	+	FOUGERA PHARMS	0.05%	N019958 001	Dec 18, 1990	Jan	CAHN
----	---	----------------	-------	-------------	--------------	-----	------

FLUTICASONE PROPIONATE

AB		FOUGERA PHARMS	0.05%	A076451 001	May 14, 2004	Jan	CAHN
----	--	----------------	-------	-------------	--------------	-----	------

@		NESHER PHARMS	0.05%	A076865 001	Sep 10, 2004	Jun	DISC
---	--	---------------	-------	-------------	--------------	-----	------

OINTMENT; TOPICAL

FLUTICASONE PROPIONATE

AB		FOUGERA PHARMS	0.005%	A076300 001	May 14, 2004	Jan	CAHN
----	--	----------------	--------	-------------	--------------	-----	------

FLUVASTATIN SODIUM

CAPSULE; ORAL

FLUVASTATIN SODIUM

AB	MYLAN PHARMS INC	EQ 20MG BASE	A090595 001	Apr 11, 2012	Mar	NEWA
AB		EQ 40MG BASE	A090595 002	Apr 11, 2012	Mar	NEWA
AB	TEVA PHARMS	EQ 20MG BASE	A078407 001	Jun 12, 2012	May	NEWA
AB		EQ 40MG BASE	A078407 002	Jun 12, 2012	May	NEWA
LESCOL						
AB	NOVARTIS	EQ 20MG BASE	N020261 001	Dec 31, 1993	Mar	CFTG
AB	+	EQ 40MG BASE	N020261 002	Dec 31, 1993	Mar	CFTG

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

LUVOX CR

	JAZZ PHARMS	100MG	N022033 001	Feb 28, 2008	Jun	CAHN
+		150MG	N022033 002	Feb 28, 2008	Jun	CAHN

FORMOTEROL FUMARATE; MOMETASONE FUROATE

AEROSOL, METERED; INHALATION

DULERA

+	MERCK SHARP DOHME	0.005MG/INH;0.1MG/INH	N022518 001	Jun 22, 2010	Jun	CAHN
+		0.005MG/INH;0.2MG/INH	N022518 002	Jun 22, 2010	Jun	CAHN

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

@	RANBAXY LABS LTD	10MG	A076580 001	Apr 23, 2004	Apr	DISC
@		20MG	A076580 002	Apr 23, 2004	Apr	DISC
@		40MG	A076580 003	Apr 23, 2004	Apr	DISC
MONOPRIL						
@	BRISTOL MYERS SQUIBB	10MG	N019915 002	May 16, 1991	Mar	DISC
@		20MG	N019915 003	May 16, 1991	Mar	DISC
@		40MG	N019915 004	Mar 28, 1995	Mar	DISC

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

AP	HIKMA MAPLE	EQ 50MG PHENYTOIN NA/ML	A077989 001	Aug 06, 2007	Jul	CAHN
	@ TEVA PARENTERAL	EQ 50MG PHENYTOIN NA/ML	A076886 001	Aug 06, 2007	Mar	DISC

FOSPROPOFOL DISODIUM

SOLUTION; INTRAVENOUS

LUSEDRA

@	EISAI INC	1050MG/30ML (35MG/ML)	N022244 001	Dec 12, 2008	Jul	DISC
---	-----------	-----------------------	-------------	--------------	-----	------

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

@	HOSPIRA	10MG/ML	A070578 001	Jul 08, 1987	Jun	DISC
---	---------	---------	-------------	--------------	-----	------

GABAPENTIN

SOLUTION; ORAL

GABAPENTIN

AA	ACELLA PHARMS LLC	250MG/5ML	A076403 001	May 01, 2012	Jun	CAHN
AA	AMNEAL PHARMS	250MG/5ML	A202024 001	Mar 23, 2012	Mar	NEWA

SOLUTION; ORAL

GABAPENTIN

AA	KIEL	250MG/5ML	A076403 001	May 01, 2012	Apr	NEWA
----	------	-----------	-------------	--------------	-----	------

GANCICLOVIR

CAPSULE; ORAL

GANCICLOVIR

@ RANBAXY LABS LTD

250MG

A076457 001 Jun 27, 2003 Apr DISC

@

500MG

A076457 002 Jun 27, 2003 Apr DISC

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE HYDROCHLORIDE

>A>	AP	EMCURE PHARMS LTD	EQ 200MG BASE/VIAL	A202063 001	Sep 11, 2012	Aug	NEWA
>A>	AP		EQ 1GM BASE/VIAL	A202063 002	Sep 11, 2012	Aug	NEWA
>A>	AP	HAMEIN RDS GMBH	EQ 200MG BASE/VIAL	A090663 001	Sep 10, 2012	Aug	NEWA
>A>	AP		EQ 1GM BASE/VIAL	A090663 002	Sep 10, 2012	Aug	NEWA
	+	HOSPIRA INC	200MG/5.26ML (38MG/ML)	N200795 001	Aug 04, 2011	Apr	CTNA
	+		1GM/26.3ML (38MG/ML)	N200795 002	Aug 04, 2011	Apr	CTNA
	+		2GM/52.6ML (38MG/ML)	N200795 003	Aug 04, 2011	Apr	CTNA

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

AB	AUROBINDO PHARMA LTD	1MG	A202759 001	Jun 29, 2012	Jun	NEWA
AB		2MG	A202759 002	Jun 29, 2012	Jun	NEWA
AB		4MG	A202759 003	Jun 29, 2012	Jun	NEWA
AB	MICRO LABS USA	1MG	A091220 001	Jun 29, 2012	Jun	NEWA
AB		2MG	A091220 002	Jun 29, 2012	Jun	NEWA
		3MG	A091220 003	Jun 29, 2012	Jun	NEWA
AB		4MG	A091220 004	Jun 29, 2012	Jun	NEWA
		6MG	A091220 005	Jun 29, 2012	Jun	NEWA
AB		8MG	A091220 006	Jun 29, 2012	Jun	NEWA
	@ RANBAXY LABS LTD	1MG	A076875 001	Oct 06, 2005	Apr	DISC
	@	2MG	A076875 002	Oct 06, 2005	Apr	DISC
	@	4MG	A076875 003	Oct 06, 2005	Apr	DISC
	@	8MG	A076875 004	Oct 06, 2005	Apr	DISC

GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

DUETACT

>D>	+	TAKEDA GLOBAL	2MG;30MG	N021925 001	Jul 28, 2006	Aug	CAHN
>D>			4MG;30MG	N021925 002	Jul 28, 2006	Aug	CAHN
>A>	+	TAKEDA PHARMS USA	2MG;30MG	N021925 001	Jul 28, 2006	Aug	CAHN
>A>			4MG;30MG	N021925 002	Jul 28, 2006	Aug	CAHN

GLYCOPYRROLATE

SOLUTION; ORAL

CUVPOSA

>A>	+	MERZ PHARMS	1MG/5ML	N022571 001	Jul 28, 2010	Aug	CAHN
>D>	+	SHIONOGI INC	1MG/5ML	N022571 001	Jul 28, 2010	Aug	CAHN

TABLET; ORAL

GLYCOPYRROLATE

AA	NEXGEN PHARMA	1.5MG	A091522 001	Mar 12, 2012	Feb	NEWA
----	---------------	-------	-------------	--------------	-----	------

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

AP	CIPLA LTD	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078262 001	Dec 31, 2007	Mar	CAHN
AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078258 001	Jun 30, 2008	Mar	CAHN
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078258 002	Jun 30, 2008	Mar	CAHN
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE						
AP	+ APP PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078096 001	Jun 30, 2008	Apr	CRLD
	@ TEVA PARENTERAL	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077165 001	Dec 31, 2007	Apr	DISC

GRISEOFULVIN, MICROCRYSTALLINE

SUSPENSION; ORAL

GRIFULVIN V

AB	+ VALEANT PHARM NORTH	125MG/5ML	A062483 001	Jan 26, 1984	Feb	CAHN
TABLET; ORAL						
GRIFULVIN V						
	@ VALEANT INTL	125MG	A062279 001		Jul	CAHN
	@	250MG	A062279 002		Jul	CAHN
	+	500MG	A062279 003		Jul	CAHN

HALOBETASOL PROPIONATE

CREAM; TOPICAL

HALOBETASOL PROPIONATE

AB	FOUGERA PHARMS	0.05%	A077001 001	Dec 16, 2004	Jan	CAHN
OINTMENT; TOPICAL						
HALOBETASOL PROPIONATE						
AB	FOUGERA PHARMS	0.05%	A076903 001	Dec 16, 2004	Jan	CAHN
	@ VENUS PHARMS	0.05%	A077109 001	Jun 14, 2005	Jun	CAHN

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	+ B BRAUN	200 UNITS/100ML	N019953 001	Jul 20, 1992	Jul	CRLD
HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER						
	@ BAXTER HLTHCARE	2,000 UNITS/100ML	N018814 002	Jul 09, 1985	Mar	DISC
HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER						
	@ BAXTER HLTHCARE	4,000 UNITS/100ML	N018814 001	Oct 31, 1983	Mar	DISC
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP	+ B BRAUN	4,000 UNITS/100ML	N019952 001	Jul 20, 1992	Jul	CRLD
HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER						
	@ BAXTER HLTHCARE	5,000 UNITS/100ML	N018814 003	Jul 09, 1985	Mar	DISC
	@	10,000 UNITS/100ML	N018814 004	Jul 02, 1987	Mar	DISC
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP	+ B BRAUN	5,000 UNITS/100ML	N019952 004	Jul 20, 1992	Jul	CRLD
AP	+	10,000 UNITS/100ML	N019952 005	Jul 20, 1992	Jul	CRLD

HEXAMINOLEVULINATE HYDROCHLORIDE

FOR SOLUTION; INTRAVESICAL

CYSVIEW KIT

	+ PHOTOCURE ASA	100MG/VIAL	N022555 001	May 28, 2010	May	CAHN
--	-----------------	------------	-------------	--------------	-----	------

HYALURONIDASE

INJECTABLE; INJECTION

HYDASE

@ AKORN INC

150 UNITS/ML

N021716 001 Oct 25, 2005 Jun DISC

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

AB LANNETT HOLDINGS INC 12.5MG

A091662 001 Jan 27, 2012 Jan NEWA

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVALIDE

AB + SANOFI AVENTIS 12.5MG;150MG

N020758 002 Sep 30, 1997 Mar CFTG

AB + 12.5MG;300MG

N020758 003 Aug 31, 1998 Mar CFTG

+ 12.5MG;300MG

N020758 003 Aug 31, 1998 Feb CRLD

IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB TEVA 12.5MG;150MG

A077369 001 Mar 30, 2012 Mar NEWA

AB 12.5MG;300MG

A077369 002 Mar 30, 2012 Mar NEWA

@ 25MG;300MG

A077369 003 Mar 30, 2012 Apr DISC

25MG;300MG

A077369 003 Mar 30, 2012 Mar NEWA

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB ALEMBIC LTD 12.5MG;50MG

A091617 001 Feb 17, 2012 Feb NEWA

AB 12.5MG;100MG

A091617 002 Feb 17, 2012 Feb NEWA

AB 25MG;100MG

A091617 003 Feb 17, 2012 Feb NEWA

AB MACLEODS PHARMS LTD 12.5MG;50MG

A202289 001 Aug 09, 2012 Jul NEWA

AB 12.5MG;100MG

A202289 002 Aug 09, 2012 Jul NEWA

AB 25MG;100MG

A202289 003 Aug 09, 2012 Jul NEWA

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DUTOPROL

ASTRAZENECA 12.5MG;EQ 25MG TARTRATE

N021956 001 Aug 28, 2006 Jan CMFD

12.5MG;EQ 50MG TARTRATE

N021956 002 Aug 28, 2006 Jan CMFD

+ 12.5MG;EQ 100MG TARTRATE

N021956 003 Aug 28, 2006 Apr CRLD

12.5MG;EQ 100MG TARTRATE

N021956 003 Aug 28, 2006 Jan CMFD

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

AB MYLAN 50MG;100MG

A076792 003 Aug 20, 2004 Jan CTEC

AB SUN PHARM INDS 25MG;50MG

A090654 001 Jan 19, 2012 Jan NEWA

AB 25MG;100MG

A090654 002 Jan 19, 2012 Jan NEWA

AB 50MG;100MG

A090654 003 Jan 19, 2012 Jan NEWA

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@ PADDOCK LLC 12.5MG;7.5MG

A090096 001 Sep 25, 2008 Jan DISC

@ 12.5MG;15MG

A090096 002 Sep 25, 2008 Jan DISC

@ 25MG;15MG

A090096 003 Sep 25, 2008 Jan DISC

HYDROCORTISONE

CREAM; TOPICAL						
NUTRACORT						
	@ DOW PHARM	0.5%	A080442 002		Jun	CAHN
	@	1%	A080442 003		Jun	CAHN
LOTION; TOPICAL						
CETACORT						
	@ DOW PHARM	0.5%	A080426 002		Jun	CAHN
	@	1%	A080426 001		Jun	CAHN
HYDROCORTISONE						
AT	+ FOUGERA PHARMS	2.5%	A040351 001	Jul 25, 2000	Jan	CAHN
NUTRACORT						
	@ DOW PHARM	0.5%	A080443 002		Jun	CAHN
AT		1%	A080443 003		Jun	CAHN
AT		2.5%	A087644 001	Aug 24, 1982	Jun	CAHN
OINTMENT; TOPICAL						
HYDROCORTISONE						
AT	+ FOUGERA PHARMS	1%	A080692 001		Jan	CAHN

HYDROCORTISONE ACETATE; UREA

CREAM; TOPICAL						
CARMOL HC						
AT	FOUGERA PHARMS	1%;10%	A080505 001		Jan	CAHN

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL						
LOCOID						
AB	+ PRECISION DERMAT	0.1%	N018514 001	Mar 31, 1982	Jun	CAHN
LOCOID LIPOCREAM						
	+ PRECISION DERMAT	0.1%	N020769 001	Sep 08, 1997	Jun	CAHN
LOTION; TOPICAL						
LOCOID						
	+ PRECISION DERMAT	0.1%	N022076 001	May 18, 2007	May	CAHN
OINTMENT; TOPICAL						
LOCOID						
AB	+ PRECISION DERMAT	0.1%	N018652 001	Oct 29, 1982	May	CAHN
SOLUTION; TOPICAL						
LOCOID						
AT	+ PRECISION DERMAT	0.1%	N019116 001	Feb 25, 1987	Jun	CAHN

HYDROCORTISONE VALERATE

CREAM; TOPICAL						
HYDROCORTISONE VALERATE						
AB	+ TARO	0.2%	A075042 001	Aug 25, 1998	Mar	CRLD
WESTCORT						
	@ RANBAXY	0.2%	N017950 001		Mar	DISC
OINTMENT; TOPICAL						
HYDROCORTISONE VALERATE						
AB	FOUGERA PHARMS	0.2%	A075085 001	Jul 31, 2001	Jan	CAHN

HYDROFLUMETHIAZIDE

TABLET; ORAL						
SALURON						
AB	+ SHIRE LLC	50MG	N011949 001		Jan	CAHN

HYDROMORPHONE HYDROCHLORIDE

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

@ NESHER PHARMS	2MG	A077311 001	Nov 09, 2005	Jun	DISC
@	4MG	A077311 002	Nov 09, 2005	Jun	DISC
@	8MG	A077311 003	Nov 09, 2005	Jun	DISC

TABLET, EXTENDED RELEASE; ORAL

EXALGO

>A>	MALLINCKRODT INC	32MG	N021217 004	Aug 24, 2012	Aug	NEWA
-----	------------------	------	-------------	--------------	-----	------

HYDROXYZINE HYDROCHLORIDE

SYRUP; ORAL

HYDROXYZINE HYDROCHLORIDE

@ STI PHARMA LLC	10MG/5ML	A086880 001		Feb	CAHN
------------------	----------	-------------	--	-----	------

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

@ MIKAH PHARMA	10MG	A040600 001	Dec 28, 2004	Jul	CAHN
@	25MG	A040602 001	Dec 28, 2004	Jul	CAHN
@	50MG	A040604 001	Dec 28, 2004	Jul	CAHN

HYDROXYZINE PAMOATE

SUSPENSION; ORAL

VISTARIL

@ PFIZER	EQ 25MG HCL/5ML	N011795 001		Jul	DISC
----------	-----------------	-------------	--	-----	------

IBANDRONATE SODIUM

TABLET; ORAL

BONIVA

AB	+	HOFFMANN LA ROCHE	EQ 150MG BASE	N021455 002	Mar 24, 2005	Mar	CFTG
----	---	-------------------	---------------	-------------	--------------	-----	------

IBANDRONATE SODIUM

AB		APOTEX INC	EQ 150MG BASE	A078948 001	Mar 19, 2012	Mar	NEWA
AB		DR REDDYS LABS LTD	EQ 150MG BASE	A078997 001	Apr 30, 2012	Apr	NEWA
AB		MUTUAL PHARM CO INC	EQ 150MG BASE	A078996 001	Aug 15, 2012	Jul	NEWA
AB		MYLAN PHARMS INC	EQ 150MG BASE	A078995 001	Mar 19, 2012	Mar	NEWA
AB		ORCHID HLTHCARE	EQ 150MG BASE	A078998 001	Mar 19, 2012	Mar	NEWA
AB		WATSON LABS INC	EQ 150MG BASE	A079003 001	Mar 20, 2012	Mar	NEWA

IBUPROFEN

TABLET; ORAL

IBUPROFEN

@ NORTHSTAR HLTHCARE	400MG	A078132 001	Sep 10, 2007	Jun	DISC
@	600MG	A078132 002	Sep 10, 2007	Jun	DISC
@	800MG	A078132 003	Sep 10, 2007	Jun	DISC
@ OHM LABS	400MG	A070818 001	Dec 26, 1985	Jun	DISC

IBUPROFEN LYSINE

INJECTABLE; INTRAVENOUS

NEOPROFEN

+	LUNDBECK LLC	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N021903 001	Apr 13, 2006	Mar	CAHN
---	--------------	------------------------------------	-------------	--------------	-----	------

ICOSAPENT ETHYL

CAPSULE; ORAL

VASCEPA

+	AMARIN PHARMA INC	1GM	N202057 001	Jul 26, 2012	Jul	NEWA
---	-------------------	-----	-------------	--------------	-----	------

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDARUBICIN HYDROCHLORIDE

@ TEVA PARENTERAL	5MG/VIAL	A065037 003	May 01, 2002	Mar	DISC
@	10MG/VIAL	A065037 002	May 01, 2002	Mar	DISC
@	20MG/VIAL	A065037 001	May 01, 2002	Mar	DISC

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

AB	PROSAM LABS	10MG	A040753 001	Feb 28, 2008	Feb	CMFD
AB		25MG	A040752 001	Feb 28, 2008	Feb	CMFD
AB		50MG	A040751 001	Feb 28, 2008	Feb	CMFD

IMIQUIMOD

CREAM; TOPICAL

IMIQUIMOD

AB	APOTEX INC	5%	A091308 001	Apr 06, 2012	Mar	NEWA
AB	FOUGERA PHARMS	5%	A078548 001	Feb 25, 2010	Jan	CAHN
AB	GLENMARK GENERICS	5%	A201994 001	Mar 06, 2012	Feb	NEWA

INDOMETHACIN SODIUM

INJECTABLE; INJECTION

INDOCIN

AP	+	LUNDBECK LLC	EQ 1MG BASE/VIAL	N018878 001	Jan 30, 1985	Mar	CAHN
----	---	--------------	------------------	-------------	--------------	-----	------

INGENOL MEBUTATE

GEL; TOPICAL

PICATO

		LEO PHARMA AS	0.015%	N202833 001	Jan 23, 2012	Jan	NEWA
	+		0.05%	N202833 002	Jan 23, 2012	Jan	NEWA

INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION

HUMALOG MIX 50/50 PEN

@ LILLY	50 UNITS/ML;50 UNITS/ML	N021018 003	Dec 22, 1999	Jun	DISC
---------	-------------------------	-------------	--------------	-----	------

HUMALOG MIX 75/25 PEN

@ LILLY	75 UNITS/ML;25 UNITS/ML	N021017 003	Dec 22, 1999	Jun	DISC
---------	-------------------------	-------------	--------------	-----	------

INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION

HUMALOG PEN

@ LILLY	100 UNITS/ML	N020563 002	Aug 06, 1998	Jun	DISC
---------	--------------	-------------	--------------	-----	------

IRBESARTAN

TABLET; ORAL

AVAPRO

AB	SANOFI AVENTIS US	75MG	N020757 001	Sep 30, 1997	Mar	CFTG
AB		150MG	N020757 002	Sep 30, 1997	Mar	CFTG
AB	+	300MG	N020757 003	Sep 30, 1997	Mar	CFTG

IRBESARTAN

AB	TEVA PHARMS	75MG	A077159 001	Mar 30, 2012	Mar	NEWA
AB		150MG	A077159 002	Mar 30, 2012	Mar	NEWA
AB		300MG	A077159 003	Mar 30, 2012	Mar	NEWA

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

AP	CIPLA LTD	40MG/2ML (20MG/ML)	A077219 001	Feb 20, 2008	Mar	CAHN
AP		100MG/5ML (20MG/ML)	A077219 002	Feb 20, 2008	Mar	CAHN
AP	EMCURE PHARMS LTD	40MG/2ML (20MG/ML)	A200771 001	Feb 14, 2012	Jan	NEWA
AP		100MG/5ML (20MG/ML)	A200771 002	Feb 14, 2012	Jan	NEWA
AP	HISUN PHARM HANGZHOU	40MG/2ML (20MG/ML)	A090016 001	Jan 28, 2009	Mar	CAHN
AP		100MG/5ML (20MG/ML)	A090016 002	Jan 28, 2009	Mar	CAHN
AP	TEVA PARENTERAL	40MG/2ML (20MG/ML)	A090101 002	Feb 27, 2008	Jun	NEWA
AP		100MG/5ML (20MG/ML)	A090101 003	Feb 27, 2008	Jun	NEWA
AP		500MG/25ML (20MG/ML)	A090101 001	Nov 26, 2008	Jun	CMFD
	@	500MG/25ML (20MG/ML)	A090101 001	Nov 26, 2008	Mar	DISC

ISOFLURANE

LIQUID; INHALATION

FORANE

AN	+ BAXTER HLTHCARE	99.9%	N017624 001		Jul	CAHN
----	-------------------	-------	-------------	--	-----	------

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE MONONITRATE

AB	ALKERMES GAINESVILLE	60MG	A075041 001	Sep 22, 1998	Jun	CAHN
	@ SKYEPHARMA AG	60MG	A075166 001	Oct 07, 1999	Jan	DISC

ISOTRETINOIN

CAPSULE; ORAL

ABSORICA

CIPHER

		10MG	N021951 001	May 25, 2012	May	NEWA
		20MG	N021951 002	May 25, 2012	May	NEWA
		30MG	N021951 003	May 25, 2012	May	NEWA
		40MG	N021951 004	May 25, 2012	May	NEWA
	MYORISAN					
AB	DOUGLAS PHARMS	10MG	A076485 001	Jan 19, 2012	Jan	NEWA
AB		20MG	A076485 002	Jan 19, 2012	Jan	NEWA
AB		40MG	A076485 003	Jan 19, 2012	Jan	NEWA

ITRACONAZOLE

CAPSULE; ORAL

ITRACONAZOLE

AB	MYLAN PHARMS INC	100MG	A200463 001	Jul 20, 2012	Jul	NEWA
----	------------------	-------	-------------	--------------	-----	------

IVACAFTOR

TABLET; ORAL

KALYDECO

	+ VERTEX PHARMS	150MG	N203188 001	Jan 31, 2012	Jan	NEWA
--	-----------------	-------	-------------	--------------	-----	------

IVERMECTIN

LOTION; TOPICAL

SKLICE

	+ SANOFI PASTEUR	0.5%	N202736 001	Feb 07, 2012	Feb	NEWA
--	------------------	------	-------------	--------------	-----	------

KETOCONAZOLE

CREAM; TOPICAL

KETOCONAZOLE

AB	FOUGERA PHARMS	2%	A076294 001	Apr 28, 2004	Jan	CAHN
----	----------------	----	-------------	--------------	-----	------

KETOPROFEN

CAPSULE; ORAL

KETOPROFEN

	DORADO PHARMA	25MG	A074014 001	Jan 29, 1993	Jul	CAHN
--	---------------	------	-------------	--------------	-----	------

AB		50MG	A074014 002	Jan 29, 1993	Jul	CAHN
----	--	------	-------------	--------------	-----	------

AB		75MG	A074014 003	Jan 29, 1993	Jul	CAHN
----	--	------	-------------	--------------	-----	------

CAPSULE, EXTENDED RELEASE; ORAL

KETOPROFEN

AB	ALKERMES GAINESVILLE	200MG	A074879 001	Dec 10, 1997	Jun	CAHN
----	----------------------	-------	-------------	--------------	-----	------

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HYDROCHLORIDE

AP	GLAND PHARMA LTD	5MG/ML	A090699 001	Apr 03, 2012	Mar	NEWA
----	------------------	--------	-------------	--------------	-----	------

TABLET; ORAL

LABETALOL HYDROCHLORIDE

AB	PAR FORM	100MG	A200908 001	Jul 10, 2012	Jun	NEWA
----	----------	-------	-------------	--------------	-----	------

AB		200MG	A200908 002	Jul 10, 2012	Jun	NEWA
----	--	-------	-------------	--------------	-----	------

AB		300MG	A200908 003	Jul 10, 2012	Jun	NEWA
----	--	-------	-------------	--------------	-----	------

LACTULOSE

FOR SOLUTION; ORAL

LACTULOSE

+	CUMBERLAND PHARMS	10GM/PACKET	A074712 001	Dec 10, 1997	Jun	CAHN
---	-------------------	-------------	-------------	--------------	-----	------

+		20GM/PACKET	A074712 002	Dec 10, 1997	Jun	CAHN
---	--	-------------	-------------	--------------	-----	------

SOLUTION; ORAL

LACTULOSE

AA	FRESENIUS KABI	10GM/15ML	A090503 001	Jan 25, 2012	Jan	NEWA
----	----------------	-----------	-------------	--------------	-----	------

SOLUTION; ORAL, RECTAL

LACTULOSE

AA	FRESENIUS KABI	10GM/15ML	A090502 001	Jan 25, 2012	Jan	NEWA
----	----------------	-----------	-------------	--------------	-----	------

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

LAMIVUDINE AND ZIDOVUDINE

AB	AUROBINDO PHARMA LTD	150MG;300MG	A202418 001	May 15, 2012	Apr	NEWA
----	----------------------	-------------	-------------	--------------	-----	------

AB	LUPIN LTD	150MG;300MG	A090246 001	May 15, 2012	Apr	NEWA
----	-----------	-------------	-------------	--------------	-----	------

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

AB	GLENMARK GENERICS	25MG	A090169 001	May 12, 2012	Apr	NEWA
----	-------------------	------	-------------	--------------	-----	------

AB		100MG	A090169 002	May 12, 2012	Apr	NEWA
----	--	-------	-------------	--------------	-----	------

AB		150MG	A090169 003	May 12, 2012	Apr	NEWA
----	--	-------	-------------	--------------	-----	------

AB		200MG	A090169 004	May 12, 2012	Apr	NEWA
----	--	-------	-------------	--------------	-----	------

>D>	AB	UPSHER SMITH	25MG	A078310 001	Feb 04, 2009	Aug	CTEC
-----	----	--------------	------	-------------	--------------	-----	------

>A>	BX		25MG	A078310 001	Feb 04, 2009	Aug	CTEC
-----	----	--	------	-------------	--------------	-----	------

>D>	AB		100MG	A078310 002	Feb 04, 2009	Aug	CTEC
-----	----	--	-------	-------------	--------------	-----	------

>A>	BX		100MG	A078310 002	Feb 04, 2009	Aug	CTEC
-----	----	--	-------	-------------	--------------	-----	------

>D>	AB		150MG	A078310 003	Feb 04, 2009	Aug	CTEC
-----	----	--	-------	-------------	--------------	-----	------

TABLET; ORAL

LAMOTRIGINE

>A>	BX	UPSHER SMITH	150MG	A078310 003	Feb 04, 2009	Aug	CTEC
>D>	AB		200MG	A078310 004	Feb 04, 2009	Aug	CTEC
>A>	BX		200MG	A078310 004	Feb 04, 2009	Aug	CTEC

LANREOTIDE ACETATE

INJECTABLE; SUBCUTANEOUS

SOMATULINE DEPOT

+	IPSEN INC	EQ 60MG BASE	N022074 001	Aug 30, 2007	Apr	CAHN
+		EQ 90MG BASE	N022074 002	Aug 30, 2007	Apr	CAHN
+		EQ 120MG BASE	N022074 003	Aug 30, 2007	Apr	CAHN
+	IPSEN PHARMA	EQ 60MG BASE	N022074 001	Aug 30, 2007	May	CAHN
+		EQ 90MG BASE	N022074 002	Aug 30, 2007	May	CAHN
+		EQ 120MG BASE	N022074 003	Aug 30, 2007	May	CAHN

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

LANSOPRAZOLE

>A>	AB	WOCKHARDT USA	15MG	A202176 001	Sep 14, 2012	Aug	NEWA
>A>	AB		30MG	A202176 002	Sep 14, 2012	Aug	NEWA

PREVACID

AB	TAKEDA PHARMS USA	15MG	N020406 001	May 10, 1995	Mar	CAHN
AB	+	30MG	N020406 002	May 10, 1995	Mar	CAHN

TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING; ORAL

LANSOPRAZOLE

@	TEVA PHARMS	15MG	A078730 001	Oct 15, 2010	Mar	DISC
@		30MG	A078730 002	Oct 15, 2010	Mar	DISC

PREVACID

	TAKEDA PHARMS USA	15MG	N021428 001	Aug 30, 2002	Mar	CTEC
+		30MG	N021428 002	Aug 30, 2002	Mar	CTEC

LANTHANUM CARBONATE

TABLET, CHEWABLE; ORAL

FOSRENOL

@	SHIRE LLC	EQ 250MG BASE	N021468 001	Oct 26, 2004	Feb	CAHN
		EQ 500MG BASE	N021468 002	Oct 26, 2004	Feb	CAHN
		EQ 750MG BASE	N021468 003	Nov 23, 2005	Feb	CAHN
+		EQ 1GM BASE	N021468 004	Nov 23, 2005	Feb	CAHN

LETROZOLE

TABLET; ORAL

LETROZOLE

AB	APOTEX INC	2.5MG	A091303 001	Apr 19, 2012	Apr	NEWA
----	------------	-------	-------------	--------------	-----	------

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

@	TEVA PARENTERAL	EQ 50MG BASE/VIAL	A081278 001	Sep 28, 1993	Mar	DISC
---	-----------------	-------------------	-------------	--------------	-----	------

LEUCOVORIN CALCIUM PRESERVATIVE FREE

>A>	AP	SAGENT PHARMS	EQ 50MG BASE/VIAL	A200753 001	Sep 06, 2012	Aug	NEWA
>A>	AP		EQ 100MG BASE/VIAL	A200753 002	Sep 06, 2012	Aug	NEWA
>A>	AP		EQ 200MG BASE/VIAL	A200753 003	Sep 06, 2012	Aug	NEWA
>A>	AP		EQ 350MG BASE/VIAL	A200855 001	Sep 06, 2012	Aug	NEWA

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LUPRON DEPOT

+	ABBOTT ENDOCRINE	3.75MG/VIAL	N020011 001	Oct 22, 1990	May	CAHN
+		7.5MG/VIAL	N019732 001	Jan 26, 1989	May	CAHN
+		11.25MG/VIAL	N020708 001	Mar 07, 1997	May	CAHN

LEVETIRACETAM

INJECTABLE; IV (INFUSION)

LEVETIRACETAM

	AP	APP PHARMS LLC	500MG/5ML (100MG/ML)	A090813 001	May 26, 2010	May	CAHN
	AP	HOSPIRA INC	500MG/ML (100MG/ML)	A202869 001	Apr 06, 2012	Mar	NEWA
>A>	AP	LUITPOLD	500MG/5ML (100MG/ML)	A202143 001	Jan 31, 2012	Aug	CAHN
>D>	AP	PHARMAFORCE	500MG/5ML (100MG/ML)	A202143 001	Jan 31, 2012	Aug	CAHN
	AP		500MG/5ML (100MG/ML)	A202143 001	Jan 31, 2012	Jan	NEWA
	AP	X GEN PHARMS	500MG/5ML (100MG/ML)	A091485 001	Aug 05, 2011	Jul	CAHN

SOLUTION; ORAL

LEVETIRACETAM

AA	HI-TECH PHARMACAL	100MG/ML	A090601 001	Feb 28, 2012	Feb	NEWA
AA	VINTAGE PHARMS	100MG/ML	A090079 001	Apr 11, 2012	Mar	NEWA

TABLET; ORAL

LEVETIRACETAM

AB	LOTUS PHARM CO LTD	500MG	A090906 001	Nov 05, 2010	Jul	CAHN
AB	WATSON LABS INC	250MG	A078797 002	Jan 15, 2009	Apr	NEWA
AB		500MG	A078797 003	Jan 15, 2009	Apr	NEWA
AB		750MG	A078797 004	Jan 15, 2009	Apr	NEWA

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

	AB	BOCA PHARMA	500MG	A201464 001	May 25, 2012	May	NEWA
	AB		750MG	A201464 002	May 25, 2012	May	NEWA
>A>	AB	ROUSES POINT PHARMS	500MG	A202524 001	Aug 27, 2012	Aug	NEWA
>A>	AB		750MG	A202524 002	Aug 27, 2012	Aug	NEWA
	AB	TORRENT PHARMS LTD	500MG	A091338 001	May 29, 2012	May	NEWA
	AB		750MG	A091338 002	May 29, 2012	May	NEWA

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB	HETERO LABS LTD III	5MG	A091264 001	Jun 29, 2012	Jun	NEWA
----	---------------------	-----	-------------	--------------	-----	------

LEVOFLOXACIN

TABLET; ORAL

LEVOFLOXACIN

	AB	CIPLA LTD	250MG	A076890 001	Mar 30, 2012	Mar	NEWA
	AB		500MG	A076890 002	Mar 30, 2012	Mar	NEWA
	AB		750MG	A076890 003	Mar 30, 2012	Mar	NEWA
	AB	MACLEODS PHARMS LTD	250MG	A200839 001	Mar 22, 2012	Mar	NEWA
	AB		500MG	A200839 002	Mar 22, 2012	Mar	NEWA
	AB		750MG	A200839 003	Mar 22, 2012	Mar	NEWA
	AB	ORCHID HLTHCARE	250MG	A202200 001	Jan 30, 2012	Jan	NEWA
	AB		500MG	A202200 002	Jan 30, 2012	Jan	NEWA
	AB		750MG	A202200 003	Jan 30, 2012	Jan	NEWA
>A>	AB	ZYDUS PHARMS USA INC	250MG	A077652 001	Sep 07, 2012	Aug	NEWA
>A>	AB		500MG	A077652 002	Sep 07, 2012	Aug	NEWA
>A>	AB		750MG	A077652 003	Sep 07, 2012	Aug	NEWA

LEVOLEUCOVORIN CALCIUM

SOLUTION; IV (INFUSION)

FUSILEV

@ SPECTRUM PHARMS

EQ 250MG BASE/25ML (EQ 10MG
BASE/ML)

N020140 003 Apr 29, 2011 Jun DISC

LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL

AB WATSON LABS INC

1.5MG

A200670 001 Jul 12, 2012 Jun NEWA

PLAN B

AB + TEVA BRANDED PHARM

0.75MG

N021045 002 Aug 24, 2006 May CAHN

@

0.75MG

N021045 001 Jul 28, 1999 May CAHN

PLAN B ONE-STEP

AB + DURAMED

1.5MG

N021998 001 Jul 10, 2009 Jun CFTG

LIDOCAINE

PATCH; TOPICAL

LIDOCAINE

>A> AB WATSON LABS INC

5%

A200675 001 Aug 23, 2012 Aug NEWA

LIDODERM

>D> + TEIKOKU PHARMA USA

5%

N020612 001 Mar 19, 1999 Aug CFTG

>A> AB +

5%

N020612 001 Mar 19, 1999 Aug CFTG

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

XYLOCAINE DENTAL

@ DENTSPLY PHARM

2%

N021380 001 May DISC

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

LIDOCAINE AND PRILOCAINE

AB FOUGERA PHARMS

2.5%;2.5%

A076453 001 Aug 18, 2003 Jan CAHN

LIDOCAINE; TETRACAINE

CREAM; TOPICAL

PLIAGLIS

+ GALDERMA LABS LP

7%;7%

N021717 001 Jun 29, 2006 Jun CTNA

>A> LINACLOTIDE

CAPSULE; ORAL

LINZESS

>A> FOREST LABS INC

145MCG

N202811 001 Aug 30, 2012 Aug NEWA

>A> +

290MCG

N202811 002 Aug 30, 2012 Aug NEWA

LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET; ORAL

JENTADUETO

BOEHRINGER INGELHEIM

2.5MG;500MG

N201281 001 Jan 30, 2012 Jan NEWA

2.5MG;850MG

N201281 002 Jan 30, 2012 Jan NEWA

+

2.5MG;1GM

N201281 003 Jan 30, 2012 Jan NEWA

LINEZOLID

INJECTABLE; INJECTION

LINEZOLID

AP	TEVA PHARMS	200MG/100ML	A200222 001	Jun 22, 2012	Jun	NEWA
ZYVOX						
AP	+ PHARMACIA AND UPJOHN	200MG/100ML	N021131 001	Apr 18, 2000	Jun	CFTG

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE; ORAL

LITHIUM CARBONATE

AB	MYLAN PHARMS INC	300MG	A202288 001	Jun 29, 2012	Jun	NEWA
AB		450MG	A202219 001	Aug 08, 2012	Jul	NEWA

LOMUSTINE

CAPSULE; ORAL

CEENU

	BRISTOL MYERS SQUIBB	10MG	N017588 001		Jun	CMFD
	@	10MG	N017588 001		May	DISC
		40MG	N017588 002		Jun	CMFD
	@	40MG	N017588 002		May	DISC
+		100MG	N017588 003		Jun	CMFD
	@	100MG	N017588 003		May	DISC

LORAZEPAM

CONCENTRATE; ORAL

LORAZEPAM

AA	HI-TECH PHARMA CO	2MG/ML	A200169 001	Jan 30, 2012	Jan	NEWA
----	-------------------	--------	-------------	--------------	-----	------

INJECTABLE; INJECTION

LORAZEPAM

	@ BEDFORD	2MG/ML	A077076 001	Jul 13, 2005	Jun	DISC
	@	4MG/ML	A077076 002	Jul 13, 2005	Jun	DISC
	@ HOSPIRA	2MG/ML	A074300 001	Apr 12, 1994	Jun	DISC

LORCASERIN HYDROCHLORIDE

TABLET; ORAL

BELVIQ

+	ARENA PHARMS INC	10MG	N022529 001	Jun 27, 2012	Jun	NEWA
+	EISAI INC	10MG	N022529 001	Jun 27, 2012	Jul	CAHN

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

AB	MACLEODS PHARMS LTD	25MG	A202230 001	May 30, 2012	May	NEWA
AB		50MG	A202230 002	May 30, 2012	May	NEWA
AB		100MG	A202230 003	May 30, 2012	May	NEWA

LOXAPINE SUCCINATE

CAPSULE; ORAL

LOXAPINE SUCCINATE

	@ MIKAH PHARMA	EQ 5MG BASE	A076868 001	Aug 04, 2005	Jul	CAHN
	@	EQ 10MG BASE	A076868 002	Aug 04, 2005	Jul	CAHN
	@	EQ 25MG BASE	A076868 003	Aug 04, 2005	Jul	CAHN
	@	EQ 50MG BASE	A076868 004	Aug 04, 2005	Jul	CAHN

LUCINACTANTSUSPENSION; INTRATRACHEAL
SURFAXIN

+ DISCOVERY LABS 8.5ML N021746 001 Mar 06, 2012 Apr NEWA

LURASIDONE HYDROCHLORIDE

TABLET; ORAL

LATUDA

>D>	SUNOVION PHARMS INC	20MG	N200603 003	Dec 07, 2011	Aug	CRLD
>A>	+	20MG	N200603 003	Dec 07, 2011	Aug	CRLD
		20MG	N200603 003	Dec 07, 2011	Apr	NEWA
>D>	+	40MG	N200603 001	Oct 28, 2010	Aug	CRLD
>A>		40MG	N200603 001	Oct 28, 2010	Aug	CRLD
	+	40MG	N200603 001	Oct 28, 2010	Apr	CRLD
		80MG	N200603 002	Oct 28, 2010	Apr	CRLD
		120MG	N200603 004	Apr 26, 2012	Apr	NEWA

LUTROPIN ALFA

INJECTABLE; SUBCUTANEOUS

LUVERIS

@ EMD SERONO

75 IU/VIAL

N021322 001 Oct 08, 2004 Jun DISC

MAFENIDE ACETATE

CREAM; TOPICAL

SULFAMYLON

+ MYLAN LLC EQ 85MG BASE/GM N016763 001 Jun CAHN

FOR SOLUTION; TOPICAL

SULFAMYLON

+ MYLAN LLC 5% N019832 003 Jun 05, 1998 Jun CAHN

MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE

TABLET; ORAL

MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE

@ SANTARUS

343MG;20MG;750MG

N022456 001 Dec 04, 2009 Jun DISC

@

343MG;40MG;750MG

N022456 002 Dec 04, 2009 Jun DISC

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE IN PLASTIC CONTAINER

HOSPIRA

20GM/500ML (40MG/ML)

N020309 004 Jan 18, 1995 Jan NEWA

40GM/1000ML (40MG/ML)

N020309 005 Jan 18, 1995 Jan NEWA

MALATHION

LOTION; TOPICAL

MALATHION

AT MYLAN PHARMS INC 0.5% A078743 001 Mar 06, 2009 Feb CAHN

AT SUVEN LIFE 0.5% A091559 001 May 23, 2012 May NEWA

MANNITOL

POWDER; INHALATION

ARIDOL KIT

+ PHARMAXIS LTD N/A, 5MG, 10MG, 20MG, 40MG N022368 001 Oct 05, 2010 May CAHN

MECASERMIN RECOMBINANT

INJECTABLE; SUBCUTANEOUS

INCRELEX

+	IPSEN INC	40MG/4ML (10MG/ML)	N021839 001	Aug 30, 2005	May	CAHN
---	-----------	--------------------	-------------	--------------	-----	------

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

AA	EPIC PHARMA LLC	12.5MG	A200294 001	Apr 13, 2012	Mar	NEWA
----	-----------------	--------	-------------	--------------	-----	------

AA		25MG	A200294 002	Apr 13, 2012	Mar	NEWA
----	--	------	-------------	--------------	-----	------

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

MEDROXYPROGESTERONE ACETATE

@	TEVA PARENTERAL	150MG/ML	A076552 001	Oct 27, 2004	Apr	DISC
---	-----------------	----------	-------------	--------------	-----	------

MEMANTINE HYDROCHLORIDE

TABLET; ORAL

MEMANTINE HYDROCHLORIDE

@	ORCHID HLTHCARE	5MG	A090044 001	Mar 12, 2012	Mar	DISC
---	-----------------	-----	-------------	--------------	-----	------

AB		5MG	A090044 001	Mar 12, 2012	Feb	NEWA
----	--	-----	-------------	--------------	-----	------

@		10MG	A090044 002	Mar 12, 2012	Mar	DISC
---	--	------	-------------	--------------	-----	------

AB		10MG	A090044 002	Mar 12, 2012	Feb	NEWA
----	--	------	-------------	--------------	-----	------

NAMENDA

FOREST LABS

		5MG	N021487 001	Oct 16, 2003	Mar	CTEC
--	--	-----	-------------	--------------	-----	------

AB		5MG	N021487 001	Oct 16, 2003	Feb	CTEC
----	--	-----	-------------	--------------	-----	------

+		10MG	N021487 002	Oct 16, 2003	Mar	CTEC
---	--	------	-------------	--------------	-----	------

AB	+	10MG	N021487 002	Oct 16, 2003	Feb	CTEC
----	---	------	-------------	--------------	-----	------

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

POLOCAINE

@	DENTSPLY PHARM	3%	A088653 001	Aug 21, 1984	May	DISC
---	----------------	----	-------------	--------------	-----	------

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL

SOLAGE

@	AQUA PHARMS	2%;0.01%	N020922 001	Dec 10, 1999	Jun	DISC
---	-------------	----------	-------------	--------------	-----	------

MESALAMINE

SUPPOSITORY; RECTAL

CANASA

@	APTALIS PHARMA US	500MG	N021252 001	Jan 05, 2001	Jul	CAHN
---	-------------------	-------	-------------	--------------	-----	------

		1GM	N021252 002	Nov 05, 2004	Jul	CAHN
--	--	-----	-------------	--------------	-----	------

ROWASA

@	MEDA PHARMS	500MG	N019919 001	Dec 18, 1990	Jan	CAHN
---	-------------	-------	-------------	--------------	-----	------

MESNA

INJECTABLE; INTRAVENOUS

MESNA

AP	MYLAN INSTITUTIONAL	100MG/ML	A076488 001	Mar 08, 2012	Feb	NEWA
----	---------------------	----------	-------------	--------------	-----	------

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

AB	MARKSANS PHARMA	500MG	A090888 001	Mar 12, 2012	Feb	NEWA
AB		850MG	A090888 002	Mar 12, 2012	Feb	NEWA
AB		1GM	A090888 003	Mar 12, 2012	Feb	NEWA

TABLET, EXTENDED RELEASE; ORAL

METFORMIN HYDROCHLORIDE

AB1	AUROBINDO PHARMA LTD	500MG	A079118 001	Jul 20, 2012	Jul	NEWA
AB		750MG	A079118 002	Jul 20, 2012	Jul	NEWA
AB1	INVENTIA HLTHCARE	500MG	A201991 001	Jan 18, 2012	Jan	NEWA
AB2	MYLAN PHARMS INC	500MG	A200690 001	Aug 01, 2012	Jul	NEWA
AB		1GM	A200690 002	Aug 01, 2012	Jul	NEWA
	@ RANBAXY LABS LTD	500MG	A076413 001	Jun 18, 2004	Apr	DISC
	@	750MG	A077211 001	Jun 29, 2005	Apr	DISC

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

ACTOPLUS MET

>D>	AB	TAKEDA GLOBAL	500MG;EQ 15MG BASE	N021842 001	Aug 29, 2005	Aug	CAHN
>D>	AB	+	850MG;EQ 15MG BASE	N021842 002	Aug 29, 2005	Aug	CAHN
>A>	AB	TAKEDA PHARMS USA	500MG;EQ 15MG BASE	N021842 001	Aug 29, 2005	Aug	CAHN
>A>	AB	+	850MG;EQ 15MG BASE	N021842 002	Aug 29, 2005	Aug	CAHN

TABLET, EXTENDED RELEASE; ORAL

ACTOPLUS MET XR

>D>		TAKEDA GLOBAL	1GM;EQ 15MG BASE	N022024 001	May 12, 2009	Aug	CAHN
>D>		+	1GM;EQ 30MG BASE	N022024 002	May 12, 2009	Aug	CAHN
>A>		TAKEDA PHARMS USA	1GM;EQ 15MG BASE	N022024 001	May 12, 2009	Aug	CAHN
>A>		+	1GM;EQ 30MG BASE	N022024 002	May 12, 2009	Aug	CAHN

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

KOMBIGLYZE XR

	BRISTOL MYERS SQUIBB	500MG;EQ 5MG BASE	N200678 001	Nov 05, 2010	Apr	CAIN
		1GM;EQ 2.5MG BASE	N200678 003	Nov 05, 2010	Apr	CAIN
+		1GM;EQ 5MG BASE	N200678 002	Nov 05, 2010	Apr	CAIN

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JANUMET

	MERCK SHARP DOHME	500MG;EQ 50MG BASE	N022044 001	Mar 30, 2007	May	CAHN
+		1GM;EQ 50MG BASE	N022044 002	Mar 30, 2007	May	CAHN

TABLET, EXTENDED RELEASE; ORAL

JANUMET XR

	MERCK SHARP DOHME	500MG;EQ 50MG BASE	N202270 001	Feb 02, 2012	Feb	NEWA
		1GM;EQ 50MG BASE	N202270 002	Feb 02, 2012	Feb	NEWA
+		1GM;EQ 100MG BASE	N202270 003	Feb 02, 2012	Feb	NEWA

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

AB	BOCA PHARMA	5MG	A202068 001	Mar 07, 2012	Feb	NEWA
AB		10MG	A202068 002	Mar 07, 2012	Feb	NEWA

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

AA	SOLCO HLTHCARE	500MG	A086989 001	Mar	CMFD
AA		750MG	A086988 001	Mar	CMFD

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE PRESERVATIVE FREE

AP	APP PHARMS LLC	EQ 1GM BASE/VIAL	A040266 001	Feb 26, 1999	Jan	CMFD
AP	PHARMACHEMIE BV	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A200171 001	Feb 27, 2012	Feb	NEWA

METHOTREXATE SODIUM

AP	+ BEDFORD	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A089341 001	Sep 16, 1986	Feb	CTEC
----	-----------	-------------------------------------	-------------	--------------	-----	------

METHOTREXATE SODIUM PRESERVATIVE FREE

AP	+ MYLAN INSTITUTIONAL	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A040767 001	Apr 30, 2007	Feb	CAHN
AP	ONCO THERAPIES LTD	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A201529 001	Mar 29, 2012	Mar	NEWA
AP		EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A201529 002	Mar 29, 2012	Mar	NEWA
AP		EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A201529 003	Mar 29, 2012	Mar	NEWA
AP		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A201529 004	Mar 29, 2012	Mar	NEWA
AP		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A201530 001	Mar 29, 2012	Mar	NEWA

METHYCLOTHIAZIDE

TABLET; ORAL

ENDURON

@ ABBOTT LABS PHARM

2.5MG

N012524 001

Mar DISC

@

5MG

N012524 004

Mar DISC

METHYCLOTHIAZIDE

AB	+ MYLAN PHARMS INC	5MG	A087672 001	Aug 17, 1982	Mar	CRLD
----	--------------------	-----	-------------	--------------	-----	------

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

METHYLDOPATE HYDROCHLORIDE

@ TEVA PARENTERAL

50MG/ML

A072974 001 Nov 22, 1991 Mar DISC

METHYLNALTREXONE BROMIDE

INJECTABLE; SUBCUTANEOUS

RELISTOR

SALIX PHARMS

8MG/0.4ML

N021964 002 Sep 27, 2010 May CAHN

+

12MG/0.6ML (12MG/0.6ML)

N021964 003 Apr 24, 2008 Jun NEWA

SOLUTION; SUBCUTANEOUS

RELISTOR

+

SALIX PHARMS

12MG/0.6ML (12MG/0.6ML)

N021964 001 Apr 24, 2008 May CAHN

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

METADATE CD

AB UCB INC

10MG

N021259 003 May 27, 2003 Jul CFTG

AB2

20MG

N021259 001 Apr 03, 2001 Jul CFTG

AB2

30MG

N021259 002 Jun 19, 2003 Jul CFTG

AB2

40MG

N021259 004 Feb 19, 2006 Jul CFTG

CAPSULE, EXTENDED RELEASE; ORAL

METADATE CD

AB	UCB INC	50MG	N021259 005	Feb 19, 2006	Jul	CFTG
AB	+	60MG	N021259 006	Feb 19, 2006	Jul	CFTG

METHYLPHENIDATE HYDROCHLORIDE

AB1	ACTAVIS	20MG	A078458 001	Dec 01, 2011	Jul	CTEC
AB1		30MG	A078458 002	Dec 01, 2011	Jul	CTEC
AB1		40MG	A078458 003	Dec 01, 2011	Jul	CTEC
AB1	BARR LABS INC	20MG	A079031 001	Jul 13, 2012	Jul	CTEC
AB		20MG	A079031 001	Jul 13, 2012	Jun	NEWA
AB1		30MG	A079031 002	Jul 13, 2012	Jul	CTEC
AB		30MG	A079031 002	Jul 13, 2012	Jun	NEWA
AB1		40MG	A079031 003	Jul 13, 2012	Jul	CTEC
AB		40MG	A079031 003	Jul 13, 2012	Jun	NEWA
AB	TEVA PHARMS	10MG	A077707 001	Jul 19, 2012	Jul	NEWA
AB2		20MG	A077707 002	Jul 19, 2012	Jul	NEWA
AB2		30MG	A077707 003	Jul 19, 2012	Jul	NEWA
AB2		40MG	A078873 001	Jul 19, 2012	Jul	NEWA
AB		50MG	A078873 002	Jul 19, 2012	Jul	NEWA
AB		60MG	A078873 003	Jul 19, 2012	Jul	NEWA

RITALIN LA

AB1	NOVARTIS	20MG	N021284 001	Jun 05, 2002	Jul	CTEC
AB1		30MG	N021284 002	Jun 05, 2002	Jul	CTEC
AB1	+	40MG	N021284 003	Jun 05, 2002	Jul	CTEC

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	SUN PHARM INDS INC	5MG	A090710 001	Mar 15, 2012	Feb	NEWA
AB		10MG	A090710 002	Mar 15, 2012	Feb	NEWA
AB		20MG	A090710 003	Mar 15, 2012	Feb	NEWA

TABLET, EXTENDED RELEASE; ORAL

METADATE ER

@	UCB INC	10MG	A040306 001	Oct 20, 1999	Jul	DISC
---	---------	------	-------------	--------------	-----	------

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED

>D>	AP	HEMOFARM	EQ 40MG BASE/VIAL	A040793 001	Nov 25, 2008	Aug	CAHN
>D>	AP		EQ 125MG BASE/VIAL	A040827 001	Nov 25, 2008	Aug	CAHN
>A>	AP	HOSPIRA INC	EQ 40MG BASE/VIAL	A040793 001	Nov 25, 2008	Aug	CAHN
>A>	AP		EQ 125MG BASE/VIAL	A040827 001	Nov 25, 2008	Aug	CAHN

METHYLPREDNISOLONE SODIUM SUCCINATE

@	BEDFORD LABS	EQ 40MG BASE/VIAL	A040662 001	Feb 21, 2007	Jun	DISC
@		EQ 125MG BASE/VIAL	A040641 002	Feb 21, 2007	Jun	DISC
@		EQ 500MG BASE/VIAL	A040641 003	Feb 21, 2007	Jun	DISC
@		EQ 500MG BASE/VIAL	A040709 001	Feb 21, 2007	Jun	DISC
@		EQ 1GM BASE/VIAL	A040641 004	Feb 21, 2007	Jun	DISC
@		EQ 1GM BASE/VIAL	A040709 002	Feb 21, 2007	Jun	DISC
@	TEVA PARENTERAL	EQ 125MG BASE/VIAL	A081266 001	Nov 30, 1992	Mar	DISC

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

METOCLOPRAMIDE HYDROCHLORIDE

@	TEVA PARENTERAL	EQ 5MG BASE/ML	A073135 001	Nov 27, 1991	Jan	DISC
---	-----------------	----------------	-------------	--------------	-----	------

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

METOPROLOL SUCCINATE

	AB	DR REDDYS LABS LTD	EQ 25MG TARTRATE	A090617 001	Aug 01, 2012	Jul	NEWA
	AB		EQ 50MG TARTRATE	A090617 002	Aug 01, 2012	Jul	NEWA
		@ NESHER PHARMS	EQ 100MG TARTRATE	A076640 002	May 18, 2007	Jun	DISC
		@	EQ 200MG TARTRATE	A076640 001	May 18, 2007	Jun	DISC
	AB	REDDYS	EQ 100MG BASE	A078889 001	Aug 15, 2012	Jul	NEWA
	AB		EQ 200MG BASE	A078889 002	Aug 15, 2012	Jul	NEWA
>D>	AB	SANDOZ	EQ 25MG TARTRATE	A076969 001	Jul 31, 2006	Aug	DISC
>A>		@	EQ 25MG TARTRATE	A076969 001	Jul 31, 2006	Aug	DISC
>D>	AB		EQ 50MG TARTRATE	A076969 002	May 18, 2007	Aug	DISC
>A>		@	EQ 50MG TARTRATE	A076969 002	May 18, 2007	Aug	DISC
>D>	AB		EQ 100MG TARTRATE	A076969 003	Mar 20, 2008	Aug	DISC
>A>		@	EQ 100MG TARTRATE	A076969 003	Mar 20, 2008	Aug	DISC
>D>	AB		EQ 200MG TARTRATE	A076969 004	Mar 20, 2008	Aug	DISC
>A>		@	EQ 200MG TARTRATE	A076969 004	Mar 20, 2008	Aug	DISC

METRONIDAZOLE

CREAM; TOPICAL

METRONIDAZOLE

AB	FOUGERA PHARMS	0.75%	A076408 001	May 28, 2004	Jan	CAHN
	NORITATE					
+	VALEANT INTL	1%	N020743 001	Sep 26, 1997	Apr	CAHN
	GEL; TOPICAL					
	METRONIDAZOLE					
AB	FOUGERA PHARMS	0.75%	A077018 001	Jun 06, 2006	Jan	CAHN
	LOTION; TOPICAL					
	METRONIDAZOLE					
AB	FOUGERA PHARMS	0.75%	A077197 001	May 24, 2006	Jan	CAHN

METYRAPONE

CAPSULE; ORAL

METOPIRONE

+	HRA PHARMA	250MG	N012911 002	Aug 09, 1996	Jun	CAHN
	TABLET; ORAL					
	METOPIRONE					
	@ HRA PHARMA	250MG	N012911 001		Jun	CAHN

METYROSINE

CAPSULE; ORAL

DEMSEER

+	BIOVAIL TECHNOLOGIES	250MG	N017871 001		May	CAHN
---	----------------------	-------	-------------	--	-----	------

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

AP	GLAND PHARMA LTD	EQ 1MG BASE/ML	A090696 001	Feb 29, 2012	Feb	NEWA
AP		EQ 5MG BASE/ML	A090850 001	Jan 25, 2012	Jan	NEWA

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

PROAMATINE

AB	SHIRE LLC	2.5MG	N019815 001	Sep 06, 1996	Jan	CAHN
AB	+	5MG	N019815 002	Sep 06, 1996	Jan	CAHN

TABLET; ORAL									
PROAMATINE									
AB	SHIRE LLC	10MG	N019815 003	Mar 20, 2002	Jan	CAHN			
<u>MIFEPRISTONE</u>									
TABLET; ORAL									
KORLYM									
+	CORCEPT THERAP	300MG	N202107 001	Feb 17, 2012	Feb	NEWA			
<u>MINOCYCLINE HYDROCHLORIDE</u>									
CAPSULE; ORAL									
MINOCIN									
AB	PRECISION DERMAT	EQ 50MG BASE	N050649 001	May 31, 1990	May	CAHN			
	@	EQ 75MG BASE	N050649 003	Feb 12, 2001	May	CAHN			
AB		EQ 100MG BASE	N050649 002	May 31, 1990	May	CAHN			
CAPSULE, EXTENDED RELEASE; ORAL									
XIMINO									
	RANBAXY LABS LTD	EQ 45MG BASE	N201922 001	Jul 11, 2012	Jul	NEWA			
		EQ 67.5MG BASE	N201922 002	Jul 11, 2012	Jul	NEWA			
		EQ 90MG BASE	N201922 003	Jul 11, 2012	Jul	NEWA			
		EQ 112.5MG BASE	N201922 004	Jul 11, 2012	Jul	NEWA			
+		EQ 135MG BASE	N201922 005	Jul 11, 2012	Jul	NEWA			
INJECTABLE; INJECTION									
MINOCIN									
+	PRECISION DERMAT	EQ 100MG BASE/VIAL	N050444 001		May	CAHN			
SUSPENSION; ORAL									
MINOCIN									
	@ PRECISION DERMAT	EQ 50MG BASE/5ML	N050445 001		May	CAHN			
<u>MIRABEGRON</u>									
TABLET, EXTENDED RELEASE; ORAL									
MYRBETRIQ									
	APGDI	25MG	N202611 001	Jun 28, 2012	Jun	NEWA			
+		50MG	N202611 002	Jun 28, 2012	Jun	NEWA			
<u>MISOPROSTOL</u>									
TABLET; ORAL									
MISOPROSTOL									
AB	NOVEL LABS INC	0.1MG	A091667 001	Jul 25, 2012	Jul	NEWA			
AB		0.2MG	A091667 002	Jul 25, 2012	Jul	NEWA			
<u>MITOMYCIN</u>									
FOR SOLUTION; TOPICAL									
MITOSOL									
+	MOBIUS THERAP	0.2MG/VIAL	N022572 001	Feb 07, 2012	Feb	NEWA			
<u>MITOXANTRONE HYDROCHLORIDE</u>									
INJECTABLE; INJECTION									
MITOXANTRONE HYDROCHLORIDE									
	@ FRESENIUS KABI ONCOL	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A078606 001	May 14, 2008	Jun	DISC			
	@	EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A078606 002	May 14, 2008	Jun	DISC			
	@	EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A078606 003	May 14, 2008	Jun	DISC			

MIVACURIUM CHLORIDE

INJECTABLE; INJECTION

MIVACURIUM CHLORIDE

@ STRIDES ARCOLAB LTD EQ 2MG BASE/ML

A078562 001 Apr 30, 2009 Jun CAHN

MODAFINIL

TABLET; ORAL

MODAFINIL

AB MYLAN PHARMS INC

100MG

A076594 001 Jul 16, 2012 Jun NEWA

AB

200MG

A076594 002 Jul 16, 2012 Jun NEWA

PROVIGIL

AB CEPHALON

100MG

N020717 001 Dec 24, 1998 Jun CFTG

AB +

200MG

N020717 002 Dec 24, 1998 Jun CFTG

MOMETASONE FUROATE

CREAM; TOPICAL

ELOCON

AB + MERCK SHARP DOHME

0.1%

N019625 001 May 06, 1987 Jun CAHN

MOMETASONE FUROATE

AB FOUGERA PHARMS

0.1%

A076171 001 Apr 08, 2005 Jan CAHN

LOTION; TOPICAL

ELOCON

AB + MERCK SHARP DOHME

0.1%

N019796 001 Mar 30, 1989 Jul CAHN

MOMETASONE FUROATE

AB FOUGERA PHARMS

0.1%

A075919 001 Nov 29, 2007 Jan CAHN

OINTMENT; TOPICAL

ELOCON

AB + MERCK SHARP DOHME

0.1%

N019543 001 Apr 30, 1987 May CAHN

MOMETASONE FUROATE

AB FOUGERA PHARMS

0.1%

A077061 001 Mar 28, 2005 Jan CAHN

MONTELUKAST SODIUM

GRANULE; ORAL

MONTELUKAST SODIUM

AB TEVA PHARMS

EQ 4MG BASE/PACKET

A090955 001 Aug 03, 2012 Jul NEWA

SINGULAIR

AB + MERCK

EQ 4MG BASE/PACKET

N021409 001 Jul 26, 2002 Jul CFTG

TABLET; ORAL

MONTELUKAST SODIUM

AB APOTEX CORP

EQ 10MG BASE

A201294 001 Aug 03, 2012 Jul NEWA

AB AUROBINDO PHARMA LTD

EQ 10MG BASE

A202468 001 Aug 03, 2012 Jul NEWA

AB DR REDDYS LABS LTD

EQ 10MG BASE

A201582 001 Aug 06, 2012 Jul NEWA

AB ENDO PHARMS

EQ 10MG BASE

A091576 001 Aug 03, 2012 Jul NEWA

AB GLENMARK GENERICS

EQ 10MG BASE

A090926 001 Aug 03, 2012 Jul NEWA

AB KUDCO IRELAND

EQ 10MG BASE

A201522 001 Aug 03, 2012 Jul NEWA

AB MYLAN PHARMS INC

EQ 10MG BASE

A079103 001 Aug 03, 2012 Jul NEWA

AB ROXANE

EQ 10MG BASE

A090655 001 Aug 03, 2012 Jul NEWA

AB SANDOZ INC

EQ 10MG BASE

A200889 001 Aug 03, 2012 Jul NEWA

AB TEVA PHARMS

EQ 10MG BASE

A078605 001 Aug 03, 2012 Jul NEWA

AB TORRENT PHARMS LTD

EQ 10MG BASE

A201515 001 Aug 03, 2012 Jul NEWA

SINGULAIR

AB + MERCK

EQ 10MG BASE

N020829 002 Feb 20, 1998 Jul CFTG

TABLET, CHEWABLE; ORAL

MONTELUKAST SODIUM

AB APOTEX INC

EQ 4MG BASE

A201508 001 Aug 03, 2012 Jul NEWA

TABLET, CHEWABLE; ORAL

MONTELUKAST SODIUM

AB	APOTEX INC	EQ 5MG BASE	A201508 002	Aug 03, 2012	Jul	NEWA
AB	AUROBINDO PHARMA LTD	EQ 4MG BASE	A202096 001	Aug 03, 2012	Jul	NEWA
AB		EQ 5MG BASE	A202096 002	Aug 03, 2012	Jul	NEWA
AB	DR REDDYS LABS LTD	EQ 4MG BASE	A201581 001	Aug 06, 2012	Jul	NEWA
AB		EQ 5MG BASE	A201581 002	Aug 06, 2012	Jul	NEWA
AB	ENDO PHARMS	EQ 4MG BASE	A091588 001	Aug 03, 2012	Jul	NEWA
AB		EQ 5MG BASE	A091588 002	Aug 03, 2012	Jul	NEWA
AB	KUDCO IRELAND	EQ 4MG BASE	A200405 001	Aug 03, 2012	Jul	NEWA
AB		EQ 5MG BASE	A200405 002	Aug 03, 2012	Jul	NEWA
AB	MYLAN PHARMS INC	EQ 4MG BASE	A079142 001	Aug 03, 2012	Jul	NEWA
AB		EQ 5MG BASE	A079142 002	Aug 03, 2012	Jul	NEWA
AB	ROXANE	EQ 4MG BASE	A091128 001	Aug 03, 2012	Jul	NEWA
AB		EQ 5MG BASE	A091128 002	Aug 03, 2012	Jul	NEWA
AB	SANDOZ INC	EQ 4MG BASE	A091414 001	Aug 03, 2012	Jul	NEWA
AB		EQ 5MG BASE	A091414 002	Aug 03, 2012	Jul	NEWA
AB	TEVA PHARMS	EQ 4MG BASE	A078723 001	Aug 03, 2012	Jul	NEWA
AB		EQ 5MG BASE	A078723 002	Aug 03, 2012	Jul	NEWA
AB	TORRENT PHARMS LTD	EQ 4MG BASE	A090984 001	Aug 03, 2012	Jul	NEWA
AB		EQ 5MG BASE	A090984 002	Aug 03, 2012	Jul	NEWA
SINGULAIR						
AB	MERCK	EQ 4MG BASE	N020830 002	Mar 03, 2000	Jul	CFTG
AB	+	EQ 5MG BASE	N020830 001	Feb 20, 1998	Jul	CFTG

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

KADIAN

	ACTAVIS ELIZABETH	40MG	N020616 009	Jul 09, 2012	Jul	NEWA
		70MG	N020616 010	Jul 09, 2012	Jul	NEWA
		130MG	N020616 011	Jul 09, 2012	Jul	NEWA
		150MG	N020616 012	Jul 09, 2012	Jul	NEWA

INJECTABLE; INJECTION

DURAMORPH PF

AP	+	HIKMA MAPLE	0.5MG/ML	N018565 001	Sep 18, 1984	Jun	CAHN
AP	+		1MG/ML	N018565 002	Sep 18, 1984	Jun	CAHN

INFUMORPH

+	HIKMA MAPLE	10MG/ML	N018565 003	Jul 19, 1991	Jun	CAHN
+		25MG/ML	N018565 004	Jul 19, 1991	Jun	CAHN

INJECTABLE, LIPOSOMAL; EPIDURAL

DEPODUR

@	PACIRA PHARMS INC	10MG/ML (10MG/ML)	N021671 001	May 18, 2004	May	CAHN
@		15MG/1.5ML (10MG/ML)	N021671 002	May 18, 2004	May	CAHN
@		20MG/2ML (10MG/ML)	N021671 003	May 18, 2004	May	CAHN

SOLUTION; ORAL

MORPHINE SULFATE

AA	PADDock LLC	100MG/5ML	A201574 001	Aug 06, 2012	Jul	NEWA
----	-------------	-----------	-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

AB	RANBAXY LABS LTD	15MG	A078761 001	May 11, 2012	Apr	NEWA
AB		30MG	A078761 002	May 11, 2012	Apr	NEWA
AB		60MG	A078761 003	May 11, 2012	Apr	NEWA
AB		100MG	A078761 004	May 11, 2012	Apr	NEWA
AB		200MG	A078761 005	May 11, 2012	Apr	NEWA

ORAMORPH SR

@	XANODYNE PHARMS INC	15MG	N019977 004	Nov 23, 1994	May	DISC
---	---------------------	------	-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

ORAMORPH SR

@ XANODYNE PHARMS INC 30MG
 @ 60MG
 @ 100MG

N019977 001 Aug 15, 1991 May DISC
 N019977 002 Aug 15, 1991 May DISC
 N019977 003 Aug 15, 1991 May DISC

MUPIROICIN

OINTMENT; TOPICAL

MUPIROICIN

AB FOUGERA PHARMS 2%

A065192 001 Nov 30, 2005 Jan CAHN

MYCOPHENOLIC ACID

TABLET, DELAYED RELEASE; ORAL

>A> MYCOPHENOLIC ACID

>A> AB APOTEX INC 180MG

A091558 001 Aug 21, 2012 Aug NEWA

MYFORTIC

>D> NOVARTIS 180MG

N050791 001 Feb 27, 2004 Aug CFTG

>A> AB 180MG

N050791 001 Feb 27, 2004 Aug CFTG

NABUMETONE

TABLET; ORAL

NABUMETONE

AB PROSAM LABS 500MG

A079093 001 Feb 27, 2009 Feb CMFD

AB 750MG

A079093 002 Feb 27, 2009 Feb CMFD

NAFCILLIN SODIUM

INJECTABLE; INJECTION

NAFCILLIN SODIUM

>D> AP ACIC FINE CHEMS EQ 1GM BASE

A090560 001 Oct 03, 2011 Aug CAHN

>D> AP EQ 2GM BASE

A090560 002 Oct 03, 2011 Aug CAHN

>A> AP ANTIBIOTICE EQ 1GM BASE

A090560 001 Oct 03, 2011 Aug CAHN

>A> AP EQ 2GM BASE

A090560 002 Oct 03, 2011 Aug CAHN

>A> AP ASTRAL PHARM INDS EQ 1GM BASE/VIAL

A090582 001 Aug 24, 2012 Aug NEWA

>A> AP EQ 2GM BASE/VIAL

A090582 002 Aug 24, 2012 Aug NEWA

>A> AP EQ 10GM BASE/VIAL

A090580 001 Aug 24, 2012 Aug NEWA

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL

NAFTIN

+ MERZ PHARMS 2%

N019599 002 Jan 13, 2012 Jan NEWA

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE

@ HIKMA MAPLE 0.4MG/ML

A070298 001 Sep 24, 1986 Jun CAHN

@ 0.4MG/ML

A070299 001 Sep 24, 1986 Jun CAHN

@ 0.4MG/ML

A070496 001 Sep 24, 1986 Jun CAHN

NALOXONE HYDROCHLORIDE

@ HIKMA MAPLE 0.02MG/ML

A071272 001 May 24, 1988 Jun CAHN

@ 1MG/ML

A071287 001 May 24, 1988 Jun CAHN

@ 1MG/ML

A071274 001 May 24, 1988 Jun CAHN

@ 1MG/ML

A071273 001 May 24, 1988 Jun CAHN

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

AB	SUN PHARMA GLOBAL	50MG	A090356 001	Feb 24, 2012	Feb	NEWA
----	-------------------	------	-------------	--------------	-----	------

NAPROXEN SODIUM

TABLET; ORAL

ANAPROX

AB	HOFFMANN LA ROCHE	EQ 250MG BASE	N018164 001		May	CAHN
----	-------------------	---------------	-------------	--	-----	------

ANAPROX DS

AB	+ HOFFMANN LA ROCHE	EQ 500MG BASE	N018164 003	Sep 30, 1987	May	CAHN
----	---------------------	---------------	-------------	--------------	-----	------

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET; ORAL

TREXIMET

	+ SMITHKLINE BEECHAM	500MG;EQ 85MG BASE	N021926 001	Apr 15, 2008	May	CAHN
--	----------------------	--------------------	-------------	--------------	-----	------

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

NARATRIPTAN

AB	MYLAN PHARMS INC	EQ 1MG BASE	A202431 001	May 31, 2012	May	NEWA
----	------------------	-------------	-------------	--------------	-----	------

AB		EQ 2.5MG BASE	A202431 002	May 31, 2012	May	NEWA
----	--	---------------	-------------	--------------	-----	------

AB	ORCHID HLTHCARE	EQ 1MG BASE	A091441 001	Apr 30, 2012	Apr	NEWA
----	-----------------	-------------	-------------	--------------	-----	------

AB		EQ 2.5MG BASE	A091441 002	Apr 30, 2012	Apr	NEWA
----	--	---------------	-------------	--------------	-----	------

NATEGLINIDE

TABLET; ORAL

NATEGLINIDE

@ TEVA PHARMS

60MG

A077467 001	Sep 09, 2009	Jul	DISC
-------------	--------------	-----	------

@

120MG

A077467 002	Sep 09, 2009	Jul	DISC
-------------	--------------	-----	------

NEDOCROMIL SODIUM

SOLUTION/DROPS; OPHTHALMIC

ALOCRIL

>D>	+ ALLERGAN	2%	N021009 001	Dec 08, 1999	Aug	CFTG
-----	------------	----	-------------	--------------	-----	------

>A>	AT +	2%	N021009 001	Dec 08, 1999	Aug	CFTG
-----	------	----	-------------	--------------	-----	------

>A>	NEDOCROMIL SODIUM					
-----	-------------------	--	--	--	--	--

>A>	AT AKORN	2%	A090638 001	Aug 22, 2012	Aug	NEWA
-----	----------	----	-------------	--------------	-----	------

NEVIRAPINE

SUSPENSION; ORAL

NEVIRAPINE

AA	AUROBINDO	50MG/5ML	A077702 001	May 22, 2012	May	NEWA
----	-----------	----------	-------------	--------------	-----	------

VIRAMUNE

AA	+ BOEHRINGER INGELHEIM	50MG/5ML	N020933 001	Sep 11, 1998	May	CFTG
----	------------------------	----------	-------------	--------------	-----	------

TABLET; ORAL

NEVIRAPINE

AB	APOTEX INC	200MG	A203021 001	May 22, 2012	May	NEWA
----	------------	-------	-------------	--------------	-----	------

AB	AUROBINDO	200MG	A077521 001	May 22, 2012	May	NEWA
----	-----------	-------	-------------	--------------	-----	------

AB	CIPLA	200MG	A077956 001	May 22, 2012	May	NEWA
----	-------	-------	-------------	--------------	-----	------

AB	HETERO LABS LTD III	200MG	A078584 001	May 22, 2012	May	NEWA
----	---------------------	-------	-------------	--------------	-----	------

AB	MICRO LABS LTD	200MG	A203080 001	May 22, 2012	May	NEWA
----	----------------	-------	-------------	--------------	-----	------

AB	MYLAN LABS	200MG	A078864 001	May 22, 2012	May	NEWA
----	------------	-------	-------------	--------------	-----	------

AB	MYLAN PHARMS INC	200MG	A202523 001	May 22, 2012	May	NEWA
----	------------------	-------	-------------	--------------	-----	------

AB	PRINSTON INC	200MG	A078644 001	May 22, 2012	May	NEWA
----	--------------	-------	-------------	--------------	-----	------

TABLET; ORAL									
NEVIRAPINE									
AB	SCIEGEN PHARMS INC	200MG	A203176	001	May 22, 2012	May	NEWA		
AB	STRIDES	200MG	A078195	001	May 22, 2012	May	NEWA		
VIRAMUNE									
AB	+ BOEHRINGER INGELHEIM	200MG	N020636	001	Jun 21, 1996	May	CFTG		
<u>NIFEDIPINE</u>									
TABLET, EXTENDED RELEASE; ORAL									
NIFEDIPINE									
AB1	ACTAVIS	90MG	A077899	003	May 25, 2012	May	NEWA		
<u>NITROFURANTOIN, MACROCRYSTALLINE</u>									
CAPSULE; ORAL									
MACRODANTIN									
AB	ALMATICA	25MG	N016620	003		Jul	CAHN		
AB		50MG	N016620	001		Jul	CAHN		
AB	+	100MG	N016620	002		Jul	CAHN		
<u>NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE</u>									
CAPSULE; ORAL									
MACROBID									
AB	+ ALMATICA	75MG;25MG	N020064	001	Dec 24, 1991	Jul	CAHN		
	NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)								
	@ RANBAXY LABS LTD	75MG;25MG	A076951	001	Mar 30, 2005	Apr	DISC		
<u>NITROGLYCERIN</u>									
FILM, EXTENDED RELEASE; TRANSDERMAL									
MINITRAN									
AB1	MEDICIS	0.1MG/HR	A089771	001	Aug 30, 1996	Jul	CAHN		
AB1		0.2MG/HR	A089772	001	Aug 30, 1996	Jul	CAHN		
AB1		0.4MG/HR	A089773	001	Aug 30, 1996	Jul	CAHN		
AB1		0.6MG/HR	A089774	001	Aug 30, 1996	Jul	CAHN		
OINTMENT; INTRA-ANAL									
RECTIV									
	+ APTALIS PHARMA	0.4%	N021359	001	Jun 21, 2011	Jan	CAHN		
<u>NIZATIDINE</u>									
CAPSULE; ORAL									
AXID									
	@ SMITHKLINE BEECHAM	150MG	N019508	001	Apr 12, 1988	Mar	DISC		
	@	300MG	N019508	002	Apr 12, 1988	Mar	DISC		
NIZATIDINE									
	@ MYLAN PHARMS INC	150MG	A075934	001	Jul 09, 2002	Apr	DISC		
	@	300MG	A075934	002	Jul 09, 2002	Apr	DISC		
AB	+	300MG	A075806	002	Jul 05, 2002	Apr	CRLD		
<u>NOREPINEPHRINE BITARTRATE</u>									
INJECTABLE; INJECTION									
NOREPINEPHRINE BITARTRATE									
AP	CLARIS LIFESCIENCES	EQ 1MG BASE/ML	A040859	001	Mar 27, 2012	May	CAHN		
AP	SINTETICA	EQ 1MG BASE/ML	A040859	001	Mar 27, 2012	Mar	NEWA		

NORETHINDRONE ACETATE

TABLET; ORAL

NORETHINDRONE ACETATE

AB	AMNEAL PHARMS	5MG	A200275 001	Jul 30, 2012	Jul	NEWA
----	---------------	-----	-------------	--------------	-----	------

NYSTATIN

CREAM; TOPICAL

NYSTATIN

AT	FOUGERA PHARMS	100,000 UNITS/GM	A062129 001		Jan	CAHN
>D>	AT	TARO	100,000 UNITS/GM	A064022 001	Jan 29, 1993	Aug CRLD
>A>	AT	+	100,000 UNITS/GM	A064022 001	Jan 29, 1993	Aug CRLD

OINTMENT; TOPICAL

NYSTATIN

AT	+	FOUGERA PHARMS	100,000 UNITS/GM	A062124 002	Sep 23, 1982	Jan CAHN
----	---	----------------	------------------	-------------	--------------	----------

POWDER; TOPICAL

NYSTATIN

	@	NESHER PHARMS	100,000 UNITS/GM	A065321 001	Aug 18, 2006	Jun DISC
--	---	---------------	------------------	-------------	--------------	----------

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

MYKACET

	@	G AND W LABS INC	100,000 UNITS/GM;0.1%	A062367 001	May 28, 1985	Jun CAHN
--	---	------------------	-----------------------	-------------	--------------	----------

OINTMENT; TOPICAL

MYKACET

	@	G AND W LABS INC	100,000 UNITS/GM;0.1%	A062733 001	Mar 09, 1987	Jun CAHN
--	---	------------------	-----------------------	-------------	--------------	----------

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

OFLOXACIN

>D>	AT	SANDOZ	0.3%	A076848 001	Nov 25, 2008	Aug DISC
>A>		@	0.3%	A076848 001	Nov 25, 2008	Aug DISC

TABLET; ORAL

OFLOXACIN

	@	RANBAXY LABS LTD	200MG	A076220 001	Sep 02, 2003	Apr DISC
	@		300MG	A076220 002	Sep 02, 2003	Apr DISC
	@		400MG	A076220 003	Sep 02, 2003	Apr DISC

OLANZAPINE

INJECTABLE; INTRAMUSCULAR

OLANZAPINE

AP	PHARMAFORCE	10MG/VIAL	A201741 001	Mar 20, 2012	Mar	NEWA
AP	SANDOZ INC	10MG/VIAL	A201588 001	Oct 24, 2011	Mar	CAHN

TABLET; ORAL

OLANZAPINE

AB	APOTEX INC	2.5MG	A090798 001	Apr 23, 2012	Apr	NEWA
AB		5MG	A090798 002	Apr 23, 2012	Apr	NEWA
AB		7.5MG	A090798 003	Apr 23, 2012	Apr	NEWA
AB		10MG	A090798 004	Apr 23, 2012	Apr	NEWA
AB		15MG	A090798 005	Apr 23, 2012	Apr	NEWA
AB		20MG	A090798 006	Apr 23, 2012	Apr	NEWA
AB	AUROBINDO PHARMA LTD	2.5MG	A202050 001	Apr 23, 2012	Apr	NEWA
AB		5MG	A202050 002	Apr 23, 2012	Apr	NEWA
AB		7.5MG	A202050 003	Apr 23, 2012	Apr	NEWA
AB		10MG	A202050 004	Apr 23, 2012	Apr	NEWA
AB		15MG	A202050 005	Apr 23, 2012	Apr	NEWA

TABLET; ORAL

OLANZAPINE

AB	AUROBINDO PHARMA LTD	20MG	A202050 006	Apr 23, 2012	Apr	NEWA
AB	DR REDDYS LABS LTD	2.5MG	A076255 001	Apr 23, 2012	Apr	NEWA
AB		5MG	A076255 002	Apr 23, 2012	Apr	NEWA
AB		7.5MG	A076255 003	Apr 23, 2012	Apr	NEWA
AB		10MG	A076255 004	Apr 23, 2012	Apr	NEWA
AB		15MG	A076133 001	Apr 23, 2012	Apr	NEWA
AB	MYLAN	2.5MG	A076866 001	Apr 23, 2012	Apr	NEWA
AB		5MG	A076866 002	Apr 23, 2012	Apr	NEWA
AB		7.5MG	A076866 003	Apr 23, 2012	Apr	NEWA
AB		10MG	A076866 004	Apr 23, 2012	Apr	NEWA
AB		15MG	A076866 005	Apr 23, 2012	Apr	NEWA
AB		20MG	A076866 006	Apr 23, 2012	Apr	NEWA
AB	ORCHID HLTHCARE	2.5MG	A202287 001	Apr 23, 2012	Apr	NEWA
AB		5MG	A202287 002	Apr 23, 2012	Apr	NEWA
AB		7.5MG	A202287 003	Apr 23, 2012	Apr	NEWA
AB		10MG	A202287 004	Apr 23, 2012	Apr	NEWA
AB		15MG	A202287 005	Apr 23, 2012	Apr	NEWA
AB		20MG	A202287 006	Apr 23, 2012	Apr	NEWA
AB	SUN PHARM INDS	2.5MG	A091038 001	Apr 23, 2012	Apr	NEWA
AB		5MG	A091038 002	Apr 23, 2012	Apr	NEWA
AB		7.5MG	A091038 003	Apr 23, 2012	Apr	NEWA
AB		10MG	A091038 004	Apr 23, 2012	Apr	NEWA
AB		15MG	A091038 005	Apr 23, 2012	Apr	NEWA
AB		20MG	A091038 006	Apr 23, 2012	Apr	NEWA
AB	TORRENT PHARMS LTD	2.5MG	A091434 001	Apr 23, 2012	Apr	NEWA
AB		5MG	A091434 002	Apr 23, 2012	Apr	NEWA
AB		7.5MG	A091434 003	Apr 23, 2012	Apr	NEWA
AB		10MG	A091434 004	Apr 23, 2012	Apr	NEWA
AB		15MG	A091434 005	Apr 23, 2012	Apr	NEWA
AB		20MG	A091434 006	Apr 23, 2012	Apr	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

OLANZAPINE

	AB	BARR LABS INC	5MG	A077243 001	Jan 30, 2012	Jan	NEWA
	AB		10MG	A077243 002	Jan 30, 2012	Jan	NEWA
	AB		15MG	A077243 003	Jan 30, 2012	Jan	NEWA
	AB		20MG	A077243 004	Jan 30, 2012	Jan	NEWA
>A>	AB	JUBILANT ORGANOSYS	5MG	A200221 001	Sep 12, 2012	Aug	NEWA
>A>	AB		10MG	A200221 002	Sep 12, 2012	Aug	NEWA
>A>	AB		15MG	A200221 003	Sep 12, 2012	Aug	NEWA
>A>	AB		20MG	A200221 004	Sep 12, 2012	Aug	NEWA
	AB	SUN PHARM INDS	5MG	A090881 001	Feb 28, 2012	Feb	NEWA
	AB		10MG	A090881 002	Feb 28, 2012	Feb	NEWA
	AB		15MG	A090881 003	Feb 28, 2012	Feb	NEWA
	AB		20MG	A090881 004	Feb 28, 2012	Feb	NEWA

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

OMEPRAZOLE

	AB	DR REDDYS LABS LTD	10MG	A078490 002	Mar 16, 2009	Apr	NEWA
	AB		20MG	A078490 003	Mar 16, 2009	Apr	NEWA
>D>	AB	LEK PHARMS	10MG	A075757 001	Jan 28, 2003	Aug	CAHN
>D>	AB		20MG	A075757 002	Jan 28, 2003	Aug	CAHN
>A>	AB	SANDOZ	10MG	A075757 001	Jan 28, 2003	Aug	CAHN
>A>	AB		20MG	A075757 002	Jan 28, 2003	Aug	CAHN

ONDANSETRON

TABLET, ORALLY DISINTEGRATING; ORAL

ONDANSETRON

		@ NESHER PHARMS	4MG	A077717	001	Jun 25, 2007	Jun	DISC
		@	8MG	A077717	002	Jun 25, 2007	Jun	DISC
>D>	AB	PAR PHARM	4MG	A076506	001	Dec 26, 2006	Aug	DISC
>A>		@	4MG	A076506	001	Dec 26, 2006	Aug	DISC
>D>	AB		8MG	A076506	002	Dec 26, 2006	Aug	DISC
>A>		@	8MG	A076506	002	Dec 26, 2006	Aug	DISC
>D>			16MG	A077406	001	Dec 26, 2006	Aug	DISC
>A>		@	16MG	A077406	001	Dec 26, 2006	Aug	DISC
>D>			24MG	A077406	002	Dec 26, 2006	Aug	DISC
>A>		@	24MG	A077406	002	Dec 26, 2006	Aug	DISC

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

AP		GLAND PHARMA LTD	EQ 2MG BASE/ML	A090648	001	Jun 15, 2012	Jun	NEWA
AP		HIKMA MAPLE	EQ 2MG BASE/ML	A077365	001	Dec 26, 2006	Jun	CAHN
>A>		@ SAGENT PHARMS	EQ 2MG BASE/ML	A078180	001	Mar 26, 2007	Aug	DISC
>D>	AP	SPECTRUM PHARMS	EQ 2MG BASE/ML	A078180	001	Mar 26, 2007	Aug	DISC
		ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE						
AP		HIKMA MAPLE	EQ 2MG BASE/ML	A077541	001	Dec 26, 2006	Jun	CAHN

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

>D>	AB	PAR PHARM	EQ 4MG BASE	A077303	001	Jun 25, 2007	Aug	DISC
>A>		@	EQ 4MG BASE	A077303	001	Jun 25, 2007	Aug	DISC
>D>	AB		EQ 8MG BASE	A077303	002	Jun 25, 2007	Aug	DISC
>A>		@	EQ 8MG BASE	A077303	002	Jun 25, 2007	Aug	DISC
>D>	AB		EQ 24MG BASE	A077303	004	Jun 25, 2007	Aug	DISC
>A>		@	EQ 24MG BASE	A077303	004	Jun 25, 2007	Aug	DISC

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE; ORAL

ORPHENADRINE CITRATE

AB		CNTY LINE PHARMS	100MG	A040249	001	Jan 29, 1999	Jul	CAHN
AB		INVAGEN PHARMS	100MG	A091158	001	Jul 27, 2012	Jul	NEWA

OSELTAMIVIR PHOSPHATE

FOR SUSPENSION; ORAL

TAMIFLU

+	ROCHE	EQ 6MG BASE/ML	N021246	002	Mar 21, 2011	Jan	CRLD
---	-------	----------------	---------	-----	--------------	-----	------

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUM

AP		SAGENT PHARMS	EQ 1GM BASE/VIAL	A091246	001	Mar 30, 2012	Mar	NEWA
AP			EQ 2GM BASE/VIAL	A091246	002	Mar 30, 2012	Mar	NEWA
AP			EQ 10GM BASE/VIAL	A091245	001	Mar 30, 2012	Mar	NEWA

OXALIPLATIN

INJECTABLE; IV (INFUSION)

OXALIPLATIN

AP		ACTAVIS TOTOWA	50MG/VIAL	A078803	001	Aug 08, 2012	Jul	NEWA
AP			100MG/VIAL	A078803	002	Aug 08, 2012	Jul	NEWA

INJECTABLE; IV (INFUSION)

OXALIPLATIN

AP	ONCO THERAPIES LTD	50MG/10ML (5MG/ML)	A091358 001	Aug 07, 2012	Jul	NEWA
AP		50MG/VIAL	A200979 001	Aug 08, 2012	Jul	NEWA
AP		100MG/20ML (5MG/ML)	A091358 002	Aug 07, 2012	Jul	NEWA
AP		100MG/VIAL	A200979 002	Aug 08, 2012	Jul	NEWA
AP	+ TEVA PHARMS	50MG/10ML (5MG/ML)	N022160 001	Aug 07, 2009	Mar	CRLD
AP	+	100MG/20ML (5MG/ML)	N022160 002	Aug 07, 2009	Mar	CRLD

OXCARBAZEPINE

SUSPENSION; ORAL

OXCARBAZEPINE

>A>	AB	AMNEAL PHARMS	300MG/5ML	A202961 001	Sep 17, 2012	Aug	NEWA
-----	----	---------------	-----------	-------------	--------------	-----	------

OXICONAZOLE NITRATE

CREAM; TOPICAL

OXISTAT

+	FOUGERA PHARMS	EQ 1% BASE	N019828 001	Dec 30, 1988	Jan	CAHN
---	----------------	------------	-------------	--------------	-----	------

OXTRIPHYLLINE

TABLET, EXTENDED RELEASE; ORAL

CHOLEDYL SA

+	WARNER CHILCOTT LLC	400MG	A087863 001	May 24, 1983	Jun	CAHN
+		600MG	A086742 001		Jun	CAHN

OXYBUTYNIN

GEL, METERED; TRANSDERMAL

ANTUROL

+	ARROW INTL	3%	N202513 001	Dec 07, 2011	Apr	CAHN
+	WATSON LABS INC	3%	N202513 001	Dec 07, 2011	Feb	CAHN

OXYBUTYNIN CHLORIDE

TABLET; ORAL

DITROPAN

@ JANSSEN PHARMS

5MG

N017577 001 Mar DISC

OXYBUTYNIN CHLORIDE

AB	+	VINTAGE PHARMS	5MG	A075079 001	Oct 31, 1997	Mar	CRLD
----	---	----------------	-----	-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

OXYBUTYNIN CHLORIDE

AB		MYLAN PHARMS INC	15MG	A076644 002	May 10, 2007	Mar	NEWA
----	--	------------------	------	-------------	--------------	-----	------

OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE HYDROCHLORIDE

AB		COASTAL PHARMS	5MG	A203107 001	Jul 26, 2012	Jul	NEWA
AB	+	LEHIGH VALLEY	5MG	N200534 001	Oct 20, 2010	Jul	CFTG

SOLUTION; ORAL

OXYCODONE HYDROCHLORIDE

AA	+	LEHIGH VALLEY	100MG/5ML	N200535 001	Oct 20, 2010	Jul	CFTG
	+	VISTAPHARM	5MG/5ML	N201194 001	Jan 12, 2012	Jan	NEWA
AA			100MG/5ML	A202537 001	Jul 30, 2012	Jul	NEWA

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

AB		MALLINCKRODT INC	5MG	A076758 003	Mar 19, 2007	Apr	NEWA
----	--	------------------	-----	-------------	--------------	-----	------

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

OPANA ER

@ ENDO PHARMS

5MG

N021610 001 Jun 22, 2006 May DISC

@

10MG

N021610 002 Jun 22, 2006 May DISC

@

20MG

N021610 003 Jun 22, 2006 May DISC

@

30MG

N021610 007 Feb 29, 2008 May DISC

>D>

40MG

N201655 007 Dec 09, 2011 Aug CRLD

>A>

+

40MG

N201655 007 Dec 09, 2011 Aug CRLD

@

40MG

N021610 004 Jun 22, 2006 May DISC

OXYMORPHONE HYDROCHLORIDE

IMPAX LABS

5MG

A079087 001 Jun 14, 2010 May CTEC

10MG

A079087 003 Jun 14, 2010 May CTEC

20MG

A079087 005 Jun 14, 2010 May CTEC

30MG

A079087 006 Jul 22, 2010 May CTEC

40MG

A079087 007 Jun 14, 2010 May CTEC

OXYTOCIN

INJECTABLE; INJECTION

OXYTOCIN

@ TEVA PARENTERAL

10USP UNITS/ML (10USP UNITS/ML)

A077453 001 Jan 24, 2008 Jan DISC

@

100USP UNITS/10ML (10USP
UNITS/ML)

A077453 002 Jan 24, 2008 Mar DISC

PITOCIN

>A>

JHP PHARMS

500USP UNITS/50ML (10USP
UNITS/ML)

N018261 003 Sep 05, 2012 Aug NEWA

PACLITAXEL

INJECTABLE; INJECTION

TAXOL

@ CORDEN PHARMA

6MG/ML

N020262 001 Dec 29, 1992 Mar CAHN

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

AREDIA

@ NOVARTIS

30MG/VIAL

N020036 001 Oct 31, 1991 Mar DISC

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE; ORAL

CREON

ABBOTT LABS

15,000USP UNITS;3,000USP
UNITS;9,500USP UNITS

N020725 004 Jul 12, 2011 Jun NEWA

30,000USP UNITS;6,000USP
UNITS;19,000USP UNITS

N020725 001 Apr 30, 2009 Feb CAHN

60,000USP UNITS;12,000USP
UNITS;38,000USP UNITS

N020725 002 Apr 30, 2009 Feb CAHN

+

120,000USP UNITS;24,000USP
UNITS;76,000USP UNITS

N020725 003 Apr 30, 2009 Feb CAHN

PERTZYE

DIGESTIVE CARE INC

30,250USP/UNITS;8,000USP/UNITS;28
,750USP/UNITS

N022175 001 May 17, 2012 May NEWA

+

60,500USP/UNITS;16,000USP/UNITS;5
7,500USP/UNITS

N022175 002 May 17, 2012 May NEWA

ULTRESA

APTALIS PHARMA US

27,600USP UNITS;13,800USP
UNITS;27,600USP UNITS

N022222 001 Mar 01, 2012 Mar NEWA

41,400USP UNITS;20,700USP
UNITS;41,400USP UNITS

N022222 002 Mar 01, 2012 Mar NEWA

CAPSULE, DELAYED RELEASE; ORAL

ULTRESA

+	APTALIS PHARMA US	46,000USP UNITS;23,000USP UNITS;46,000USP UNITS	N022222 003	Mar 01, 2012	Mar	NEWA
---	-------------------	---	-------------	--------------	-----	------

ZENPEP

	APTALIS PHARMA US	16,000USP UNITS;3,000USP UNITS;10,000USP UNITS	N022210 005	Jun 15, 2011	Apr	NEWA
		109,000USP UNITS;20,000USP UNITS;68,000USP UNITS	N022210 004	Aug 27, 2009	Apr	CRLD
+		136,000USP UNITS;25,000USP UNITS;85,000USP UNITS	N022210 006	Jul 13, 2011	Apr	NEWA

TABLET; ORAL

VIOKACE

	APTALIS PHARMA US	39,150USP UNITS;10,440USP UNITS;39,150USP UNITS	N022542 001	Mar 01, 2012	Mar	NEWA
+		78,300USP UNITS;20,880USP UNITS;78,300USP UNITS	N022542 002	Mar 01, 2012	Mar	NEWA

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

AB	APOTEX INC	EQ 20MG BASE	A090807 001	May 02, 2012	Apr	NEWA
AB		EQ 40MG BASE	A090807 002	May 02, 2012	Apr	NEWA
AB	MACLEODS PHARMS LTD	EQ 20MG BASE	A200821 001	Feb 16, 2012	Jan	NEWA
AB		EQ 40MG BASE	A200821 002	Feb 16, 2012	Jan	NEWA
AB	RANBAXY LABS LTD	EQ 20MG BASE	A200794 001	May 02, 2012	Apr	NEWA
AB		EQ 40MG BASE	A200794 002	May 02, 2012	Apr	NEWA

PAROXETINE HYDROCHLORIDE

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	EQ 10MG BASE	A076968 001	Jun 21, 2010	Feb	CMFD
AB		EQ 20MG BASE	A076968 002	Jun 21, 2010	Feb	CMFD
AB		EQ 30MG BASE	A076968 003	Jun 21, 2010	Feb	CMFD
AB		EQ 40MG BASE	A076968 004	Jun 21, 2010	Feb	CMFD

PEGAPTANIB SODIUM

INJECTABLE; INTRAVITREAL

MACUGEN

+	VALEANT PHARMS LLC	EQ 0.3MG ACID/0.09ML	N021756 001	Dec 17, 2004	May	CAHN
---	--------------------	----------------------	-------------	--------------	-----	------

PEGINESATIDE ACETATE

SOLUTION; INTRAVENOUS, SUBCUTANEOUS

OMONTYS

+	AFFYMAX	EQ 10MG BASE/ML (EQ 10MG BASE/ML)	N202799 007	Mar 27, 2012	Mar	NEWA
+		EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N202799 008	Mar 27, 2012	Mar	NEWA

OMONTYS PRESERVATIVE FREE

+	AFFYMAX	EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)	N202799 001	Mar 27, 2012	Mar	NEWA
+		EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)	N202799 002	Mar 27, 2012	Mar	NEWA
+		EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N202799 003	Mar 27, 2012	Mar	NEWA
+		EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML)	N202799 004	Mar 27, 2012	Mar	NEWA
+		EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML)	N202799 005	Mar 27, 2012	Mar	NEWA
+		EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML)	N202799 006	Mar 27, 2012	Mar	NEWA

PENTOBARBITAL SODIUM

INJECTABLE; INJECTION

NEMBUTAL SODIUM

+	OAK PHARMS	50MG/ML	A083246 001		Feb	CAHN
---	------------	---------	-------------	--	-----	------

PERINDOPRIL ERBUMINE

TABLET; ORAL

ACEON

AB	XOMA	2MG	N020184 001	Dec 30, 1993	Jan	CAHN
AB		4MG	N020184 002	Dec 30, 1993	Jan	CAHN
AB	+	8MG	N020184 003	Dec 30, 1993	Jan	CAHN

PERMETHRIN

CREAM; TOPICAL

ELIMITE

AB	+	RENAISSANCE PHARMA	5%	N019855 001	Aug 25, 1989	May	CAHN
----	---	--------------------	----	-------------	--------------	-----	------

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIBENZYLINE

AB	+	WELLSPRING PHARM	10MG	N008708 001		Jun	CFTG
----	---	------------------	------	-------------	--	-----	------

PHENOXYBENZAMINE HYDROCHLORIDE

AB		ROXANE	10MG	A201050 001	Jul 16, 2012	Jun	NEWA
----	--	--------	------	-------------	--------------	-----	------

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE

AA	LANNETT	15MG	A087022 002	Jan 20, 2012	Feb	NEWA
	@ MIKAH PHARMA	15MG	A040460 001	Jan 14, 2003	Jul	CAHN
	@	30MG	A040448 001	Jan 22, 2003	Jul	CAHN
	@	30MG	A040227 001	Jun 18, 1997	Jul	CAHN
	@	37.5MG	A040228 001	Jun 19, 1997	Jul	CAHN

TABLET; ORAL

PHENTERMINE HYDROCHLORIDE

@ MIKAH PHARMA 37.5MG

A040190 001 May 30, 1997 Jul CAHN

@ SANDOZ INC 30MG

A088605 001 Sep 28, 1987 Feb DISC

TABLET, ORALLY DISINTEGRATING; ORAL

SUPRENZA

CITIUS PHARMS 30MG

N202088 002 Jun 13, 2011 Apr CRLD

+

37.5MG

N202088 003 Mar 27, 2012 Apr CRLD

37.5MG

N202088 003 Mar 27, 2012 Mar NEWA

PHENTERMINE HYDROCHLORIDE; TOPIRAMATE

CAPSULE, EXTENDED RELEASE; ORAL

QSYMIA

VIVUS

EQ 3.75MG BASE;23MG

N022580 001 Jul 17, 2012 Jul NEWA

EQ 7.5MG BASE;46MG

N022580 002 Jul 17, 2012 Jul NEWA

EQ 11.25MG BASE;69MG

N022580 003 Jul 17, 2012 Jul NEWA

+

EQ 15MG BASE;92MG

N022580 004 Jul 17, 2012 Jul NEWA

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

PHENTERMINE RESIN COMPLEX

+

LANNETT HOLDINGS INC EQ 15MG BASE

A040872 001 Jul 28, 2011 Jan CRLD

+

EQ 30MG BASE

A040872 002 Jul 28, 2011 Jan CRLD

PHENYTOIN SODIUM

INJECTABLE; INJECTION						
PHENYTOIN SODIUM						
AP	+ HIKMA MAPLE	50MG/ML	A084307 001		Jun	CAHN

PHYTONADIONE

INJECTABLE; INJECTION						
PHYTONADIONE						
BP	+ INTL MEDICATION	1MG/0.5ML	A083722 001		Feb	CRLD
TABLET; ORAL						
MEPHYTON						
	+ VALEANT PHARMS	5MG	N010104 003		Jun	CAHN

PINDOLOL

TABLET; ORAL						
PINDOLOL						
	@ MYLAN PHARMS INC	5MG	A074013 001	Sep 24, 1992	May	CAHN
	@	10MG	A074018 001	Sep 24, 1992	May	CAHN

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL						
ACTOS						
>D>	TAKEDA PHARMS USA	EQ 15MG BASE	N021073 001	Jul 15, 1999	Aug	CFTG
>A>	AB	EQ 15MG BASE	N021073 001	Jul 15, 1999	Aug	CFTG
		EQ 15MG BASE	N021073 001	Jul 15, 1999	Mar	CAHN
>D>		EQ 30MG BASE	N021073 002	Jul 15, 1999	Aug	CFTG
>A>	AB	EQ 30MG BASE	N021073 002	Jul 15, 1999	Aug	CFTG
		EQ 30MG BASE	N021073 002	Jul 15, 1999	Mar	CAHN
>D>	+	EQ 45MG BASE	N021073 003	Jul 15, 1999	Aug	CFTG
>A>	AB +	EQ 45MG BASE	N021073 003	Jul 15, 1999	Aug	CFTG
	+	EQ 45MG BASE	N021073 003	Jul 15, 1999	Mar	CAHN
>A>	PIOGLITAZONE HYDROCHLORIDE					
>A>	AB	MYLAN PHARMS INC	EQ 15MG BASE	Aug 17, 2012	Aug	NEWA
>A>	AB		EQ 30MG BASE	Aug 17, 2012	Aug	NEWA
>A>	AB		EQ 45MG BASE	Aug 17, 2012	Aug	NEWA

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL						
K+10						
	@ FUTURE PAK	10MEQ	A070999 001	Oct 22, 1987	Mar	DISC
KAON CL-10						
	@ SAVAGE LABS	10MEQ	N017046 002		Mar	DISC
KLOR-CON M20						
AB	+ UPSHER SMITH LABS	20MEQ	A074726 001	Nov 20, 1998	Mar	CRLD
KLOTRIX						
	@ APOTHECON	10MEQ	N017850 001		Mar	DISC
POTASSIUM CHLORIDE						
	@ NESHER PHARMS	20MEQ	A076044 001	Apr 05, 2002	Mar	DISC
	@ SCHERING	10MEQ	N019439 002	Jun 13, 1986	Mar	DISC
	@	20MEQ	N019439 001	Jun 13, 1986	Mar	DISC

POTASSIUM CITRATE

FOR SOLUTION; ORAL						
POTASSIUM CITRATE						
	@ NOVA K	10MEQ/PACKET	N019647 002	Oct 13, 1988	Feb	CAHN

FOR SOLUTION; ORAL
 POTASSIUM CITRATE
 @ NOVA K

20MEQ/PACKET

N019647 001 Oct 13, 1988 Feb CAHN

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB	APOTEX INC	0.125MG	A090151 001	Apr 30, 2012	Apr	NEWA
AB		0.25MG	A090151 002	Apr 30, 2012	Apr	NEWA
AB		0.5MG	A090151 003	Apr 30, 2012	Apr	NEWA
AB		0.75MG	A090151 006	Apr 30, 2012	Apr	NEWA
AB		1MG	A090151 004	Apr 30, 2012	Apr	NEWA
AB		1.5MG	A090151 005	Apr 30, 2012	Apr	NEWA

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVASTATIN SODIUM

@ PLIVA HRVATSKA DOO 10MG
 @ 20MG
 @ 30MG
 @ 40MG
 @ RANBAXY LABS LTD 10MG
 @ 20MG
 @ 40MG
 @ 80MG

A077730 001 Nov 21, 2006 Jun DISC
 A077730 002 Nov 21, 2006 Jun DISC
 A077730 003 Nov 21, 2006 Jun DISC
 A077730 005 Nov 21, 2006 Jun DISC
 A076445 001 Apr 23, 2007 Apr DISC
 A076445 002 Apr 23, 2007 Apr DISC
 A076445 003 Apr 23, 2007 Apr DISC
 A076445 004 Apr 23, 2007 Apr DISC

PREDNICARBATE

CREAM; TOPICAL

PREDNICARBATE

AB	FOUGERA PHARMS	0.1%	A077287 001	Sep 19, 2006	Jan	CAHN
----	----------------	------	-------------	--------------	-----	------

OINTMENT; TOPICAL

PREDNICARBATE

AB	FOUGERA PHARMS	0.1%	A077236 001	Mar 09, 2007	Jan	CAHN
----	----------------	------	-------------	--------------	-----	------

PREDNISOLONE

SYRUP; ORAL

PREDNISOLONE

AA	+ HI TECH PHARMA CO	15MG/5ML	A040401 001	Feb 27, 2003	Jul	CRLD
	@ NESHER PHARMS	5MG/5ML	A040423 001	Oct 22, 2001	Jun	DISC
	@	15MG/5ML	A040364 001	Apr 10, 2002	Jun	DISC

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PREDNISOLONE SODIUM PHOSPHATE

+ MISSION PHARMA EQ 25MG BASE/5ML
 @ NESHER PHARMS EQ 5MG BASE/5ML

A091396 001 Sep 13, 2010 Jul CAHN
 A076982 001 May 24, 2005 Jun DISC

PREDNISONE

TABLET, DELAYED RELEASE; ORAL

RAYOS

HORIZON PHARMA 1MG

N202020 001 Jul 26, 2012 Jul NEWA

2MG

N202020 002 Jul 26, 2012 Jul NEWA

+ 5MG

N202020 003 Jul 26, 2012 Jul NEWA

PREGABALIN

CAPSULE; ORAL

LYRICA

AB	PF PRISM	25MG	N021446 001	Dec 30, 2004	Jun	CFTG
		25MG	N021446 001	Dec 30, 2004	Jan	CAHN
AB		50MG	N021446 002	Dec 30, 2004	Jun	CFTG
		50MG	N021446 002	Dec 30, 2004	Jan	CAHN
AB		75MG	N021446 003	Dec 30, 2004	Jun	CFTG
		75MG	N021446 003	Dec 30, 2004	Jan	CAHN
		100MG	N021446 004	Dec 30, 2004	Jan	CAHN
AB		150MG	N021446 005	Dec 30, 2004	Jun	CFTG
		150MG	N021446 005	Dec 30, 2004	Jan	CAHN
AB		200MG	N021446 006	Dec 30, 2004	Jun	CFTG
		200MG	N021446 006	Dec 30, 2004	Jan	CAHN
AB		225MG	N021446 007	Dec 30, 2004	Jun	CFTG
		225MG	N021446 007	Dec 30, 2004	Jan	CAHN
AB	+	300MG	N021446 008	Dec 30, 2004	Jun	CFTG
	+	300MG	N021446 008	Dec 30, 2004	Jan	CAHN

PREGABALIN

AB	LUPIN LTD	25MG	A091040 001	Jul 03, 2012	Jun	NEWA
AB		50MG	A091040 002	Jul 03, 2012	Jun	NEWA
AB		75MG	A091040 003	Jul 03, 2012	Jun	NEWA
AB		100MG	A091040 004	Jul 03, 2012	Jun	NEWA
AB		150MG	A091040 005	Jul 03, 2012	Jun	NEWA
AB		200MG	A091040 006	Jul 03, 2012	Jun	NEWA
AB		225MG	A091040 007	Jul 03, 2012	Jun	NEWA
AB		300MG	A091040 008	Jul 03, 2012	Jun	NEWA
AB	TEVA PHARMS	25MG	A091219 001	Jul 03, 2012	Jun	NEWA
AB		50MG	A091219 002	Jul 03, 2012	Jun	NEWA
AB		75MG	A091224 001	Jul 03, 2012	Jun	NEWA
AB		100MG	A091224 002	Jul 03, 2012	Jun	NEWA
AB		150MG	A091224 003	Jul 03, 2012	Jun	NEWA
AB		200MG	A091224 004	Jul 03, 2012	Jun	NEWA
AB		225MG	A091224 005	Jul 03, 2012	Jun	NEWA
AB		300MG	A091224 006	Jul 03, 2012	Jun	NEWA
AB	WATSON LABS INC	25MG	A091221 001	Jul 03, 2012	Jun	NEWA
AB		50MG	A091221 002	Jul 03, 2012	Jun	NEWA
AB		75MG	A091221 003	Jul 03, 2012	Jun	NEWA
AB		100MG	A091221 004	Jul 03, 2012	Jun	NEWA
AB		150MG	A091221 005	Jul 03, 2012	Jun	NEWA
AB		200MG	A091221 006	Jul 03, 2012	Jun	NEWA
AB		225MG	A091221 007	Jul 03, 2012	Jun	NEWA
AB		300MG	A091221 008	Jul 03, 2012	Jun	NEWA

SOLUTION; ORAL

LYRICA

+	PF PRISM	20MG/ML	N022488 001	Jan 04, 2010	Jan	CAHN
---	----------	---------	-------------	--------------	-----	------

PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST PLAIN DENTAL

@ DENTSPLY PHARM 4%

N021382 001 May DISC

PRILOCAINE HYDROCHLORIDE

+	SEPTODONT INC	4%	A079235 001	Sep 29, 2010	May	CRLD
---	---------------	----	-------------	--------------	-----	------

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINAMIDE HYDROCHLORIDE

@ HIKMA MAPLE 100MG/ML

A089029 001 Apr 17, 1986 Jun CAHN

@ 500MG/ML

A089030 001 Apr 17, 1986 Jun CAHN

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE

@ HIKMA MAPLE EQ 5MG BASE/ML

A089523 001 May 03, 1988 Jun CAHN

AP + EQ 5MG BASE/ML

A089903 001 Aug 29, 1989 Jun CAHN

PROGESTERONE

CAPSULE; ORAL

PROGESTERONE

AB TEVA PHARMS 100MG

A202121 001 Feb 29, 2012 Feb NEWA

AB 200MG

A202121 002 Feb 29, 2012 Feb NEWA

PROMETRIUM

AB ABBOTT LABS 100MG

N019781 001 May 14, 1998 Feb CFTG

AB + 200MG

N019781 002 Oct 15, 1999 Feb CFTG

PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE

AA TRIS PHARMA INC 6.25MG/5ML

A091675 001 Jun 28, 2012 Jun NEWA

PROPAFENONE HYDROCHLORIDE

TABLET; ORAL

PROPAFENONE HYDROCHLORIDE

@ NESHER PHARMS 150MG

A076193 001 Feb 07, 2002 Jun DISC

@ 225MG

A076193 002 Feb 07, 2002 Jun DISC

@ 300MG

A076193 003 Feb 07, 2002 Jun DISC

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

VIVACTIL

@ TEVA WOMENS R AND D 5MG

N016012 001 Jul CAHN

@ 10MG

N016012 002 Jul CAHN

PYRIDOSTIGMINE BROMIDE

TABLET; ORAL

MESTINON

AB + VALEANT PHARMS LLC 60MG

N009829 002 Jun CAHN

TABLET, EXTENDED RELEASE; ORAL

MESTINON

+ VALEANT PHARMS LLC 180MG

N011665 001 Jun CAHN

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

AB ACCORD HLTHCARE INC EQ 25MG BASE

A202152 001 Mar 27, 2012 Mar NEWA

AB EQ 50MG BASE

A202152 002 Mar 27, 2012 Mar NEWA

AB EQ 100MG BASE

A202152 003 Mar 27, 2012 Mar NEWA

AB EQ 200MG BASE

A202152 004 Mar 27, 2012 Mar NEWA

AB EQ 300MG BASE

A202152 005 Mar 27, 2012 Mar NEWA

TABLET; ORAL

QUETIAPINE FUMARATE

AB	ACCORD HLTHCARE INC	EQ 400MG BASE	A202152 006	Mar 27, 2012	Mar	NEWA
AB	APOTEX INC	EQ 25MG BASE	A090960 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A090960 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A090960 003	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A090960 004	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A090960 005	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A090960 006	Mar 27, 2012	Mar	NEWA
AB	AUROBINDO PHARMA LTD	EQ 25MG BASE	A091388 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A091388 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A091388 003	Mar 27, 2012	Mar	NEWA
AB		EQ 150MG BASE	A091388 004	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A091388 005	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A091388 006	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A091388 007	Mar 27, 2012	Mar	NEWA
AB	DR REDDYS LABS LTD	EQ 25MG BASE	A077380 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A077380 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A077380 003	Mar 27, 2012	Mar	NEWA
AB		EQ 150MG BASE	A077380 004	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A077380 005	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A077380 006	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A077380 007	Mar 27, 2012	Mar	NEWA
AB	LUPIN LTD	EQ 25MG BASE	A201109 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A201109 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A201109 003	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A201109 004	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A201109 005	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A201109 006	Mar 27, 2012	Mar	NEWA
AB	MYLAN PHARMS INC	EQ 25MG BASE	A090323 001	Mar 27, 2012	Mar	NEWA
AB	ROXANE	EQ 25MG BASE	A090120 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A090749 001	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A090749 002	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A090749 003	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A090749 004	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A090749 005	Mar 27, 2012	Mar	NEWA
AB	SUN PHARMA GLOBAL	EQ 25MG BASE	A201190 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A201190 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A201190 003	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A201190 004	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A201190 005	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A201190 006	Mar 27, 2012	Mar	NEWA
AB	TEVA PHARMS	EQ 25MG BASE	A077745 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A077745 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A077745 003	Mar 27, 2012	Mar	NEWA
AB		EQ 150MG BASE	A077745 004	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A077745 005	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A077745 006	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A077745 007	Mar 27, 2012	Mar	NEWA
AB	TORRENT PHARMS LTD	EQ 25MG BASE	A200363 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A200363 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A200363 003	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A200363 004	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A200363 005	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A200363 006	Mar 27, 2012	Mar	NEWA

TABLET; ORAL

SEROQUEL

AB	+	ASTRAZENECA	EQ 25MG BASE	N020639 001	Sep 26, 1997	Mar	CFTG
AB			EQ 50MG BASE	N020639 007	Oct 04, 2005	Mar	CFTG
AB			EQ 100MG BASE	N020639 002	Sep 26, 1997	Mar	CFTG
AB			EQ 200MG BASE	N020639 003	Sep 26, 1997	Mar	CFTG
AB	+		EQ 300MG BASE	N020639 005	Jul 26, 2000	Mar	CFTG
AB			EQ 400MG BASE	N020639 006	Oct 04, 2005	Mar	CFTG

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

>D>	AB	SANDOZ	EQ 5MG BASE	A076803 001	Mar 02, 2005	Aug	DISC
>A>		@	EQ 5MG BASE	A076803 001	Mar 02, 2005	Aug	DISC
>D>	AB		EQ 10MG BASE	A076803 002	Mar 02, 2005	Aug	DISC
>A>		@	EQ 10MG BASE	A076803 002	Mar 02, 2005	Aug	DISC
>D>	AB		EQ 20MG BASE	A076803 003	Mar 02, 2005	Aug	DISC
>A>		@	EQ 20MG BASE	A076803 003	Mar 02, 2005	Aug	DISC
>D>	AB		EQ 40MG BASE	A076803 004	Mar 02, 2005	Aug	DISC
>A>		@	EQ 40MG BASE	A076803 004	Mar 02, 2005	Aug	DISC

RAMELTEON

TABLET; ORAL

ROZEREM

+	TAKEDA PHARMS USA	8MG	N021782 001	Jul 22, 2005	Jul	CAHN
---	-------------------	-----	-------------	--------------	-----	------

RAMIPRIL

CAPSULE; ORAL

RAMIPRIL

@ RANBAXY LABS LTD

5MG

A078849 001 Mar 06, 2009 Apr DISC

@

10MG

A078849 002 Mar 06, 2009 Apr DISC

TABLET; ORAL

ALTACE

@ KING PFIZER

1.25MG

N022021 001 Feb 27, 2007 Jan DISC

@

2.5MG

N022021 002 Feb 27, 2007 Jan DISC

@

5MG

N022021 003 Feb 27, 2007 Jan DISC

@

10MG

N022021 004 Feb 27, 2007 Jan DISC

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

ZANTAC

AP	+	COVIS PHARMA	EQ 25MG BASE/ML	N019090 001	Oct 19, 1984	Mar	CAHN
		ZANTAC IN PLASTIC CONTAINER					
	+	COVIS PHARMA	EQ 1MG BASE/ML	N019593 002	Sep 27, 1991	Mar	CAHN
		@	EQ 50MG BASE/100ML	N019593 001	Dec 17, 1986	Mar	CAHN

RIFAMPIN

CAPSULE; ORAL

RIMACTANE

AB		PROSAM LABS	300MG	N050429 001		Feb	CMFD
----	--	-------------	-------	-------------	--	-----	------

RILPIVIRINE HYDROCHLORIDE

TABLET; ORAL

EDURANT

+	JANSSEN PRODS	EQ 25MG BASE	N202022 001	May 20, 2011	Feb	CAHN
---	---------------	--------------	-------------	--------------	-----	------

RISEDRONATE SODIUM

TABLET; ORAL

ACTONEL

AB	WARNER CHILCOTT LLC	5MG	N020835 002	Apr 14, 2000	Jun	CAHN
AB		30MG	N020835 001	Mar 27, 1998	Jun	CAHN
AB	+	35MG	N020835 003	May 25, 2002	Jun	CAHN
	@	75MG	N020835 004	Apr 16, 2007	Jun	CAHN
	+	150MG	N020835 005	Apr 22, 2008	Jun	CAHN

TABLET, DELAYED RELEASE; ORAL

ATELVIA

+	WARNER CHILCOTT LLC	35MG	N022560 001	Oct 08, 2010	Jun	CAHN
---	---------------------	------	-------------	--------------	-----	------

RISPERIDONE

TABLET; ORAL

RISPERIDONE

AB	PROSAM LABS	0.25MG	A078071 001	Jun 17, 2009	Feb	CMFD
AB		0.5MG	A078071 002	Jun 17, 2009	Feb	CMFD
AB		1MG	A078071 003	Jun 17, 2009	Feb	CMFD
AB		2MG	A078071 004	Jun 17, 2009	Feb	CMFD
AB		3MG	A078071 005	Jun 17, 2009	Feb	CMFD
AB		4MG	A078071 006	Jun 17, 2009	Feb	CMFD

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERIDONE

AB	TEVA	0.5MG	A076908 001	Mar 12, 2012	Feb	NEWA
AB		1MG	A076908 002	Mar 12, 2012	Feb	NEWA
AB		2MG	A076908 003	Mar 12, 2012	Feb	NEWA

RIVASTIGMINE

FILM, EXTENDED RELEASE; TRANSDERMAL

EXELON

>A>	NOVARTIS	13.3MG/24HR	N022083 005	Aug 31, 2012	Aug	NEWA
-----	----------	-------------	-------------	--------------	-----	------

RIVASTIGMINE TARTRATE

CAPSULE; ORAL

RIVASTIGMINE TARTRATE

AB	ALEMBIC PHARMS LTD	EQ 1.5MG BASE	A091689 001	Jun 12, 2012	May	NEWA
AB		EQ 3MG BASE	A091689 002	Jun 12, 2012	May	NEWA
AB		EQ 4.5MG BASE	A091689 003	Jun 12, 2012	May	NEWA
AB		EQ 6MG BASE	A091689 004	Jun 12, 2012	May	NEWA

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ROCURONIUM BROMIDE

>A>	AP	TAMARANG	50MG/5ML (10MG/ML)	A091115 001	Aug 27, 2012	Aug	NEWA
>A>	AP		100MG/10ML (10MG/ML)	A091115 002	Aug 27, 2012	Aug	NEWA

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

AB	APOTEX	EQ 0.25MG BASE	A079165 001	Feb 07, 2012	Jan	NEWA
AB		EQ 0.5MG BASE	A079165 002	Feb 07, 2012	Jan	NEWA
AB		EQ 1MG BASE	A079165 003	Feb 07, 2012	Jan	NEWA
AB		EQ 2MG BASE	A079165 004	Feb 07, 2012	Jan	NEWA
AB		EQ 3MG BASE	A079165 005	Feb 07, 2012	Jan	NEWA
AB		EQ 4MG BASE	A079165 006	Feb 07, 2012	Jan	NEWA

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

AB	APOTEX	EQ 5MG BASE	A079165 007	Feb 07, 2012	Jan	NEWA
----	--------	-------------	-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

REQUIP XL

AB	+	SMITHKLINE BEECHAM	EQ 2MG BASE	N022008 001	Jun 13, 2008	Apr	CFTG
AB			EQ 4MG BASE	N022008 003	Jun 13, 2008	Apr	CFTG
AB			EQ 6MG BASE	N022008 006	Apr 10, 2009	Apr	CFTG
AB			EQ 8MG BASE	N022008 004	Jun 13, 2008	Apr	CFTG
AB			EQ 12MG BASE	N022008 005	Oct 31, 2008	Apr	CFTG

ROPINIROLE HYDROCHLORIDE

AB		ACTAVIS	EQ 2MG BASE	A090869 001	May 17, 2012	Apr	NEWA
AB			EQ 4MG BASE	A090869 002	May 17, 2012	Apr	NEWA
AB			EQ 6MG BASE	A090869 003	May 17, 2012	Apr	NEWA
AB			EQ 8MG BASE	A090869 004	May 17, 2012	Apr	NEWA
AB			EQ 12MG BASE	A090869 005	May 17, 2012	Apr	NEWA
AB		DR REDDYS LABS LTD	EQ 2MG BASE	A201576 001	Jun 06, 2012	May	NEWA
AB			EQ 4MG BASE	A201576 002	Jun 06, 2012	May	NEWA
AB			EQ 6MG BASE	A201576 003	Jun 06, 2012	May	NEWA
AB			EQ 8MG BASE	A201576 004	Jun 06, 2012	May	NEWA
AB			EQ 12MG BASE	A201576 005	Jun 06, 2012	May	NEWA
AB		SANDOZ INC	EQ 2MG BASE	A201047 001	Jun 06, 2012	May	NEWA
AB			EQ 4MG BASE	A201047 003	Jun 06, 2012	May	NEWA
AB			EQ 6MG BASE	A201047 004	Jun 06, 2012	May	NEWA
AB			EQ 8MG BASE	A201047 005	Jun 06, 2012	May	NEWA
AB			EQ 12MG BASE	A201047 006	Jun 06, 2012	May	NEWA
AB		WATSON LABS INC	EQ 2MG BASE	A200431 001	Jun 06, 2012	May	NEWA
AB			EQ 4MG BASE	A200431 002	Jun 06, 2012	May	NEWA
AB			EQ 6MG BASE	A200431 003	Jun 06, 2012	May	NEWA
AB			EQ 8MG BASE	A200431 004	Jun 06, 2012	May	NEWA
AB			EQ 12MG BASE	A200431 005	Jun 06, 2012	May	NEWA
>A>	AB	WOCKHARDT LTD	EQ 2MG BASE	A091395 001	Aug 27, 2012	Aug	NEWA
>A>	AB		EQ 4MG BASE	A091395 002	Aug 27, 2012	Aug	NEWA
>A>	AB		EQ 6MG BASE	A091395 003	Aug 27, 2012	Aug	NEWA
>A>	AB		EQ 8MG BASE	A091395 004	Aug 27, 2012	Aug	NEWA
>A>	AB		EQ 12MG BASE	A091395 005	Aug 27, 2012	Aug	NEWA

ROTIGOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

NEUPRO

UCB INC

		1MG/24HR	N021829 004	Apr 02, 2012	Apr	NEWA
		2MG/24HR	N021829 001	May 09, 2007	Apr	CMFD
		3MG/24HR	N021829 005	Apr 02, 2012	Apr	NEWA
		4MG/24HR	N021829 002	May 09, 2007	Apr	CMFD
		6MG/24HR	N021829 003	May 09, 2007	Apr	CMFD
+		8MG/24HR	N021829 006	Apr 02, 2012	Apr	NEWA

SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

INJECTABLE; INJECTION

QUADRAMET

+	JAZZ EUSA PHARMA	50mCi/ML	N020570 001	Mar 28, 1997	Jul	CAHN
---	------------------	----------	-------------	--------------	-----	------

SERTACONAZOLE NITRATE

CREAM; TOPICAL

ERTACZO

+	VALEANT INTL	2%	N021385 001	Dec 10, 2003	Jan	CAHN
---	--------------	----	-------------	--------------	-----	------

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL

SERTRALINE HYDROCHLORIDE

>D>	AA	RANBAXY	EQ 20MG BASE/ML	A078053 001	Feb 05, 2007	Aug	DISC
>A>		@ RANBAXY LABS LTD	EQ 20MG BASE/ML	A078053 001	Feb 05, 2007	Aug	DISC

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

AB	PROSAM LABS	EQ 25MG BASE	A078175 001	Jul 21, 2010	Feb	CMFD
AB		EQ 50MG BASE	A078175 002	Jul 21, 2010	Feb	CMFD
AB		EQ 100MG BASE	A078175 003	Jul 21, 2010	Feb	CMFD

SILDENAFIL CITRATE

>A> FOR SUSPENSION; ORAL

>A> REVATIO

>A>	+	PFIZER	10MG/ML	N203109 001	Aug 30, 2012	Aug	NEWA
-----	---	--------	---------	-------------	--------------	-----	------

SILVER SULFADIAZINE

CREAM; TOPICAL

THERMAZENE

AB	THEPHARMANETWORK LLC	1%	N018810 001	Dec 23, 1985	Jun	CAHN
----	----------------------	----	-------------	--------------	-----	------

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

AB	PROSAM LABS	5MG	A078735 001	Aug 30, 2010	Feb	CMFD
AB		10MG	A078735 002	Aug 30, 2010	Feb	CMFD
AB		20MG	A078735 003	Aug 30, 2010	Feb	CMFD
AB		40MG	A078735 004	Aug 30, 2010	Feb	CMFD
AB		80MG	A078735 005	Aug 30, 2010	Feb	CMFD

SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JANUVIA

MERCK SHARP DOHME

		EQ 25MG BASE	N021995 001	Oct 16, 2006	May	CAHN
		EQ 50MG BASE	N021995 002	Oct 16, 2006	May	CAHN
+		EQ 100MG BASE	N021995 003	Oct 16, 2006	May	CAHN

SODIUM BICARBONATE; TARTARIC ACID

GRANULE, EFFERVESCENT; ORAL

BAROS

@ MALLINCKRODT INC

460MG/GM; 420MG/GM

N018509 001	Aug 07, 1985	Jan	CAHN
-------------	--------------	-----	------

SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9%

AP	HIKMA (MAPLE)	9MG/ML	A201850 001	Jan 20, 2012	Jan	NEWA
----	---------------	--------	-------------	--------------	-----	------

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

MEDEFIL

9MG/ML

N202832 001	Jan 06, 2012	Jan	NEWA
-------------	--------------	-----	------

SODIUM CHROMATE CR-51

INJECTABLE; INJECTION

CHROMITOPES SODIUM

@ BRACCO

200uCi/ML

N013993 001		Jun	DISC
-------------	--	-----	------

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE; INJECTION

SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE					
AB	HIKMA PHARMS	62.5MG/5ML	A078215 001	Mar 31, 2011	May CAHN

SODIUM IODIDE I-123

CAPSULE; ORAL

SODIUM IODIDE I 123

@ GE HEALTHCARE	100uCi	N017630 001		May	DISC
-----------------	--------	-------------	--	-----	------

SOLUTION; ORAL

SODIUM IODIDE I 123

@ GE HEALTHCARE	2mCi/ML	N017630 002		Jul	DISC
-----------------	---------	-------------	--	-----	------

SODIUM IODIDE I-131

CAPSULE; ORAL

SODIUM IODIDE I-131

JUBILANT DRAXIMAGE

9-100mCi

N021305 006	May 19, 2005	Feb	CAHN
-------------	--------------	-----	------

@

2-200mCi

N021305 004	Nov 18, 2004	Jan	DISC
-------------	--------------	-----	------

SOLUTION; ORAL

HICON

@ JUBILANT DRAXIMAGE

1-1000mCi/ML

N021305 005	Apr 04, 2006	Feb	DISC
-------------	--------------	-----	------

@

1-250mCi/0.25ML

N021305 002	Jan 24, 2003	Feb	DISC
-------------	--------------	-----	------

@

1-500mCi/0.5ML

N021305 003	Jan 24, 2003	Feb	DISC
-------------	--------------	-----	------

+

250-1000mCi

N021305 007	Dec 05, 2011	Jan	NEWA
-------------	--------------	-----	------

SODIUM NITRITE

SOLUTION; INTRAVENOUS

SODIUM NITRITE

+	HOPE PHARMS	300MG/10ML (30MG/ML)
---	-------------	----------------------

N203922 001	Feb 14, 2012	Feb	NEWA
-------------	--------------	-----	------

SODIUM OXYBATE

SOLUTION; ORAL

XYREM

+	JAZZ PHARMS	500MG/ML
---	-------------	----------

N021196 001	Jul 17, 2002	Jun	CAHN
-------------	--------------	-----	------

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

@ CITRUSPHRMA 454GM/BOT

A040909 001	Dec 03, 2008	Jun	DISC
-------------	--------------	-----	------

SODIUM THIOSULFATE

SOLUTION; INTRAVENOUS

SODIUM THIOSULFATE

+	HOPE PHARMS	12.5GM/50ML (250MG/ML)
---	-------------	------------------------

N203923 001	Feb 14, 2012	Feb	NEWA
-------------	--------------	-----	------

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

NORDITROPIN

@ NOVO NORDISK INC 5MG/1.5ML

N021148 001	Jun 20, 2000	Jul	DISC
-------------	--------------	-----	------

@

10MG/1.5ML

N021148 002	Jun 20, 2000	Jul	DISC
-------------	--------------	-----	------

@

15MG/1.5ML

N021148 003	Jun 20, 2000	Jul	DISC
-------------	--------------	-----	------

SOTALOL HYDROCHLORIDE

TABLET; ORAL

SOTALOL HYDROCHLORIDE

AB2	EPIC PHARMA INC	80MG	A077070 001	Nov 04, 2005	Jun	CAHN
AB2		120MG	A077070 002	Nov 04, 2005	Jun	CAHN
AB2		160MG	A077070 003	Nov 04, 2005	Jun	CAHN

SPINOSAD

SUSPENSION; TOPICAL

NATROBA

+	PARAPRO LLC	0.9%	N022408 001	Jan 18, 2011	May	CAHN
---	-------------	------	-------------	--------------	-----	------

SUCCIMER

CAPSULE; ORAL

CHEMET

+	LUNDBECK LLC	100MG	N019998 002	Jan 30, 1991	Mar	CAHN
---	--------------	-------	-------------	--------------	-----	------

SULFACETAMIDE SODIUM

LOTION; TOPICAL

SULFACETAMIDE SODIUM

AB	FOUGERA PHARMS	10%	A077015 001	Nov 17, 2006	Jan	CAHN
----	----------------	-----	-------------	--------------	-----	------

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL

SULFATRIM

>D>	@ ACTAVIS MID ATLANTIC	200MG/5ML;40MG/5ML	N018615 002	Jan 07, 1983	Aug	CAHN
-----	------------------------	--------------------	-------------	--------------	-----	------

>A>	@ STI PHARMA LLC	200MG/5ML;40MG/5ML	N018615 002	Jan 07, 1983	Aug	CAHN
-----	------------------	--------------------	-------------	--------------	-----	------

SULFATRIM PEDIATRIC

>D>	AB	ACTAVIS MID ATLANTIC	200MG/5ML;40MG/5ML	N018615 001	Jan 07, 1983	Aug	CAHN
-----	----	----------------------	--------------------	-------------	--------------	-----	------

>A>	AB	STI PHARMA LLC	200MG/5ML;40MG/5ML	N018615 001	Jan 07, 1983	Aug	CAHN
-----	----	----------------	--------------------	-------------	--------------	-----	------

SULFANILAMIDE

CREAM; VAGINAL

AVC

+	JAZZ PHARMS COMMERCL	15%	N006530 003	Jan 27, 1987	Mar	CAHN
---	----------------------	-----	-------------	--------------	-----	------

+	JAZZ PHARMS II	15%	N006530 003	Jan 27, 1987	Jul	CAHN
---	----------------	-----	-------------	--------------	-----	------

+	JAZZ PHARMS III	15%	N006530 003	Jan 27, 1987	Jun	CAHN
---	-----------------	-----	-------------	--------------	-----	------

SUPPOSITORY; VAGINAL

AVC

@	JAZZ PHARMS COMMERCL	1.05GM	N006530 004	Jan 27, 1987	Mar	CAHN
---	----------------------	--------	-------------	--------------	-----	------

@	JAZZ PHARMS II	1.05GM	N006530 004	Jan 27, 1987	Jul	CAHN
---	----------------	--------	-------------	--------------	-----	------

@	JAZZ PHARMS III	1.05GM	N006530 004	Jan 27, 1987	Jun	CAHN
---	-----------------	--------	-------------	--------------	-----	------

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

ALSUMA

BX	MERIDIAN MEDCL	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022377 001	Jun 29, 2010	Jun	CRLD
----	----------------	-------------------------------------	-------------	--------------	-----	------

SUMATRIPTAN SUCCINATE

AP	INJECTALIA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090310 001	Aug 11, 2010	Mar	CAHN
----	------------	-------------------------------------	-------------	--------------	-----	------

SUMAVEL DOSEPRO

BX	+	ZOGENIX INC	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022239 001	Jul 15, 2009	Jun	CTEC
----	---	-------------	-------------------------------------	-------------	--------------	-----	------

TABLET; ORAL

SUMATRIPTAN SUCCINATE

AB	APOTEX INC	EQ 25MG BASE	A200263 001	Jun 19, 2012	Jun	NEWA
AB		EQ 50MG BASE	A200263 002	Jun 19, 2012	Jun	NEWA
AB		EQ 100MG BASE	A200263 003	Jun 19, 2012	Jun	NEWA

TAFLUPROST

SOLUTION/DROPS; OPHTHALMIC

ZIOPTAN

+	MERCK SHARP DOHME	0.0015%	N202514 001	Feb 10, 2012	Feb	NEWA
---	-------------------	---------	-------------	--------------	-----	------

TALIGLUCERASE ALFA

POWDER; IV (INFUSION)

ELELYSO

+	PFIZER	200 UNITS/VIAL	N022458 001	May 01, 2012	May	NEWA
---	--------	----------------	-------------	--------------	-----	------

TAMOXIFEN CITRATE

SOLUTION; ORAL

SOLTAMOX

>A>	ONCOGENERIX PHARMS	EQ 10MG BASE/5ML	N021807 001	Oct 29, 2005	Aug	CMFD
>D>	@ ROSEMONT	EQ 10MG BASE/5ML	N021807 001	Oct 29, 2005	Aug	CMFD

TABLET; ORAL

TAMOXIFEN CITRATE

@ AEGIS PHARMS

@

EQ 10MG BASE	A076398 001	Mar 31, 2003	Jun	DISC
EQ 20MG BASE	A076398 002	Mar 31, 2003	Jun	DISC

TAZAROTENE

AEROSOL, FOAM; TOPICAL

FABIOR

+	STIEFEL LABS INC	0.1%	N202428 001	May 11, 2012	May	NEWA
---	------------------	------	-------------	--------------	-----	------

TECHNETIUM TC-99M MEDRONATE

INJECTABLE; INJECTION

DRAXIMAGE MDP-10

@ JUBILANT DRAXIMAGE

DRAXIMAGE MDP-25

+	JUBILANT DRAXIMAGE	N/A	N018035 001		May	CAHN
---	--------------------	-----	-------------	--	-----	------

DRAXIMAGE MDP-25

+	JUBILANT DRAXIMAGE	N/A	N018035 002	Feb 27, 2004	May	CAHN
---	--------------------	-----	-------------	--------------	-----	------

TEMAZEPAM

CAPSULE; ORAL

TEMAZEPAM

AB	NOVEL LABS INC	7.5MG	A071457 002	Jun 22, 2012	Jun	NEWA
AB		22.5MG	A071457 003	Jun 22, 2012	Jun	NEWA

TEMOZOLOMIDE

CAPSULE; ORAL

TEMODAR

AB	MERCK SHARP DOHME	5MG	N021029 001	Aug 11, 1999	Jun	CAHN
AB		20MG	N021029 002	Aug 11, 1999	Jun	CAHN
AB		100MG	N021029 003	Aug 11, 1999	Jun	CAHN
AB		140MG	N021029 005	Oct 19, 2006	Jun	CAHN
AB		180MG	N021029 006	Oct 19, 2006	Jun	CAHN
AB	+	250MG	N021029 004	Aug 11, 1999	Jun	CAHN

POWDER; INTRAVENOUS

TEMODAR

+	MERCK SHARP DOHME	100MG/VIAL	N022277 001	Feb 27, 2009	Jun	CAHN
---	-------------------	------------	-------------	--------------	-----	------

TENOFOVIR DISOPROXIL FUMARATE

POWDER; ORAL

VIREAD

+	GILEAD SCIENCES INC	40MG/SC00PFUL	N022577	001	Jan 18, 2012	Jan	NEWA
---	---------------------	---------------	---------	-----	--------------	-----	------

TABLET; ORAL

VIREAD

	GILEAD SCIENCES INC	150MG	N021356	002	Jan 18, 2012	Apr	NEWA
		200MG	N021356	003	Jan 18, 2012	Apr	NEWA
		250MG	N021356	004	Jan 18, 2012	Apr	NEWA

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

	@ RANBAXY LABS LTD	EQ 1MG BASE	A076021	001	Aug 22, 2002	Apr	DISC
	@	EQ 2MG BASE	A076021	002	Aug 22, 2002	Apr	DISC
	@	EQ 5MG BASE	A076021	003	Aug 22, 2002	Apr	DISC
	@	EQ 10MG BASE	A076021	004	Aug 22, 2002	Apr	DISC

TERBUTALINE SULFATE

INJECTABLE; INJECTION

TERBUTALINE SULFATE

	@ TEVA PARENTERAL	1MG/ML	A076853	001	Jul 20, 2004	Jan	DISC
--	-------------------	--------	---------	-----	--------------	-----	------

TERCONAZOLE

CREAM; VAGINAL

TERCONAZOLE

AB	FOUGERA PHARMS	0.4%	A076712	001	Feb 18, 2005	Jan	CAHN
----	----------------	------	---------	-----	--------------	-----	------

SUPPOSITORY; VAGINAL

TERCONAZOLE

AB	FOUGERA PHARMS	80MG	A076850	001	Jul 12, 2006	Jan	CAHN
----	----------------	------	---------	-----	--------------	-----	------

TESAMORELIN ACETATE

POWDER; SUBCUTANEOUS

EGRIFTA

	@ EMD SERONO	EQ 1MG BASE/VIAL	N022505	001	Nov 10, 2010	Jun	DISC
+		EQ 1MG BASE/VIAL	N022505	001	Nov 10, 2010	May	CAHN
+		EQ 2MG BASE/VIAL	N022505	002	Nov 29, 2011	Jun	NEWA

TESTOSTERONE

GEL; TRANSDERMAL

ANDROGEL

BX	+ ABBOTT LABS	1% (50MG/5GM PACKET)	N021015	002	Feb 28, 2000	Feb	CPOT
		1% (25MG/2.5GM PACKET)	N021015	001	Feb 28, 2000	Feb	CPOT

TESTIM

BX	+ AUXILIUM PHARMS	1% (50MG/5GM PACKET)	N021454	001	Oct 31, 2002	Feb	CPOT
----	-------------------	----------------------	---------	-----	--------------	-----	------

TESTOSTERONE

	TEVA PHARMS	25MG/2.5GM PACKET	N202763	001	Feb 14, 2012	Feb	NEWA
		50MG/5GM PACKET	N202763	002	Feb 14, 2012	Feb	NEWA

GEL, METERED; TRANSDERMAL

ANDROGEL

	+ ABBOTT LABS	1% (1.25GM/ACTUATION)	N021015	003	Sep 26, 2003	Jun	CPOT
--	---------------	-----------------------	---------	-----	--------------	-----	------

PELLET; IMPLANTATION

TESTOPEL

	+ ACTIENT PHARMS	75MG	A080911	001		May	CAHN
--	------------------	------	---------	-----	--	-----	------

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

TESTOSTERONE CYPIONATE

AO	HIKMA FARMACEUTICA	200MG/ML	A091244 001	May 01, 2012	Apr	NEWA
AO	MYLAN INSTITUTIONAL	200MG/ML	A040652 001	Dec 11, 2006	Feb	CAHN

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

TESTOSTERONE ENANTHATE

AO	MYLAN INSTITUTIONAL	200MG/ML	A040647 001	Oct 05, 2009	Feb	CAHN
----	---------------------	----------	-------------	--------------	-----	------

TETRABENAZINE

TABLET; ORAL

XENAZINE

	VALEANT PHARMS	12.5MG	N021894 001	Aug 15, 2008	Apr	CAHN
+		25MG	N021894 002	Aug 15, 2008	Apr	CAHN

TETRAHYDROZOLINE HYDROCHLORIDE

SOLUTION; NASAL

TYZINE

+	FOUGERA PHARMS	0.05%	A086576 002		Jan	CAHN
		0.1%	A086576 001		Jan	CAHN

SPRAY; NASAL

TYZINE

+	FOUGERA PHARMS	0.1%	A086576 003		Jan	CAHN
---	----------------	------	-------------	--	-----	------

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

THEO-24

	UCB INC	100MG	A087942 001	Aug 22, 1983	May	CTEC
		200MG	A087943 001	Aug 22, 1983	May	CTEC
		300MG	A087944 001	Aug 22, 1983	May	CTEC
+		400MG	A081034 001	Feb 28, 1992	May	CRLD

THEOPHYLLINE

	@ INWOOD LABS	100MG	A040052 001	Feb 14, 1994	May	DISC
	@	125MG	A040052 002	Feb 14, 1994	May	DISC
	@	200MG	A040052 003	Feb 14, 1994	May	DISC
	@	300MG	A040052 004	Feb 14, 1994	May	DISC

INJECTABLE; INJECTION

THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER

	@ BAXTER HLTHCARE	4MG/ML	N018649 007	Jul 26, 1982	Mar	DISC
	@	40MG/100ML	N018649 001	Jul 26, 1982	Mar	DISC
	@	80MG/100ML	N018649 002	Jul 26, 1982	Mar	DISC
	@	160MG/100ML	N018649 003	Jul 26, 1982	Mar	DISC
	@	200MG/100ML	N018649 004	Jul 26, 1982	Mar	DISC
	@	320MG/100ML	N018649 006	Nov 13, 1985	Mar	DISC
	@	400MG/100ML	N018649 005	Jul 26, 1982	Mar	DISC

SOLUTION; ORAL

THEOPHYLLINE

AA	+	SILARX	80MG/15ML	A091156 001	Apr 13, 2011	Jun	CTEC
AA		TRIS PHARMA INC	80MG/15ML	A091586 001	Jun 15, 2012	Jun	NEWA

TABLET; ORAL

THEOLAIR

+	MEDICIS	125MG	A086399 001		Jul	CAHN
+		250MG	A086399 002		Jul	CAHN

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HYDROCHLORIDE

AP	MYLAN INSTITUTIONAL	100MG/ML	A091623 001	Jun 25, 2012	Jun	NEWA
----	---------------------	----------	-------------	--------------	-----	------

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

GABITRIL

@ CEPHALON

6MG

N020646 006 Nov 29, 2005 Jan DISC

@

8MG

N020646 007 Nov 29, 2005 Jan DISC

@

10MG

N020646 008 Nov 29, 2005 Jan DISC

TINIDAZOLE

TABLET; ORAL

TINDAMAX

AB	MISSION PHARMA	250MG	N021618 001	May 17, 2004	Apr	CFTG
----	----------------	-------	-------------	--------------	-----	------

AB	+	500MG	N021618 002	May 17, 2004	Apr	CFTG
----	---	-------	-------------	--------------	-----	------

TINIDAZOLE

AB	NOVEL LABS INC	250MG	A202044 001	Apr 30, 2012	Apr	NEWA
----	----------------	-------	-------------	--------------	-----	------

AB		500MG	A202044 002	Apr 30, 2012	Apr	NEWA
----	--	-------	-------------	--------------	-----	------

AB	ROXANE	250MG	A201172 001	Apr 30, 2012	Apr	NEWA
----	--------	-------	-------------	--------------	-----	------

AB		500MG	A201172 002	Apr 30, 2012	Apr	NEWA
----	--	-------	-------------	--------------	-----	------

TINZAPARIN SODIUM

INJECTABLE; INJECTION

INNOHEP

@ LEO PHARMA AS

20,000 IU/ML

N020484 001 Jul 14, 2000 Jun DISC

TIZANIDINE HYDROCHLORIDE

CAPSULE; ORAL

TIZANIDINE HYDROCHLORIDE

AB	APOTEX INC	EQ 2MG BASE	A078868 001	Feb 03, 2012	Jan	NEWA
----	------------	-------------	-------------	--------------	-----	------

AB		EQ 4MG BASE	A078868 002	Feb 03, 2012	Jan	NEWA
----	--	-------------	-------------	--------------	-----	------

AB		EQ 6MG BASE	A078868 003	Feb 03, 2012	Jan	NEWA
----	--	-------------	-------------	--------------	-----	------

ZANAFLEX

AB	ACORDA	EQ 2MG BASE	N021447 001	Aug 29, 2002	Jan	CFTG
----	--------	-------------	-------------	--------------	-----	------

AB		EQ 4MG BASE	N021447 002	Aug 29, 2002	Jan	CFTG
----	--	-------------	-------------	--------------	-----	------

AB	+	EQ 6MG BASE	N021447 003	Aug 29, 2002	Jan	CFTG
----	---	-------------	-------------	--------------	-----	------

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

AB	PROSAM LABS	EQ 2MG BASE	A076281 001	Oct 20, 2003	Feb	CMFD
----	-------------	-------------	-------------	--------------	-----	------

AB		EQ 4MG BASE	A076281 002	Oct 20, 2003	Feb	CMFD
----	--	-------------	-------------	--------------	-----	------

AB	SANDOZ INC	EQ 2MG BASE	A076280 001	Nov 26, 2002	Feb	NEWA
----	------------	-------------	-------------	--------------	-----	------

TOLBUTAMIDE

TABLET; ORAL

TOLBUTAMIDE

+	MYLAN PHARMS INC	500MG	A086445 001		Mar	CRLD
---	------------------	-------	-------------	--	-----	------

@ WATSON LABS

500MG

A087318 001 Mar DISC

@

500MG

A086109 001 Mar DISC

TOLCAPONE

TABLET; ORAL

TASMAR

+	VALEANT PHARMS LLC	100MG	N020697 001	Jan 29, 1998	May	CAHN
---	--------------------	-------	-------------	--------------	-----	------

TABLET; ORAL

TASMAR

@ VALEANT PHARMS LLC 200MG

N020697 002 Jan 29, 1998 May CAHN

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

TOPOTECAN HYDROCHLORIDE

AP	INNOPHARMA INC	EQ 4MG BASE/VIAL	A201166 001	Aug 08, 2012	Jul	NEWA
>A>	ONCO THERAPIES LTD	EQ 4MG BASE/VIAL	A091542 001	Aug 28, 2012	Aug	NEWA

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

>D>	AB	SANDOZ	50MG	A075968 001	Jun 25, 2002	Aug	DISC
>A>		@	50MG	A075968 001	Jun 25, 2002	Aug	DISC

TABLET, EXTENDED RELEASE; ORAL

TRAMADOL HYDROCHLORIDE

AB2	ACTAVIS	100MG	A091609 001	Jun 27, 2012	Jun	NEWA
AB2		200MG	A091609 002	Jun 27, 2012	Jun	NEWA
AB2		300MG	A091609 003	Jun 27, 2012	Jun	NEWA
AB2	ANCHEN PHARMS	100MG	A200491 001	Jun 27, 2012	Jun	NEWA
AB2		200MG	A200491 002	Jun 27, 2012	Jun	NEWA
AB2		300MG	A200491 003	Jun 27, 2012	Jun	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

RYBIX ODT

+	SHIONOGI INC	50MG	N021693 001	May 05, 2005	Mar	CTNA
---	--------------	------	-------------	--------------	-----	------

TRANEXAMIC ACID

INJECTABLE; INJECTION

TRANEXAMIC ACID

AP	APP PHARMS LLC	100MG/ML	A091596 001	Mar 02, 2012	May	CAHN
AP	NEXUS PHARMS	100MG/ML	A091596 001	Mar 02, 2012	Feb	NEWA

TRANLYCYPROMINE SULFATE

TABLET; ORAL

PARNATE

AB	+	COVIS PHARMA	EQ 10MG BASE	N012342 003	Aug 16, 1985	Jan	CAHN
----	---	--------------	--------------	-------------	--------------	-----	------

TRETINOIN

CREAM; TOPICAL

AVITA

AB	MYLAN PHARMS INC	0.025%	N020404 003	Jan 14, 1997	Jun	CAHN
----	------------------	--------	-------------	--------------	-----	------

RENOVA

+	VALEANT INTL	0.02%	N021108 001	Aug 31, 2000	Jan	CAHN
---	--------------	-------	-------------	--------------	-----	------

AB2	+		0.05%	N019963 001	Dec 29, 1995	Jan	CAHN
-----	---	--	-------	-------------	--------------	-----	------

RETIN-A

AB	+	VALEANT INTL	0.025%	N019049 001	Sep 16, 1988	Jan	CAHN
----	---	--------------	--------	-------------	--------------	-----	------

AB1	+		0.05%	N017522 001		Jan	CAHN
-----	---	--	-------	-------------	--	-----	------

AB	+		0.1%	N017340 001		Jan	CAHN
----	---	--	------	-------------	--	-----	------

TRETINOIN

AB	PRECISION DERMAT	0.025%	A075264 001	Dec 24, 1998	May	CAHN
----	------------------	--------	-------------	--------------	-----	------

+		0.0375%	A090098 001	Mar 22, 2010	May	CAHN
---	--	---------	-------------	--------------	-----	------

AB1		0.05%	A075265 001	Dec 24, 1998	May	CAHN
-----	--	-------	-------------	--------------	-----	------

AB		0.1%	A075213 001	Dec 24, 1998	May	CAHN
----	--	------	-------------	--------------	-----	------

AB2	SUNEVA MEDCL	0.05%	A076498 001	Sep 15, 2005	May	CAHN
-----	--------------	-------	-------------	--------------	-----	------

GEL; TOPICAL									
RETIN-A									
AB	+	VALEANT INTL	0.01%	N017955 001			Jan	CAHN	
AB	+		0.025%	N017579 002			Jan	CAHN	
TRETINOIN									
AB		PRECISION DERMAT	0.01%	A075589 001	Jun 11, 2002	May	CAHN		
AB			0.025%	A075529 001	Feb 22, 2000	May	CAHN		
SOLUTION; TOPICAL									
RETIN-A									
AT	+	VALEANT INTL	0.05%	N016921 001			Jan	CAHN	
SWAB; TOPICAL									
RETIN-A									
	@	VALEANT INTL	0.05%	N016921 002			Jan	CAHN	
<u>TRIAMCINOLONE ACETONIDE</u>									
AEROSOL, METERED; INHALATION									
AZMACORT									
	@	ABBOTT	0.1MG/INH	N018117 001	Apr 23, 1982	May	DISC		
CREAM; TOPICAL									
TRIAMCINOLONE ACETONIDE									
AT		FOUGERA PHARMS	0.025%	A085692 001			Jan	CAHN	
AT			0.1%	A085692 003			Jan	CAHN	
AT	+		0.5%	A085692 002			Jan	CAHN	
LOTION; TOPICAL									
TRIAMCINOLONE ACETONIDE									
AT		FOUGERA PHARMS	0.025%	A040467 001	Apr 21, 2003	Jan	CAHN		
AT			0.1%	A040467 002	Apr 21, 2003	Jan	CAHN		
OINTMENT; TOPICAL									
TRIAMCINOLONE ACETONIDE									
AT		FOUGERA PHARMS	0.025%	A085691 001			Jan	CAHN	
AT			0.1%	A085691 003			Jan	CAHN	
AT			0.5%	A085691 002			Jan	CAHN	
SPRAY, METERED; NASAL									
TRIAMCINOLONE ACETONIDE									
AB		TEVA PHARMS	0.055MG/SPRAY	A078104 001	Jul 30, 2009	Mar	CAHN		
<u>TRIMETHOBENZAMIDE HYDROCHLORIDE</u>									
INJECTABLE; INJECTION									
TRIMETHOBENZAMIDE HYDROCHLORIDE									
	@	HOSPIRA	100MG/ML	A088804 001	Apr 03, 1987	Jun	DISC		
<u>VALACYCLOVIR HYDROCHLORIDE</u>									
TABLET; ORAL									
VALACYCLOVIR HYDROCHLORIDE									
AB		JUBILANT ORGANOSYS	EQ 500MG BASE	A201506 001	Apr 03, 2012	Mar	NEWA		
AB			EQ 1GM BASE	A201506 002	Apr 03, 2012	Mar	NEWA		
<u>VALGANCICLOVIR HYDROCHLORIDE</u>									
FOR SOLUTION; ORAL									
VALCYTE									
	+	HOFFMANN LA ROCHE	50MG/ML	N022257 001	Aug 28, 2009	May	CAHN		
TABLET; ORAL									
VALCYTE									
	+	HOFFMANN LA ROCHE	EQ 450MG BASE	N021304 001	Mar 29, 2001	May	CAHN		

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

VANCOCIN HYDROCHLORIDE

AB	VIROPHARMA	EQ 125MG BASE	N050606 001	Apr 15, 1986	Mar	CFTG
AB	+	EQ 250MG BASE	N050606 002	Apr 15, 1986	Mar	CFTG

VANCOMYCIN HYDROCHLORIDE

AB	AKORN	EQ 125MG BASE	A065478 001	Apr 09, 2012	Mar	NEWA
AB		EQ 250MG BASE	A065478 002	Apr 09, 2012	Mar	NEWA
AB	APP PHARMS LLC	EQ 125MG BASE	A065453 001	Jun 18, 2012	Jun	NEWA
AB		EQ 250MG BASE	A065453 002	Jun 18, 2012	Jun	NEWA
AB	STRIDES ARCOLAB LTD	EQ 125MG BASE	A065490 001	Apr 09, 2012	Mar	NEWA
AB		EQ 250MG BASE	A065490 002	Apr 09, 2012	Mar	NEWA
AB	WATSON LABS	EQ 125MG BASE	A065510 001	Apr 09, 2012	Mar	NEWA
AB		EQ 250MG BASE	A065510 002	Apr 09, 2012	Mar	NEWA

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

AP	SAGENT PHARMS	EQ 5GM BASE/VIAL	A200837 001	Aug 10, 2012	Jul	NEWA
AP	SANDOZ INC	EQ 5GM BASE/VIAL	A201048 001	Aug 10, 2012	Jul	NEWA
AP		EQ 10GM BASE/VIAL	A201048 002	Aug 10, 2012	Jul	NEWA

VANDETANIB

TABLET; ORAL

CAPRELSA

	IPR PHARMS INC	100MG	N022405 001	Apr 06, 2011	Feb	CTNA
	+	300MG	N022405 002	Apr 06, 2011	Feb	CTNA

VARDENAFIL HYDROCHLORIDE

TABLET; ORAL

LEVITRA

AB	BAYER HLTHCARE	2.5MG	N021400 003	Aug 19, 2003	Apr	CFTG
AB		5MG	N021400 001	Aug 19, 2003	Apr	CFTG
AB		10MG	N021400 002	Aug 19, 2003	Apr	CFTG
AB	+	20MG	N021400 004	Aug 19, 2003	Apr	CFTG

VARDENAFIL HYDROCHLORIDE

AB	TEVA PHARMS	2.5MG	A091347 001	May 03, 2012	Apr	NEWA
AB		5MG	A091347 002	May 03, 2012	Apr	NEWA
AB		10MG	A091347 003	May 03, 2012	Apr	NEWA
AB		20MG	A091347 004	May 03, 2012	Apr	NEWA

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

AP	BEDFORD	10MG/VIAL	A075549 001	Jun 13, 2000	Jun	CRLD	
		20MG/VIAL	A075549 002	Jun 13, 2000	Jun	CRLD	
AP	+	SUN PHARMA GLOBAL	10MG/VIAL	A079001 001	Jun 17, 2009	Jun	CRLD
AP	+		20MG/VIAL	A079001 002	Jun 17, 2009	Jun	CRLD

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

AB	ANCHEN PHARMS	EQ 37.5MG BASE	A078087 001	Mar 16, 2012	Mar	NEWA
AB		EQ 75MG BASE	A078087 002	Mar 16, 2012	Mar	NEWA
AB		EQ 150MG BASE	A078087 003	Mar 16, 2012	Mar	NEWA

TABLET; ORAL

VENLAFAXINE HYDROCHLORIDE

>D>	AB	ACTAVIS TOTOWA	EQ 25MG BASE	A078554 001	Jan 09, 2009	Aug	CAHN
>D>	AB		EQ 37.5MG BASE	A078554 002	Jan 09, 2009	Aug	CAHN
>D>	AB		EQ 50MG BASE	A078554 003	Jan 09, 2009	Aug	CAHN
>D>	AB		EQ 75MG BASE	A078554 004	Jan 09, 2009	Aug	CAHN
>D>	AB		EQ 100MG BASE	A078554 005	Jan 09, 2009	Aug	CAHN
>A>	AB	HERITAGE PHARMS INC	EQ 25MG BASE	A078554 001	Jan 09, 2009	Aug	CAHN
>A>	AB		EQ 37.5MG BASE	A078554 002	Jan 09, 2009	Aug	CAHN
>A>	AB		EQ 50MG BASE	A078554 003	Jan 09, 2009	Aug	CAHN
>A>	AB		EQ 75MG BASE	A078554 004	Jan 09, 2009	Aug	CAHN
>A>	AB		EQ 100MG BASE	A078554 005	Jan 09, 2009	Aug	CAHN

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CALAN SR

AB	+	PFIZER	120MG	N019152 003	Mar 06, 1991	Feb	CTNA
AB	+		180MG	N019152 002	Dec 15, 1989	Feb	CTNA
AB	+		240MG	N019152 001	Dec 16, 1986	Feb	CTNA

VERAPAMIL HYDROCHLORIDE

AB		APOTEX CORP	120MG	A200878 001	Apr 20, 2012	Apr	NEWA
AB			180MG	A200878 002	Apr 20, 2012	Apr	NEWA
AB			240MG	A200878 003	Apr 20, 2012	Apr	NEWA

VIGABATRIN

FOR SOLUTION; ORAL

SABRIL

+	LUNDBECK LLC	500MG/PACKET	N022006 001	Aug 21, 2009	Apr	CAHN
---	--------------	--------------	-------------	--------------	-----	------

TABLET; ORAL

SABRIL

+	LUNDBECK LLC	500MG	N020427 001	Aug 21, 2009	Apr	CAHN
---	--------------	-------	-------------	--------------	-----	------

VILAZODONE HYDROCHLORIDE

TABLET; ORAL

VIIBRYD

+	FOREST LABS INC	10MG	N022567 001	Jan 21, 2011	Apr	CRLD
		40MG	N022567 003	Jan 21, 2011	Apr	CRLD

VINCRISTINE SULFATE

>A>		INJECTABLE, LIPOSOMAL; INTRAVENOUS					
>A>		MARQIBO KIT					
>A>	+	TALON THERAP	5MG/5ML (1MG/ML)	N202497 001	Aug 09, 2012	Aug	NEWA

VINORELBINE

INJECTABLE; INJECTION

VINORELBINE

>A>	AP	ONCO THERAPIES LTD	EQ 10MG BASE/ML	A200148 001	Aug 31, 2012	Aug	NEWA
-----	----	--------------------	-----------------	-------------	--------------	-----	------

VISMODEGIB

CAPSULE; ORAL

ERIVEDGE

+	GENENTECH	150MG	N203388 001	Jan 30, 2012	Jan	NEWA
---	-----------	-------	-------------	--------------	-----	------

VORICONAZOLE

INJECTABLE; IV (INFUSION)

VFEND

AP	+	PFIZER	200MG/VIAL	N021267	001	May 24, 2002	May	CFTG
AP		VORICONAZOLE						
AP		SANDOZ INC	200MG/VIAL	A090862	001	May 30, 2012	May	NEWA
		TABLET; ORAL						
		VORICONAZOLE						
AB		TEVA PHARMS	50MG	A091658	001	Apr 06, 2012	Mar	NEWA
AB			200MG	A091658	002	Apr 06, 2012	Mar	NEWA

ZICONOTIDE

INJECTABLE; INTRATHECAL

PRIALT

		@ JAZZ PHARMS COMMERCL	200MCG/2ML (100MCG/ML)	N021060	003	Dec 28, 2004	Mar	CAHN
		@ JAZZ PHARMS INTL	200MCG/2ML (100MCG/ML)	N021060	003	Dec 28, 2004	Jun	CAHN

ZICONOTIDE ACETATE

INJECTABLE; INTRATHECAL

PRIALT

+		JAZZ PHARMS COMMERCL	100MCG/1ML (100MCG/ML)	N021060	002	Dec 28, 2004	Mar	CAHN
+			500MCG/5ML (100MCG/ML)	N021060	004	Dec 28, 2004	Mar	CAHN
+			500MCG/20ML (25MCG/ML)	N021060	001	Dec 28, 2004	Mar	CAHN
+		JAZZ PHARMS INTL	100MCG/1ML (100MCG/ML)	N021060	002	Dec 28, 2004	Jun	CAHN
+			500MCG/5ML (100MCG/ML)	N021060	004	Dec 28, 2004	Jun	CAHN
+			500MCG/20ML (25MCG/ML)	N021060	001	Dec 28, 2004	Jun	CAHN

ZIDOVUDINE

TABLET; ORAL

ZIDOVUDINE

		@ RANBAXY LABS LTD	300MG	A077327	001	Sep 19, 2005	Apr	DISC
--	--	--------------------	-------	---------	-----	--------------	-----	------

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

GEODON

AB	+	PFIZER	EQ 20MG BASE	N020825	001	Feb 05, 2001	Feb	CFTG
AB			EQ 40MG BASE	N020825	002	Feb 05, 2001	Feb	CFTG
AB			EQ 60MG BASE	N020825	003	Feb 05, 2001	Feb	CFTG
AB			EQ 80MG BASE	N020825	004	Feb 05, 2001	Feb	CFTG

ZIPRASIDONE HYDROCHLORIDE

AB		APOTEX CORP	EQ 20MG BASE	A077561	001	Mar 02, 2012	Feb	NEWA
AB			EQ 40MG BASE	A077561	002	Mar 02, 2012	Feb	NEWA
AB			EQ 60MG BASE	A077561	003	Mar 02, 2012	Feb	NEWA
AB			EQ 80MG BASE	A077561	004	Mar 02, 2012	Feb	NEWA
AB		DR REDDYS LABS INC	EQ 20MG BASE	A077565	001	Mar 02, 2012	Feb	NEWA
AB			EQ 40MG BASE	A077565	002	Mar 02, 2012	Feb	NEWA
AB			EQ 60MG BASE	A077565	003	Mar 02, 2012	Feb	NEWA
AB			EQ 80MG BASE	A077565	004	Mar 02, 2012	Feb	NEWA
AB		LUPIN PHARMS	EQ 20MG BASE	A077560	001	Mar 02, 2012	Feb	NEWA
AB			EQ 40MG BASE	A077560	002	Mar 02, 2012	Feb	NEWA
AB			EQ 60MG BASE	A077560	003	Mar 02, 2012	Feb	NEWA
AB			EQ 80MG BASE	A077560	004	Mar 02, 2012	Feb	NEWA
AB		SANDOZ INC	EQ 20MG BASE	A077562	001	Jun 01, 2012	May	NEWA
AB			EQ 40MG BASE	A077562	002	Jun 01, 2012	May	NEWA
AB			EQ 60MG BASE	A077562	003	Jun 01, 2012	May	NEWA

CAPSULE; ORAL

ZIPRASIDONE HYDROCHLORIDE

AB	SANDOZ INC	EQ 80MG BASE	A077562 004	Jun 01, 2012	May	NEWA
>A>	AB	WOCKHARDT LTD	EQ 20MG BASE	A090348 001	Sep 05, 2012	Aug
>A>	AB		EQ 40MG BASE	A090348 002	Sep 05, 2012	Aug
>A>	AB		EQ 60MG BASE	A090348 003	Sep 05, 2012	Aug
>A>	AB		EQ 80MG BASE	A090348 004	Sep 05, 2012	Aug

ZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

AB	CIPLA LTD	5MG	A077388 001	Jul 30, 2012	Jul	NEWA
AB		10MG	A077388 002	Jul 30, 2012	Jul	NEWA

OTC DRUG PRODUCT LIST - 32ND EDITION

OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

2-1

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE; ORAL

PEPCID COMPLETE

+	MCNEIL CONS	800MG;10MG;165MG	N020958	001	Oct 16, 2000	Mar	CAHN
---	-------------	------------------	---------	-----	--------------	-----	------

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

	@ RANBAXY LABS LTD	5MG/5ML	A090183	002	Apr 24, 2008	Jul	DISC
--	--------------------	---------	---------	-----	--------------	-----	------

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

	@ RANBAXY LABS LTD	5MG/5ML	A090183	001	Apr 24, 2008	Jul	DISC
--	--------------------	---------	---------	-----	--------------	-----	------

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SWAB; TOPICAL

CHLORAPREP ONE-STEP SEPP

>D>	+	CARDINAL HLTH	2%;70% (0.67ML)	N021555	001	Oct 07, 2002	Aug	CAHN
-----	---	---------------	-----------------	---------	-----	--------------	-----	------

>A>	+	CAREFUSION	2%;70% (0.67ML)	N021555	001	Oct 07, 2002	Aug	CAHN
-----	---	------------	-----------------	---------	-----	--------------	-----	------

CHLORAPREP SINGLE SWABSTICK

>D>	+	CARDINAL HLTH	2%;70% (1.75ML)	N021555	002	May 10, 2005	Aug	CAHN
-----	---	---------------	-----------------	---------	-----	--------------	-----	------

>A>	+	CAREFUSION	2%;70% (1.75ML)	N021555	002	May 10, 2005	Aug	CAHN
-----	---	------------	-----------------	---------	-----	--------------	-----	------

CHLORAPREP TRIPLE SWABSTICK

>D>	+	CARDINAL HLTH	2%;70% (5.25ML)	N021555	003	Jun 10, 2009	Aug	CAHN
-----	---	---------------	-----------------	---------	-----	--------------	-----	------

>A>	+	CAREFUSION	2%;70% (5.25ML)	N021555	003	Jun 10, 2009	Aug	CAHN
-----	---	------------	-----------------	---------	-----	--------------	-----	------

CHLORASCRUB MAXI SWABSTICK

+	PROF DSPLS	3.15%;70% (5.1ML)	N021524	003	Jun 03, 2005	Mar	CAHN
---	------------	-------------------	---------	-----	--------------	-----	------

CHLORASCRUB SWAB

+	PROF DSPLS	3.15%;70% (1ML)	N021524	001	Jun 03, 2005	Mar	CAHN
---	------------	-----------------	---------	-----	--------------	-----	------

CHLORASCRUB SWABSTICK

+	PROF DSPLS	3.15%;70% (1.6ML)	N021524	002	Jun 03, 2005	Mar	CAHN
---	------------	-------------------	---------	-----	--------------	-----	------

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

DEXTROMETHORPHAN POLISTIREX

	TRIS PHARMA INC	EQ 30MG HBR/5ML	A091135	001	May 25, 2012	May	NEWA
--	-----------------	-----------------	---------	-----	--------------	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE; ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

	STRIDES ARCOLAB LTD	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A200888	001	Mar 05, 2012	Feb	NEWA
--	---------------------	--	---------	-----	--------------	-----	------

FAMOTIDINE

TABLET, CHEWABLE; ORAL

PEPCID AC

	@ MCNEIL CONS	10MG	N020801	001	Sep 24, 1998	Mar	CAHN
--	---------------	------	---------	-----	--------------	-----	------

+		20MG	N020801	002	Dec 17, 2007	Mar	CAHN
---	--	------	---------	-----	--------------	-----	------

TABLET; ORAL

PEPCID AC

	MCNEIL CONS	10MG	N020325	001	Apr 28, 1995	Mar	CAHN
--	-------------	------	---------	-----	--------------	-----	------

+		20MG	N020325	002	Sep 23, 2003	Mar	CAHN
---	--	------	---------	-----	--------------	-----	------

PEPCID AC (GELTAB)

	MCNEIL CONS	10MG	N020902	001	Aug 05, 1999	Mar	CAHN
--	-------------	------	---------	-----	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

SUN PHARM INDS	30MG	A091567	002	Feb 06, 2012	Jan	NEWA
----------------	------	---------	-----	--------------	-----	------

WOCKHARDT LTD	30MG	A079112	002	Feb 08, 2012	Jan	NEWA
---------------	------	---------	-----	--------------	-----	------

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

SUN PHARM INDS	30MG	A091567	001	Feb 06, 2012	Jan	NEWA
----------------	------	---------	-----	--------------	-----	------

WOCKHARDT LTD	30MG	A079112	001	Feb 08, 2012	Jan	NEWA
---------------	------	---------	-----	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE ALLERGY

SUN PHARM INDS	60MG	A091567	004	Feb 06, 2012	Jan	NEWA
----------------	------	---------	-----	--------------	-----	------

	180MG	A091567	006	Feb 06, 2012	Jan	NEWA
--	-------	---------	-----	--------------	-----	------

WOCKHARDT LTD	60MG	A079112	004	Feb 08, 2012	Jan	NEWA
---------------	------	---------	-----	--------------	-----	------

	180MG	A079112	006	Feb 08, 2012	Jan	NEWA
--	-------	---------	-----	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE HIVES

SUN PHARM INDS	60MG	A091567	003	Feb 06, 2012	Jan	NEWA
----------------	------	---------	-----	--------------	-----	------

	180MG	A091567	005	Feb 06, 2012	Jan	NEWA
--	-------	---------	-----	--------------	-----	------

WOCKHARDT LTD	60MG	A079112	003	Feb 08, 2012	Jan	NEWA
---------------	------	---------	-----	--------------	-----	------

	180MG	A079112	005	Feb 08, 2012	Jan	NEWA
--	-------	---------	-----	--------------	-----	------

IBUPROFEN

CAPSULE; ORAL

IBUPROFEN

ACCUCAPS INDS	EQ 200MG FREE ACID AND POTASSIUM SALT	A077338	001	Jul 10, 2009	Jan	CAHN
---------------	---------------------------------------	---------	-----	--------------	-----	------

IBUPROFEN SODIUM

TABLET; ORAL

ADVIL

+ PFIZER CONS HLTHCARE	EQ 200MG BASE	N201803	001	Jun 12, 2012	Jun	NEWA
------------------------	---------------	---------	-----	--------------	-----	------

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

LANSOPRAZOLE

DR REDDYS LABS LTD	15MG	A202194	001	May 18, 2012	Apr	NEWA
--------------------	------	---------	-----	--------------	-----	------

PERRIGO R AND D	15MG	A202319	001	May 18, 2012	Apr	NEWA
-----------------	------	---------	-----	--------------	-----	------

WOCKHARDT LTD	15MG	A202727	001	May 18, 2012	Apr	NEWA
---------------	------	---------	-----	--------------	-----	------

PREVACID 24 HR

+ NOVARTIS	15MG	N022327	001	May 18, 2009	Apr	CFTG
------------	------	---------	-----	--------------	-----	------

LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL

WATSON LABS INC	1.5MG	A200670	001	Jul 12, 2012	Jun	NEWA
-----------------	-------	---------	-----	--------------	-----	------

PLAN B

+ TEVA BRANDED PHARM	0.75MG	N021045	002	Aug 24, 2006	May	CAHN
----------------------	--------	---------	-----	--------------	-----	------

PLAN B ONE-STEP

+ DURAMED	1.5MG	N021998	001	Jul 10, 2009	Jun	CFTG
-----------	-------	---------	-----	--------------	-----	------

LORATADINE

SYRUP; ORAL

LORATADINE

@ RANBAXY LABS LTD	1MG/ML	A076529	001	Aug 20, 2004	Jul	DISC
--------------------	--------	---------	-----	--------------	-----	------

NICOTINEFILM, EXTENDED RELEASE; TRANSDERMAL
NICOTINE

AVEVA	7MG/24HR	A074612 002	Jul 28, 2003	Apr	NEWA
	14MG/24HR	A074612 003	Oct 20, 1997	Apr	NEWA

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

APOTEX INC	EQ 150MG BASE	A200172 001	May 31, 2012	May	NEWA
SHASUN CHEMS	EQ 75MG BASE	A201745 001	Feb 29, 2012	Feb	NEWA

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 08 AUGUST 2012

NO AUGUST 2012 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO AUGUST 2012 ADDITIONS

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST - 32ND EDITION

A - 1

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ACETYL CYSTEINE - ACETADOTE</u>						
N021539 001	8148356	May 21, 2026	DP			
<u>ACOLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N02450 001	>A> 5840279	Jun 21, 2016	DP		NCE	Jul 23, 2017
	>A> 6071498	Jun 21, 2016	DP			
	>A> 6681768	Aug 07, 2022	DP			
	>A> 6750226	Sep 05, 2020	DS DP U-1264			
	>A> 7078412	Jul 16, 2020	DS DP U-1263			
	>A> 8051851	Apr 22, 2027	DP			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N022320 001	8105618	Dec 23, 2022	U-1078			
	8129362	Jul 18, 2027	U-1078			
	>A> 8241649	Dec 23, 2022	DP			
<u>ALBUMIN HUMAN - OPTISON</u>						
N020899 001					>A> M-120	Aug 17, 2015
<u>ALBUTEROL SULFATE - PROAIR HFA</u>						
N021457 001	6446627	Dec 18, 2017	DP			
	8132712	Sep 07, 2028	DP			
<u>ALBUTEROL SULFATE - VENTOLIN HFA</u>						
N020983 001	>A> 7832351	Jun 19, 2023	DP			
	>A> 7832351*PED	Dec 19, 2023				
<u>ALENDRONATE SODIUM - BINOSTO</u>						
N022344 001	7488496	Aug 11, 2023	DS DP			
	7964212	Mar 06, 2023	DS DP			
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA</u>						
N022217 001	8168616	Jul 05, 2025	DP			
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA</u>						
N022217 002	8168616	Jul 05, 2025	DP			
<u>ALVIMOPAN - ENTEREG</u>						
N021775 001	8112290	Jul 31, 2030	U-1225			
<u>AMBRISANTAN - LETAIRIS</u>						
N022081 001	RE42462	Jul 29, 2018	DS			
<u>AMBRISANTAN - LETAIRIS</u>						
N022081 002	RE42462	Jul 29, 2018	DS			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N020965 001	>A> 8216289	May 01, 2018	U-289			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 001	8101599	May 16, 2023	DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 002	8101599	May 16, 2023	DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 003	8101599	May 16, 2023	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 004	8101599	May 16, 2023	DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 005	8101599	May 16, 2023	DP			
<u>ARFORMOTEROL TARTRATE - BROVANA</u>						
N021912 001	6589508	Apr 03, 2013	U-793			
	6667344	Jun 22, 2021	DP			
	6814953	Jun 22, 2021	U-793			
	8110706	Nov 09, 2021	DP			
<u>ATOVAQUONE; PROGUANIL HYDROCHLORIDE - ATOVAQUONE AND PROGUANIL HYDROCHLORIDE</u>						
A091211 001					PC	Mar 13, 2012
<u>AVANAFIL - STENDRA</u>						
N202276 001	6656935	Sep 13, 2020	DS DP U-155		NCE	Apr 27, 2017
<u>AVANAFIL - STENDRA</u>						
N202276 002	6656935	Sep 13, 2020	DS DP U-155		NCE	Apr 27, 2017
<u>AVANAFIL - STENDRA</u>						
N202276 003	6656935	Sep 13, 2020	DS DP U-155		NCE	Apr 27, 2017
<u>AXITINIB - INLYTA</u>						
N202324 001	6534524	Jun 30, 2020	DS DP		NCE	Jan 27, 2017
	7141581	Jun 30, 2020	U-1220			
<u>AXITINIB - INLYTA</u>						
N202324 002	6534524	Jun 30, 2020	DS DP		NCE	Jan 27, 2017
	7141581	Jun 30, 2020	U-1220			
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N202236 001	8163723	Aug 29, 2023	U-81		NC	May 01, 2015
	8163723	Aug 29, 2023	U-77			
	8163723	Aug 29, 2023	U-707			
	8163723	Aug 29, 2023	U-644			
	8168620	Feb 24, 2026	DP			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N202331 001	5583141	Dec 10, 2013	DS DP U-3			
	5736555	Jun 25, 2012	DS DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N202331 002	5583141	Dec 10, 2013	DS DP U-3			
	5736555	Jun 25, 2012	DS DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
<u>BALSALAZIDE DISODIUM - GIAZO</u>						
N022205 001	6197341	Mar 13, 2018	DP U-1229		NDF	Feb 03, 2015
	7452872	Aug 24, 2026	U-1229			
	7625884	Aug 24, 2026	U-1229			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BECLOMETHASONE DIPROPIONATE - QNASL</u>						
N202813 001	5605674	Feb 25, 2014	DP		NP	Mar 23, 2015
	5683677	Nov 04, 2014	DP			
	5776432	Jul 07, 2015	DP			
	7780038	Jan 24, 2027	DP			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N022249 001					NCE	Mar 20, 2013
					ODE	Mar 20, 2015
					PED	Sep 20, 2015
					PED	Sep 20, 2013
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N022249 002					NCE	Mar 20, 2013
					ODE	Mar 20, 2015
					PED	Sep 20, 2015
					PED	Sep 20, 2013
<u>BIMATOPROST - LATISSE</u>						
N022369 001	8101161	May 25, 2024	U-1218			
	8101161	May 25, 2024	U-1217			
<u>BIVALIRUDIN - ANGIOMAX</u>						
N020873 001	5196404	Dec 15, 2014	DS DP U-1232			
	5196404	Dec 15, 2014	DS DP U-1040			
	5196404*PED	Jun 15, 2015				
<u>BOCEPREVIR - VICTRELIS</u>						
N202258 001	8119602	Mar 17, 2027	U-1233			
	RE43298	Feb 22, 2022	DS DP U-1128			
<u>BORTEZOMIB - VELCADE</u>						
N021602 001					NR	Jan 23, 2015
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N021398 001	8133890	Apr 19, 2022	U-1235			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N021929 001	8143239	Jan 29, 2023	DP U-1073			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N021929 002	8143239	Jan 29, 2023	DP U-1073			
<u>BUPIVACAINE - EXPAREL</u>						
N022496 001	6132766	Nov 16, 2013	DP			
	8182835	Sep 18, 2018	DP U-1246			
<u>BUPIVACAINE - EXPAREL</u>						
N022496 002	6132766	Nov 16, 2013	DP			
	8182835	Sep 18, 2018	DP U-1246			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N022410 003					>A> NDF	Aug 30, 2013
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N022410 004					>A> NDF	Aug 30, 2013

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CARFILZOMIB - KYPROLIS</u>						
N020714 001	7232818	Apr 14, 2025	DS DP		NCE	Jul 20, 2017
	7417042	Jun 07, 2026	DS DP		>A> ODE	Jul 20, 2019
	7491704	Apr 14, 2025	U-1260			
	7737112	Dec 07, 2027	DP			
	8129346	Dec 25, 2026	U-1260			
	8207125	Apr 14, 2025	DS DP			
	8207126	Apr 14, 2025	DP			
	8207127	Apr 14, 2025	U-1260			
	8207297	Apr 14, 2025	DS DP			
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 001	6022562	Oct 17, 2015	DP	Y		
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 002	6022562	Oct 17, 2015	DP	Y		
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 003	6022562	Oct 17, 2015	DP	Y		
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 004	6022562	Oct 17, 2015	DP	Y		
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
<u>CHLORHEXIDINE GLUCONATE - CHLORHEXIDINE GLUCONATE</u>						
N021669 001	7717889	Feb 27, 2025	DP U-1022			
<u>CICLESONIDE - ZETONNA</u>						
N202129 001	5482934	Oct 24, 2017	DS DP U-1002		NP	Jan 20, 2015
	5605674	Feb 25, 2014	DP			
	5683677	Nov 04, 2014	DP			
	5775321	Jul 07, 2015	DP			
	6006745	Dec 28, 2016	DP			
	6036942	Apr 30, 2013	DP			
	6120752	May 13, 2018	DP			
	6264923	May 13, 2018	DP			
<u>CICLOPIROX - LOPROX</u>						
N021159 001	8227490	Sep 16, 2017	U-1256			
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - PREPOPIK</u>						
N202535 001					NP	Jul 16, 2015
<u>CLEVIDIPINE BUTYRATE - CLEVIPREX</u>						
N022156 001	5856346	Jan 05, 2021	DS DP U-893			
<u>CLEVIDIPINE BUTYRATE - CLEVIPREX</u>						
N022156 002	5856346	Jan 05, 2021	DS DP U-893			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
A078223 001					PC	Jun 30, 2012
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
A078854 001					PC	Jun 30, 2012
<u>CLOPIDOGREL BISULFATE - CLOPIDOGREL BISULFATE</u>						
A077665 002					PC	Nov 13, 2012
<u>CLOPIDOGREL BISULFATE - CLOPIDOGREL BISULFATE</u>						
A091023 001					PC	Nov 13, 2012
<u>COLCHICINE - COLCRYS</u>						
N022352 001	7964648	Oct 06, 2028	U-1161			
	8097655	Oct 06, 2028	U-1020			
<u>CRIZOTINIB - XALKORI</u>						
N202570 001	8217057	Nov 06, 2029	DS DP			
<u>CRIZOTINIB - XALKORI</u>						
N202570 002	8217057	Nov 06, 2029	DS DP			
<u>DAPTOMYCIN - CUBICIN</u>						
N021572 002	8129342	Nov 28, 2020	DS DP			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 001	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-935			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	>A> RE43596	May 09, 2017	DS DP			
	>A> RE43596*PED	Nov 09, 2017				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 002	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-935			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	>A> RE43596	May 09, 2017	DS DP			
	>A> RE43596*PED	Nov 09, 2017				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 003	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-935			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	>A> RE43596	May 09, 2017	DS DP			
	>A> RE43596*PED	Nov 09, 2017				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 004	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-935			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	>A> RE43596	May 09, 2017	DS DP			
	>A> RE43596*PED	Nov 09, 2017				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 005	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-935			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	>A> RE43596	May 09, 2017	DS DP			
	>A> RE43596*PED	Nov 09, 2017				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N020895 001	5843946	Dec 01, 2015	DP U-1209			
	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-1209			
	6037157*PED	Dec 26, 2016				
	6248775	Aug 13, 2014	DS			
	6248775*PED	Feb 13, 2015				
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	RE42889	Oct 19, 2016	DP			
	RE42889*PED	Apr 19, 2017				
	>A> RE43596	May 09, 2017	DS DP			
	>A> RE43596*PED	Nov 09, 2017				
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N022201 001	5925730	May 18, 2021	DS DP U-943			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N022201 002	5925730	May 18, 2021	DS DP U-943			
<u>DESLOMATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX-D 12 HOUR</u>						
N021313 001	8187630	Dec 19, 2020	DP U-1017			
<u>DEXAMETHASONE - OZURDEX</u>						
N022315 001	8088407	Oct 20, 2020	DP U-1205			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N022287 001	8105626	Sep 27, 2026	DP			
	8105626*PED	Mar 27, 2027				
	8173158	Mar 17, 2030	U-951			
	8173158	Mar 17, 2030	U-950			
	8173158	Mar 17, 2030	U-949			
	8173158*PED	Sep 17, 2030				
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N022287 002	8105626	Sep 27, 2026	DP			
	8105626*PED	Mar 27, 2027				
	8173158	Mar 17, 2030	U-951			
	8173158	Mar 17, 2030	U-950			
	8173158	Mar 17, 2030	U-949			
	8173158*PED	Sep 17, 2030				
<u>DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE - NUEDEXTA</u>						
N021879 001	8227484	Jul 17, 2023	U-1093			
<u>DICLOFENAC POTASSIUM - CAMBIA</u>						
N022165 001	8097651	Jun 16, 2026	DS DP U-436			
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N022202 001	8110606	Feb 24, 2029	U-980			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N020947 001	8217078	Jul 10, 2029	U-1248			
<u>DIENOGEST; ESTRADIOL VALERATE - NATAZIA</u>						
N022252 001	8153616	Jan 30, 2028	U-1240		I-648	Mar 14, 2015
<u>DIFLUPREDNATE - DUREZOL</u>						
N022212 001					I-653 ODE	Jun 13, 2015 Jun 13, 2019
<u>DORIPENEM - DORIBAX</u>						
N022106 001	>A> 8247402	Mar 30, 2021	DS DP			
<u>DORIPENEM - DORIBAX</u>						
N022106 002	>A> 8247402	Mar 30, 2021	DS DP			
<u>DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE - COSOPT PF</u>						
N202667 001					NP	Feb 01, 2015
<u>DOXYCYCLINE - ORACEA</u>						
N050805 001	8206740	Dec 24, 2025	DP U-925			
<u>DRONEDARONE HYDROCHLORIDE - MULTAQ</u>						
N022425 001	>A> 5223510	Jul 26, 2013	DS DP U-992			
	>A> 5223510	Jul 26, 2013	DS DP U-1261			
<u>DROSPIRENONE; ESTRADIOL - ANGELIQ</u>						
N021355 001					NS	Mar 01, 2015
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427 001	5023269	Jun 11, 2013	DS DP U-882		I-632	Nov 04, 2013
	5023269	Jun 11, 2013	DS DP U-839		I-617	Nov 19, 2012
	5023269	Jun 11, 2013	DS DP U-799		PED	May 04, 2014
	5023269	Jun 11, 2013	DS DP U-797		PED	May 19, 2013
	5023269	Jun 11, 2013	DS DP U-796			
	5023269	Jun 11, 2013	DS DP U-795			
	5023269	Jun 11, 2013	DS DP U-605			
	5023269	Jun 11, 2013	DS DP U-398			
	5023269	Jun 11, 2013	DS DP U-1094			
	5023269*PED	Dec 11, 2013				
	5508276	Jul 18, 2014	DP			
	5508276*PED	Jan 18, 2015				
	6596756	Sep 10, 2019	U-882			
	6596756*PED	Mar 10, 2020				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427 002	5023269	Jun 11, 2013	DS DP U-882		I-632	Nov 04, 2013
	5023269	Jun 11, 2013	DS DP U-839		I-617	Nov 19, 2012
	5023269	Jun 11, 2013	DS DP U-799		PED	May 04, 2014
	5023269	Jun 11, 2013	DS DP U-797		PED	May 19, 2013
	5023269	Jun 11, 2013	DS DP U-796			
	5023269	Jun 11, 2013	DS DP U-795			
	5023269	Jun 11, 2013	DS DP U-605			
	5023269	Jun 11, 2013	DS DP U-398			
	5023269	Jun 11, 2013	DS DP U-1094			
	5023269*PED	Dec 11, 2013				
	5508276	Jul 18, 2014	DP			
	5508276*PED	Jan 18, 2015				
	6596756	Sep 10, 2019	U-882			
	6596756*PED	Mar 10, 2020				
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427 004	5023269	Jun 11, 2013	DS DP U-882		I-632	Nov 04, 2013
	5023269	Jun 11, 2013	DS DP U-839		I-617	Nov 19, 2012
	5023269	Jun 11, 2013	DS DP U-799		PED	May 04, 2014
	5023269	Jun 11, 2013	DS DP U-797		PED	May 19, 2013
	5023269	Jun 11, 2013	DS DP U-796			
	5023269	Jun 11, 2013	DS DP U-795			
	5023269	Jun 11, 2013	DS DP U-605			
	5023269	Jun 11, 2013	DS DP U-398			
	5023269	Jun 11, 2013	DS DP U-1094			
	5023269*PED	Dec 11, 2013				
	5508276	Jul 18, 2014	DP			
	5508276*PED	Jan 18, 2015				
	6596756	Sep 10, 2019	U-882			
	6596756*PED	Mar 10, 2020				
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N021937 001	5663169	Sep 02, 2014	U-750			
	5663169	Sep 02, 2014	U-1170			
	5811423	Aug 07, 2012	U-750			
	5811423	Aug 07, 2012	U-1170			
	5922695	Jul 25, 2017	DS U-750			
	5922695	Jul 25, 2017	DS U-1170			
	5935946	Jul 25, 2017	DS DP U-750			
	5935946	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-750			
	5977089	Jul 25, 2017	DS DP U-1170			
	6043230	Jul 25, 2017	U-750			
	6043230	Jul 25, 2017	U-1170			
	6642245	Nov 04, 2020	U-750			
	6642245	Nov 04, 2020	U-1170			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 001	>A> 7160870	Nov 20, 2022	DS DP U-930			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 002	>A> 7160870	Nov 20, 2022	DS DP U-930			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 003	>A> 7160870	Nov 20, 2022	DS DP U-930			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 004	>A> 7160870	Nov 20, 2022	DS DP U-930			
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u>						
N202123 001	8080551	Apr 11, 2023	DS DP		NCE	May 20, 2016
	8101629	Aug 09, 2022	DP			
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N021752 001	5922695	Jul 25, 2017	DS U-1259			
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-541			
	5922695	Jul 25, 2017	DS U-1170			
	5935946	Jul 25, 2017	DS DP U-541			
	5935946	Jul 25, 2017	DS DP U-1170			
	5935946	Jul 25, 2017	DS DP U-1259			
	5935946	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-1259			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-541			
	5977089	Jul 25, 2017	DS DP U-1170			
	6043230	Jul 25, 2017	DP U-541			
	6043230	Jul 25, 2017	DP U-1170			
	6043230	Jul 25, 2017	DP U-1259			
	6043230	Jul 25, 2017	DP U-248			
<u>ENZALUTAMIDE - XTANDI</u>						
N203415 001					>A> NCE	Aug 31, 2017
<u>EPINEPHRINE - AUVI-Q</u>						
N201739 001	>A> 8226610	Apr 10, 2029	DP			
	>A> 8231573	Nov 25, 2028	DP			
<u>EPROSARTAN MESYLATE - EPROSARTAN MESYLATE</u>						
A202012 001					PC	Jun 17, 2012
<u>EPROSARTAN MESYLATE - EPROSARTAN MESYLATE</u>						
A202012 002					PC	Jun 17, 2012
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N201532 001	8097648	Jan 22, 2021	U-1096			
<u>ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE</u>						
A076765 001					PC	Sep 10, 2012
<u>ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE</u>						
A076765 002					PC	Sep 10, 2012
<u>ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE</u>						
A076765 003					PC	Sep 10, 2012
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 001	5877192	May 27, 2014	U-773			
	5877192	May 27, 2014	U-729			
	5877192	May 27, 2014	U-1207			
	5877192*PED	Nov 27, 2014				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 002	5877192	May 27, 2014	U-773			
	5877192	May 27, 2014	U-729			
	5877192	May 27, 2014	U-1207			
	5877192*PED	Nov 27, 2014				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 003	5690960	Nov 25, 2014	DP U-1207			
	5690960*PED	May 25, 2015				
	5714504	Feb 03, 2015	DP U-1207			
	5714504*PED	Aug 03, 2015				
	5877192	May 27, 2014	U-1207			
	5877192*PED	Nov 27, 2014				
	5900424	May 04, 2016	DS U-1207			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1207			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-1207			
	6428810*PED	May 03, 2020				
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS			
	7411070*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 004	5690960	Nov 25, 2014	DP U-1207			
	5690960*PED	May 25, 2015				
	5714504	Feb 03, 2015	DP U-1207			
	5714504*PED	Aug 03, 2015				
	5877192	May 27, 2014	U-1207			
	5877192*PED	Nov 27, 2014				
	5900424	May 04, 2016	DS U-1207			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1207			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-1207			
	6428810*PED	May 03, 2020				
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS			
	7411070*PED	Nov 25, 2018				
<u>ESZOPICLONE - LUNESTA</u>						
N021476 001	6319926	Jan 16, 2012	U-620			
	6319926*PED	Jul 16, 2012				
	6444673	Feb 14, 2014	DS DP			
	6444673*PED	Aug 14, 2014				
	6864257	Aug 30, 2012	U-629			
	6864257*PED	Mar 02, 2013				
	7381724	Jan 16, 2012	DS DP U-629			
	7381724*PED	Jul 16, 2012				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESZOPICLONE - LUNESTA</u>						
N021476 002	6319926	Jan 16, 2012	U-620			
	6319926*PED	Jul 16, 2012				
	6444673	Feb 14, 2014	DS DP			
	6444673*PED	Aug 14, 2014				
	6864257	Aug 30, 2012	U-629			
	6864257*PED	Mar 02, 2013				
	7381724	Jan 16, 2012	DS DP U-629			
	7381724*PED	Jul 16, 2012				
<u>ESZOPICLONE - LUNESTA</u>						
N021476 003	6319926	Jan 16, 2012	U-620			
	6319926*PED	Jul 16, 2012				
	6444673	Feb 14, 2014	DS DP			
	6444673*PED	Aug 14, 2014				
	6864257	Aug 30, 2012	U-629			
	6864257*PED	Mar 02, 2013				
	7381724	Jan 16, 2012	DS DP U-629			
	7381724*PED	Jul 16, 2012				
<u>ETONOGESTREL - NEXPLANON</u>						
N021529 002					NP	May 31, 2014
<u>ETRAVIRINE - INTELENCE</u>						
N022187 001	6878717	Nov 05, 2019	U-256		NPP	Mar 26, 2015
	6878717	Nov 05, 2019	U-1237			
	6878717	Nov 05, 2019	U-1016			
	7037917	Dec 13, 2020	DS DP U-256			
	7037917	Dec 13, 2020	DS DP U-1237			
	7037917	Dec 13, 2020	DS DP U-1016			
<u>ETRAVIRINE - INTELENCE</u>						
N022187 002	6878717	Nov 05, 2019	U-256		NPP	Mar 26, 2015
	6878717	Nov 05, 2019	U-1237			
	6878717	Nov 05, 2019	U-1016			
	7037917	Dec 13, 2020	DS DP U-256			
	7037917	Dec 13, 2020	DS DP U-1237			
	7037917	Dec 13, 2020	DS DP U-1016			
<u>ETRAVIRINE - INTELENCE</u>						
N022187 003	6878717	Nov 05, 2019	U-256		NPP	Mar 26, 2015
	6878717	Nov 05, 2019	U-1237		NCE	Jan 18, 2013
	6878717	Nov 05, 2019	U-1016			
	7037917	Dec 13, 2020	DS DP U-1237			
	7887845	Mar 25, 2019	DP			
	8003789	Nov 01, 2019	DS DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE	
EVEROLIMUS - AFINITOR								
N022334 001	5665772	Sep	09, 2019	DS DP		I-655	Jul	20, 2015
	5665772*PED	Mar	09, 2020			I-650	Apr	26, 2015
	6004973	Jul	12, 2016	DP		I-638	May	05, 2014
	6004973*PED	Jan	12, 2017			I-630	Oct	29, 2013
	7297703	Dec	06, 2019	DP		NCE	Mar	30, 2014
	7297703*PED	Jun	06, 2020			ODE	Apr	26, 2019
						ODE	May	05, 2018
						ODE	Oct	29, 2017
						PED	Oct	26, 2019
						PED	Nov	05, 2018
						PED	Apr	29, 2018
						PED	Oct	26, 2015
						PED	Nov	05, 2014
						PED	Sep	30, 2014
						PED	Apr	29, 2014
EVEROLIMUS - AFINITOR								
N022334 002	5665772	Sep	09, 2019	DS DP		I-655	Jul	20, 2015
	5665772*PED	Mar	09, 2020			I-650	Apr	26, 2015
	6004973	Jul	12, 2016	DP		I-638	May	05, 2014
	6004973*PED	Jan	12, 2017			I-630	Oct	29, 2013
	7297703	Dec	06, 2019	DP		NCE	Mar	30, 2014
	7297703*PED	Jun	06, 2020			ODE	Apr	26, 2019
						ODE	May	05, 2018
						ODE	Oct	29, 2017
						PED	Oct	26, 2019
						PED	Nov	05, 2018
						PED	Apr	29, 2018
						PED	Oct	26, 2015
						PED	Nov	05, 2014
						PED	Sep	30, 2014
						PED	Apr	29, 2014
EVEROLIMUS - AFINITOR								
N022334 003	5665772	Sep	09, 2019	DS DP		I-655	Jul	20, 2015
	5665772*PED	Mar	09, 2020			I-650	Apr	26, 2015
	6004973	Jul	12, 2016	DP		I-638	May	05, 2014
	6004973*PED	Jan	12, 2017			I-630	Oct	29, 2013
	7297703	Dec	06, 2019	DP		NCE	Mar	30, 2014
	7297703*PED	Jun	06, 2020			ODE	Apr	26, 2019
						ODE	May	05, 2018
						ODE	Oct	29, 2017
						PED	Oct	26, 2019
						PED	Nov	05, 2018
						PED	Apr	29, 2018
						PED	Oct	26, 2015
						PED	Nov	05, 2014
						PED	Sep	30, 2014
						PED	Apr	29, 2014
EVEROLIMUS - AFINITOR								
N022334 004	5665772	Sep	09, 2019	DS DP		I-655	Jul	20, 2015
	5665772*PED	Mar	09, 2020			I-650	Apr	26, 2015
	6004973	Jul	12, 2016	DP		I-638	May	05, 2014
	6004973*PED	Jan	12, 2017			I-630	Oct	29, 2013
	7297703	Dec	06, 2019	DP		NCE	Mar	30, 2014
	7297703*PED	Jun	06, 2020			ODE	Apr	26, 2019
						ODE	May	05, 2018
						ODE	Oct	29, 2017
						PED	Oct	26, 2019
						PED	Nov	05, 2018
						PED	Apr	29, 2018
						PED	Oct	26, 2015
						PED	Nov	05, 2014
						PED	Sep	30, 2014
						PED	Apr	29, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N203985 001					>A> I-630	Oct 29, 2013
					>A> NCE	Mar 30, 2014
					>A> ODE	Oct 29, 2017
					>A> PED	Apr 29, 2018
					>A> PED	Sep 30, 2014
					>A> PED	Apr 29, 2014
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N203985 002					>A> I-630	Oct 29, 2013
					>A> NCE	Mar 30, 2014
					>A> ODE	Oct 29, 2017
					>A> PED	Apr 29, 2018
					>A> PED	Sep 30, 2014
					>A> PED	Apr 29, 2014
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N203985 003					>A> I-630	Oct 29, 2013
					>A> NCE	Mar 30, 2014
					>A> ODE	Oct 29, 2017
					>A> PED	Apr 29, 2018
					>A> PED	Sep 30, 2014
					>A> PED	Apr 29, 2014
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 001	5665772	Sep 09, 2019	DS DP U-1049		NP	Apr 20, 2013
	5665772*PED	Mar 09, 2020			NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP U-1049		PED	Sep 30, 2014
	6004973*PED	Jan 12, 2017			PED	Oct 20, 2013
	6239124	Aug 11, 2017	U-1049			
	6239124*PED	Feb 11, 2018				
	6440990	Sep 24, 2013	DP U-1049			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518*PED	Jan 29, 2018				
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 002	5665772	Sep 09, 2019	DS DP U-1049		NP	Apr 20, 2013
	5665772*PED	Mar 09, 2020			NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP U-1049		PED	Sep 30, 2014
	6004973*PED	Jan 12, 2017			PED	Oct 20, 2013
	6239124	Aug 11, 2017	U-1049			
	6239124*PED	Feb 11, 2018				
	6440990	Sep 24, 2013	DP U-1049			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518*PED	Jan 29, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 003	5665772	Sep 09, 2019	DS DP U-1049		NP	Apr 20, 2013
	5665772*PED	Mar 09, 2020			NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP U-1049		PED	Sep 30, 2014
	6004973*PED	Jan 12, 2017			PED	Oct 20, 2013
	6239124	Aug 11, 2017	U-1049			
	6239124*PED	Feb 11, 2018				
	6440990	Sep 24, 2013	DP U-1049			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518*PED	Jan 29, 2018				
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N022200 001	5424286	Dec 01, 2016	U-1108		NP	Jan 27, 2015
	6479065	Aug 10, 2020	DP			
	6495164	May 25, 2020	DP			
	6667061	May 25, 2020	DP			
	6824822	Oct 09, 2022	DP			
	6858576	Jan 06, 2017	U-656			
	6872700	Jan 14, 2020	U-654			
	6956026	Jan 07, 2018	U-687			
	7223440	Aug 31, 2021	DP			
	7456254	Jun 30, 2025	DP U-1223			
	7563871	Apr 15, 2024	DP			
	7612176	Apr 13, 2025	DP U-1223			
	7741269	Jan 07, 2018	U-1224			
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N021773 001					M-113	Oct 19, 2014
					M-111	Oct 19, 2014
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N021773 002					M-113	Oct 19, 2014
					M-111	Oct 19, 2014
<u>EZETIMIBE - ZETIA</u>						
N021445 001					M-109	Jan 24, 2015
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 001					M-109	Jan 24, 2015
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 002					M-109	Jan 24, 2015
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 003					M-109	Jan 24, 2015
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 004					M-109	Jan 24, 2015
<u>FAMCICLOVIR - FAMVIR</u>						
N020363 001					M-112	Feb 09, 2015
<u>FAMCICLOVIR - FAMVIR</u>						
N020363 002					M-112	Feb 09, 2015
<u>FAMCICLOVIR - FAMVIR</u>						
N020363 003					M-112	Feb 09, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FENOFIBRATE - FENOGLIDE</u>						
N022118 001	8124125	Oct 01, 2024	DP U-1234			
<u>FENOFIBRATE - FENOGLIDE</u>						
N022118 002	8124125	Oct 01, 2024	DP U-1234			
<u>FENTANYL - SUBSYS</u>						
N202788 001					NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788 002					NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788 003					NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788 004					NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788 005					NP	Jan 04, 2015
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 001	8092832	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 002	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 003	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 004	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 005	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N022569 001	8216604	Oct 03, 2024	U-767			
<u>FENTANYL CITRATE - LAZANDA</u>						
N022569 002	8216604	Oct 03, 2024	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 001	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 002	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 003	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 004	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 005	7579019	Jan 22, 2020	U-767			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030 001	>A> 6858650	Jul 03, 2022	DS U-913			
	8088398	Jun 07, 2027	DP U-913			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030 002	>A> 6858650	Jul 03, 2022	DS U-913			
	8088398	Jun 07, 2027	DP U-913			
<u>FINGOLIMOD - GILENYA</u>						
N022527 001	6004565	Sep 23, 2017	U-1086			
<u>FLORBETAPIR F-18 - AMYVID</u>						
N202008 001	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
<u>FLORBETAPIR F-18 - AMYVID</u>						
N202008 002	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
<u>FLORBETAPIR F-18 - AMYVID</u>						
N202008 003	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
<u>FLUNISOLIDE - AEROSPAN HFA</u>						
N021247 001	5776433	Jul 07, 2015	DP			
	5980867	Jul 06, 2018	DP			
<u>FLUOCINONIDE - VANOS</u>						
N021758 001	8232264	Mar 09, 2023	DP			
<u>FLUTICASONE FUROATE - VERAMYST</u>						
N022051 001	>A> 8062264	Apr 05, 2026	DP			
	>A> 8147461	Mar 10, 2025	DP			
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N021433 001	>A> 7832351	Jun 19, 2023	DP			
	>A> 7832351*PED	Dec 19, 2023				
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N021433 002	>A> 7832351	Jun 19, 2023	DP			
	>A> 7832351*PED	Dec 19, 2023				
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N021433 003	>A> 7832351	Jun 19, 2023	DP			
	>A> 7832351*PED	Dec 19, 2023				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N021254 001	>A> 7832351	Jun 19, 2023	DP			
	>A> 7832351*PED	Dec 19, 2023				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N021254 002	>A> 7832351	Jun 19, 2023	DP			
	>A> 7832351*PED	Dec 19, 2023				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N021254 003	>A> 7832351	Jun 19, 2023	DP			
	>A> 7832351*PED	Dec 19, 2023				
<u>FOSAMPRENAVIR CALCIUM - LEXIVA</u>						
N021548 001					NPP PED	Apr 27, 2015 Oct 27, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FOSAMPRENAVIR CALCIUM - LEXIVA</u>						
N022116 001					NPP PED	Apr 27, 2015 Oct 27, 2015
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N022023 002	5512570	Mar 04, 2014	U-850			
	5538982	Jul 23, 2013	U-850			
	5716942	Feb 10, 2015	U-850			
	7214692	Sep 18, 2012	U-850			
<u>FOSPROPOFOL DISODIUM - LUSEDRA</u>						
N022244 001	6204257	Jul 01, 2022	DS DP U-945			
<u>GABAPENTIN - GRALISE</u>						
N022544 001	8192756	Oct 25, 2022	DP U-1114			
<u>GABAPENTIN - GRALISE</u>						
N022544 002	8192756	Oct 25, 2022	DP U-1114			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N022399 001	8048917	Nov 06, 2022	DS DP U-1247		I-652	Jun 06, 2015
	8114909	Apr 11, 2026	U-1231			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N022399 002	8048917	Nov 06, 2022	DS DP U-1247		I-652	Jun 06, 2015
	8114909	Apr 11, 2026	U-1231			
<u>GADOBENATE DIMEGLUMINE - MULTIANCE</u>						
N021357 001					I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIANCE</u>						
N021357 002					I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIANCE</u>						
N021357 003					I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIANCE</u>						
N021357 004					I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIANCE MULTIPACK</u>						
N021358 001					I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIANCE MULTIPACK</u>						
N021358 002					I-654	Jul 06, 2015
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711 001	6676929	May 04, 2020	DP			
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711 002	6676929	May 04, 2020	DP			
<u>GADOXETATE DISODIUM - EOVIIST</u>						
N022090 001	5798092	Aug 25, 2015	DS DP			
	6039931	Nov 13, 2021	U-1239			
<u>GLYCOPYRROLATE - CUVPOSA</u>						
N022571 001					ODE	Jul 28, 2017
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - IRBESARTAN AND HYDROCHLOROTHIAZIDE</u>						
A077369 001					PC	Sep 26, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - IRBESARTAN AND HYDROCHLOROTHIAZIDE</u>						
A077369 002					PC	Sep 26, 2012
<u>HYDROMORPHONE HYDROCHLORIDE - EXALGO</u>						
N021217 004	>A> 5702725	Jul 07, 2014	DP U-1043			
	>A> 5914131	Jul 07, 2014	DP U-1043			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N202057 001	8188146	Jan 27, 2020	DS DP			
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N021588 001					ODE	Dec 19, 2015
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N021588 002					ODE	Dec 19, 2015
<u>IMIQUIMOD - ZYCLARA</u>						
N022483 001	8236816	Dec 11, 2029	U-68			
<u>IMIQUIMOD - ZYCLARA</u>						
N022483 002	8222270	Dec 11, 2029	U-68			
<u>INGENOL MEBUTATE - PICATO</u>						
N202833 001	6432452	Aug 19, 2018	DS U-68		NCE	Jan 23, 2017
	6844013	Aug 19, 2018	DS DP U-1221			
	7410656	Aug 19, 2018	DS U-1222			
<u>INGENOL MEBUTATE - PICATO</u>						
N202833 002	6432452	Aug 19, 2018	DS U-68		NCE	Jan 23, 2017
	6844013	Aug 19, 2018	DS DP U-1221			
	7410656	Aug 19, 2018	DS U-1222			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR</u>						
N021536 001	5750497	Jun 16, 2019	DS DP U-668		M-117 M-115	May 18, 2015 Apr 06, 2015
<u>IOFLUPANE I-123 - DATSCAN</u>						
N022454 001	5310912	Feb 25, 2013	DS			
<u>IRBESARTAN - IRBESARTAN</u>						
A077159 001					PC	Sep 26, 2012
<u>IRBESARTAN - IRBESARTAN</u>						
A077159 002					PC	Sep 26, 2012
<u>IRBESARTAN - IRBESARTAN</u>						
A077159 003					PC	Sep 26, 2012
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 001	7435427	Sep 21, 2021	DP		NP	May 25, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 002	7435427	Sep 21, 2021	DP		NP	May 25, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 003	7435427	Sep 21, 2021	DP		NP	May 25, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 004	7435427	Sep 21, 2021	DP		NP	May 25, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR - KALYDECO</u>						
N203188 001	7495103	May 20, 2027	DS DP		NCE ODE	Jan 31, 2017 Jan 31, 2019
<u>IVERMECTIN - SKLICE</u>						
N202736 001	6103248	May 22, 2018	DP		NP	Feb 07, 2015
<u>IXABEPILONE - IXEMPRA KIT</u>						
N022065 001	RE41911	Sep 28, 2020	DS DP U-961			
	RE41911*PED	Mar 28, 2021				
<u>IXABEPILONE - IXEMPRA KIT</u>						
N022065 002	RE41911	Sep 28, 2020	DS DP U-961			
	RE41911*PED	Mar 28, 2021				
<u>KETOCONAZOLE - EXTINA</u>						
N021738 001	8026238	Oct 19, 2018	DP U-1213			
<u>KETOCONAZOLE - XOLEGEL</u>						
N021946 001	>A> 8232276	Nov 24, 2020	DP			
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N021528 001	8008338*PED	Nov 24, 2027				
	8207215	May 28, 2024	U-1251			
	8207215*PED	Nov 28, 2024				
<u>LAMIVUDINE; ZIDOVUDINE - LAMIVUDINE AND ZIDOVUDINE</u>						
A079081 001					PC	May 15, 2012
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 001	5635517	Oct 04, 2019	DS U-1211			
	6045501	Aug 28, 2018	U-1210			
	6281230	Jul 24, 2016	U-1212			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7968569	Oct 07, 2023	U-1216			
	8204763	Aug 28, 2018	U-1249			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 002	5635517	Oct 04, 2019	DS		U-1211	
	6045501	Aug 28, 2018			U-1210	
	6281230	Jul 24, 2016			U-1212	
	6315720	Oct 23, 2020			U-1210	
	6555554	Jul 24, 2016	DP		U-1211	
	6561976	Aug 28, 2018			U-1210	
	6561977	Oct 23, 2020			U-1210	
	6755784	Oct 23, 2020			U-1210	
	6908432	Aug 28, 2018			U-1210	
	7189740	Apr 11, 2023			U-1215	
	7465800	Apr 27, 2027	DS DP			
	7968569	Oct 07, 2023			U-1216	
	8204763	Aug 28, 2018			U-1249	
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 003	5635517	Oct 04, 2019	DS		U-1211	
	6045501	Aug 28, 2018			U-1210	
	6281230	Jul 24, 2016			U-1212	
	6315720	Oct 23, 2020			U-1210	
	6555554	Jul 24, 2016	DP		U-1211	
	6561976	Aug 28, 2018			U-1210	
	6561977	Oct 23, 2020			U-1210	
	6755784	Oct 23, 2020			U-1210	
	6908432	Aug 28, 2018			U-1210	
	7189740	Apr 11, 2023			U-1215	
	7465800	Apr 27, 2027	DS DP			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023			U-1216	
	8204763	Aug 28, 2018			U-1249	
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 004	5635517	Oct 04, 2019	DS		U-1211	
	6045501	Aug 28, 2018			U-1210	
	6281230	Jul 24, 2016			U-1212	
	6315720	Oct 23, 2020			U-1210	
	6555554	Jul 24, 2016	DP		U-1211	
	6561976	Aug 28, 2018			U-1210	
	6561977	Oct 23, 2020			U-1210	
	6755784	Oct 23, 2020			U-1210	
	6908432	Aug 28, 2018			U-1210	
	7189740	Apr 11, 2023			U-1215	
	7465800	Apr 27, 2027	DS DP			
	7968569	Oct 07, 2023			U-1216	
	8204763	Aug 28, 2018			U-1249	

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 005	5635517	Oct 04, 2019	DS		U-1211	
	6045501	Aug 28, 2018			U-1210	
	6281230	Jul 24, 2016			U-1212	
	6315720	Oct 23, 2020			U-1210	
	6555554	Jul 24, 2016	DP		U-1211	
	6561976	Aug 28, 2018			U-1210	
	6561977	Oct 23, 2020			U-1210	
	6755784	Oct 23, 2020			U-1210	
	6908432	Aug 28, 2018			U-1210	
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023			U-1215	
	7465800	Apr 27, 2027	DS DP			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023			U-1216	
	8204763	Aug 28, 2018			U-1249	
<u>LEVETIRACETAM - KEPRA</u>						
N021035 001					NPP	Dec 16, 2014
					>A> PED	Jun 16, 2015
<u>LEVETIRACETAM - KEPRA</u>						
N021035 002					NPP	Dec 16, 2014
					>A> PED	Jun 16, 2015
<u>LEVETIRACETAM - KEPRA</u>						
N021035 003					NPP	Dec 16, 2014
					>A> PED	Jun 16, 2015
<u>LEVETIRACETAM - KEPRA</u>						
N021035 004					NPP	Dec 16, 2014
					>A> PED	Jun 16, 2015
<u>LEVETIRACETAM - KEPRA</u>						
N021505 001					NPP	Dec 16, 2014
					>A> PED	Jun 16, 2015
<u>LIDOCAINE; TETRACAINE - SYNERA</u>						
N021623 001	6465709	Jul 07, 2020	DP			
<u>LINACLOTIDE - LINZESS</u>						
N202811 001					>A> NCE	Aug 30, 2017
<u>LINACLOTIDE - LINZESS</u>						
N202811 002					>A> NCE	Aug 30, 2017

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LINAGLIPTIN - TRADJENTA</u>						
N201280 001	>A> 6303661	Apr 24, 2017	U-774		>A> M-121	Aug 13, 2015
	>A> 6303661	Apr 24, 2017	U-1270		>A> M-118	Aug 13, 2015
	>A> 6890898	Feb 02, 2019	U-493			
	>A> 6890898	Feb 02, 2019	U-1270			
	>A> 7078381	Feb 02, 2019	U-493			
	>A> 7078381	Feb 02, 2019	U-1270			
	>A> 7459428	Feb 02, 2019	U-493			
	>A> 7459428	Feb 02, 2019	U-1270			
	>A> 8119648	Aug 12, 2023	U-774			
	>A> 8119648	Aug 12, 2023	U-1270			
	>A> 8178541	Aug 12, 2023	U-775			
	>A> 8178541	Aug 12, 2023	U-1270			
	>A> 8178541	Aug 12, 2023	U-1245			
	>A> 8178541	Aug 12, 2023	U-1244			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N201281 001	6303661	Apr 24, 2017	U-802		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-1039		NC	Jan 30, 2015
	7078381	Feb 02, 2019	U-1039			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N201281 002	6303661	Apr 24, 2017	U-802		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-1039		NC	Jan 30, 2015
	7078381	Feb 02, 2019	U-1039			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N201281 003	6303661	Apr 24, 2017	U-802		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-1039		NC	Jan 30, 2015
	7078381	Feb 02, 2019	U-1039			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N022341 001	8114833	Aug 13, 2025	DP		M-115	Apr 06, 2015
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 001	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 002	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N021977 003	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N021977 004	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7671030	Feb 24, 2023	DP U-727			
	7674774	Mar 18, 2023	DP U-842			
	7678771	Mar 25, 2023	DP U-842			
	7687467	Apr 08, 2023	DP U-842			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N021977 005	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N021977 006	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
LORCASERIN HYDROCHLORIDE - BELVIQ						
N022529 001	6953787	Apr 10, 2023	DS DP U-1253		NCE	Jun 27, 2017
	6953787	Apr 10, 2023	DS DP U-1254			
	6953787	Apr 10, 2023	DS DP U-1255			
	6953787	Apr 10, 2023	DS DP U-1252			
	7514422	Apr 10, 2023	U-1255			
	7514422	Apr 10, 2023	U-1252			
	7514422	Apr 10, 2023	U-1253			
	7514422	Apr 10, 2023	U-1254			
	7977329	Apr 10, 2023	DS DP U-1253			
	7977329	Apr 10, 2023	DS DP U-1254			
	7977329	Apr 10, 2023	DS DP U-1255			
	7977329	Apr 10, 2023	DS DP U-1252			
	8168624	Apr 18, 2029	DS DP			
	8207158	Apr 10, 2023	U-1255			
	8207158	Apr 10, 2023	U-1252			
	8207158	Apr 10, 2023	U-1253			
	8207158	Apr 10, 2023	U-1254			
LUBIPROSTONE - AMITIZA						
N021908 001	8097649	Oct 16, 2020	DP			
	8097653	Nov 14, 2022	U-1214			
	8114890	Sep 05, 2020	DP			
LUBIPROSTONE - AMITIZA						
N021908 002	8097649	Oct 16, 2020	DP			
	8114890	Sep 05, 2020	DP			
LUCINACTANT - SURFAXIN						
N021746 001	5407914	Nov 17, 2012	DS DP U-1242			
LURASIDONE HYDROCHLORIDE - LATUDA						
N200603 001					D-134	Apr 26, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603	002				D-134	Apr 26, 2015
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603	003				D-134 NCE	Apr 26, 2015 Oct 28, 2015
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603	004				D-134 NCE	Apr 26, 2015 Oct 28, 2015
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N021842	001				M-116	May 17, 2015
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N021842	002				M-116	May 17, 2015
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE</u>						
A090406	001				>A> PC	Feb 13, 2013
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE</u>						
A090406	002				>A> PC	Feb 13, 2013
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N021410	001	>A> 8236345	Oct 07, 2022	DP		
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N021410	002	>A> 8236345	Oct 07, 2022	DP		
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N021410	003	>A> 8236345	Oct 07, 2022	DP		
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N021410	004	>A> 8236345	Oct 07, 2022	DP		
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N021410	005	>A> 8236345	Oct 07, 2022	DP		
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N202270	001	6303661	Apr 24, 2017	U-1227		
		6340475	Sep 19, 2016	DP		
		6635280	Sep 19, 2016	DP		
		6699871	Jul 26, 2022	DS DP	U-1227	
		6890898	Feb 02, 2019		U-1228	
		7078381	Feb 02, 2019		U-1227	
		7125873	Jul 26, 2022	DP	U-1227	
		7326708	Apr 11, 2026	DS DP	U-1227	
		7459428	Feb 02, 2019		U-1227	
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N202270	002	6303661	Apr 24, 2017	U-1227		
		6340475	Sep 19, 2016	DP		
		6635280	Sep 19, 2016	DP		
		6699871	Jul 26, 2022	DS DP	U-1227	
		6890898	Feb 02, 2019		U-1228	
		7078381	Feb 02, 2019		U-1227	
		7125873	Jul 26, 2022	DP	U-1227	
		7326708	Apr 11, 2026	DS DP	U-1227	
		7459428	Feb 02, 2019		U-1227	

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N202270 003	6303661	Apr 24, 2017	U-1227			
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP U-1227			
	6890898	Feb 02, 2019	U-1228			
	7078381	Feb 02, 2019	U-1227			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Apr 11, 2026	DS DP U-1227			
	7459428	Feb 02, 2019	U-1227			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N021964 001	>A> 8247425	Dec 31, 2030	U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N021964 002	>A> 8247425	Dec 31, 2030	U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N021964 003	>A> 8247425	Dec 31, 2030	U-1185			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 001	8163798	Jul 31, 2017	DP			
	8163798*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 002	8163798	Jul 31, 2017	DP			
	8163798*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 003	8163798	Jul 31, 2017	DP			
	8163798*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 004	8163798	Jul 31, 2017	DP			
	8163798*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE</u>						
A078458 001					PC	Jul 01, 2012
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE</u>						
A078458 002					PC	Jul 01, 2012
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE</u>						
A078458 003					PC	Jul 01, 2012
<u>MICONAZOLE - ORAVIG</u>						
N022404 001	7651698	Sep 11, 2022	U-1051			
<u>MIFEPRISTONE - KORLYM</u>						
N202107 001					NP	Feb 17, 2015
<u>MINOCYCLINE HYDROCHLORIDE - ARESTIN</u>						
N050781 001	6682348	Mar 29, 2022	DP			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 001	>A> 8252776	Jun 24, 2025	U-124			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 002	>A> 8252776	Jun 24, 2025	U-124			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 003	>A> 8252776	Jun 24, 2025	U-124			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 004	>A> 8252776	Jun 24, 2025	U-124			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 005	>A> 8252776	Jun 24, 2025	U-124			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 006	>A> 8252776	Jun 24, 2025	U-124			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 007	>A> 8252776	Jun 24, 2025	U-124			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 008	>A> 8252776	Jun 24, 2025	U-124			
<u>MIRABEGRON - MYRBETRIQ</u>						
N202611 001	6346532	Oct 15, 2018	DS DP		NCE	Jun 28, 2017
	6562375	Aug 01, 2020	DP			
	6699503	Sep 10, 2013	DP			
	7342117	Nov 04, 2023	DS			
	7750029	Dec 18, 2023	U-913			
	7982049	Nov 04, 2023	DP			
<u>MIRABEGRON - MYRBETRIQ</u>						
N202611 002	6346532	Oct 15, 2018	DS DP		NCE	Jun 28, 2017
	6562375	Aug 01, 2020	DP			
	6699503	Sep 10, 2013	DP			
	7342117	Nov 04, 2023	DS			
	7750029	Dec 18, 2023	U-913			
	7982049	Nov 04, 2023	DP			
<u>MITOMYCIN - MITOSOL</u>						
N022572 001	7806265	Feb 01, 2029	DP		ODE	Feb 07, 2019
	8186511	Jul 19, 2026	DP			
<u>MOMETASONE FUROATE - ASMANEX TWISTHALER</u>						
N021067 001	8173172	Mar 17, 2018	DP			
	8173172*PED	Sep 17, 2018				
<u>MOMETASONE FUROATE - ASMANEX TWISTHALER</u>						
N021067 002	8173172	Mar 17, 2018	DP			
	8173172*PED	Sep 17, 2018				
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N020829 002					NPP	Mar 26, 2015
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N020830 001					NPP	Mar 26, 2015
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N020830 002					NPP	Mar 26, 2015
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N021409 001					NPP	Mar 26, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 001	>A> 7682633	Jun 19, 2027	U-1241			
	8158156	Jun 19, 2027	U-1241			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 002	>A> 7682633	Jun 19, 2027	U-1241			
	8158156	Jun 19, 2027	U-1241			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 003	>A> 7682633	Jun 19, 2027	U-1241			
	8158156	Jun 19, 2027	U-1241			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 004	>A> 7682633	Jun 19, 2027	U-1241			
	8158156	Jun 19, 2027	U-1241			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 005	>A> 7682633	Jun 19, 2027	U-1241			
	8158156	Jun 19, 2027	U-1241			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 006	>A> 7682633	Jun 19, 2027	U-1241			
	8158156	Jun 19, 2027	U-1241			
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N019599 002					NS	Jan 13, 2015
<u>NICOTINE - NICODERM CQ</u>						
N020165 004	8075911	May 22, 2021	DP			
<u>NICOTINE - NICODERM CQ</u>						
N020165 005	8075911	May 22, 2021	DP			
<u>NICOTINE - NICODERM CQ</u>						
N020165 006	8075911	May 22, 2021	DP			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N022068 001	8163904	Aug 23, 2028	DS DP			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N022068 002	8163904	Aug 23, 2028	DS DP			
<u>NITRIC OXIDE - INOMAX</u>						
N020845 002	5558083	Nov 22, 2013	DP U-1226			
	5558083*PED	May 22, 2014				
	5732693	Dec 13, 2016	DP U-1230			
	5732693*PED	Jun 13, 2017				
	5752504	Dec 13, 2016	DP U-1230			
	5752504*PED	Jun 13, 2017				
<u>NITRIC OXIDE - INOMAX</u>						
N020845 003	5558083	Nov 22, 2013	DP U-1226			
	5558083*PED	May 22, 2014				
	5732693	Dec 13, 2016	DP U-1230			
	5732693*PED	Jun 13, 2017				
	5752504	Dec 13, 2016	DP U-1230			
	5752504*PED	Jun 13, 2017				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NITROGLYCERIN - NITROLINGUAL PUMPSPRAY</u>						
N018705 002	7872049	Mar 14, 2028	DP U-39			
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N021285 001	8119148	Dec 19, 2020	DP U-724			
	8119148*PED	Jun 19, 2021				
<u>OXYBUTYNIN - ANTUROL</u>						
N202513 001	7029694	Apr 26, 2020	DP U-318			
	7179483	Apr 26, 2020	U-318			
	7198801	Jun 25, 2022	DP			
	>A> 8241662	Apr 26, 2020	U-318			
<u>OXYBUTYNIN CHLORIDE - GELNIQUE</u>						
N022204 001	>A> 8241662	Apr 26, 2020	U-318			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 001	8114383	Oct 10, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 002	8114383	Oct 10, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 003	8114383	Oct 10, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 004	8114383	Oct 10, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 005	8114383	Oct 10, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 006	8114383	Oct 10, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 007	8114383	Oct 10, 2024	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 001	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 002	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 003	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 004	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 005	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 006	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 007	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
<u>PACLITAXEL - ABRAXANE</u>						
N021660 001	8138229	Dec 09, 2023	DP U-1092			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264 001					>A> M-119	Aug 29, 2015
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264 002					>A> M-119	Aug 29, 2015
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264 003					>A> M-119	Aug 29, 2015
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264 004					>A> M-119	Aug 29, 2015
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264 005					>A> M-119	Aug 29, 2015
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N020725 004					I-625 M-93 NCE	Apr 30, 2013 Jul 29, 2019 Apr 30, 2014
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PERTZYE</u>						
N022175 001					NCE	May 17, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PERTZYE</u>						
N022175 002					NCE	May 17, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N022222 001					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N022222 002					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N022222 003					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - VIOKACE</u>						
N022542 001					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - VIOKACE</u>						
N022542 002					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 001	>A> 8221747	Feb 20, 2028	DP			
	>A> 8246950	Feb 20, 2028			U-1274	

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 002	>A> 8221747	Feb 20, 2028	DP			
	>A> 8246950	Feb 20, 2028	U-1274			
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 003	>A> 8221747	Feb 20, 2028	DP			
	>A> 8246950	Feb 20, 2028	U-1274			
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 004	>A> 8221747	Feb 20, 2028	DP			
	>A> 8246950	Feb 20, 2028	U-1274			
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 005	>A> 8221747	Feb 20, 2028	DP		NCE	Aug 27, 2014
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 006	>A> 8221747	Feb 20, 2028	DP		NCE	Aug 27, 2014
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N022465 001	8114885	Dec 19, 2021	DS DP		I-649 ODE	Apr 26, 2015 Apr 26, 2019
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N022465 002	8114885	Dec 19, 2021	DS DP		I-649 ODE	Apr 26, 2015 Apr 26, 2019
<u>PEGINESATIDE ACETATE - OMONTYS</u>						
N202799 007	7084245	May 12, 2024	DS DP	U-1238		
	7414105	May 12, 2024	DS DP	U-1238		
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026		U-1238		
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026		U-1238		
<u>PEGINESATIDE ACETATE - OMONTYS</u>						
N202799 008	7084245	May 12, 2024	DS DP	U-1238		
	7414105	May 12, 2024	DS DP	U-1238		
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026		U-1238		
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026		U-1238		
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 001	7084245	May 12, 2024	DS DP	U-1238	NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP	U-1238		
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026		U-1238		
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026		U-1238		
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 002	7084245	May 12, 2024	DS DP	U-1238	NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP	U-1238		
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026		U-1238		
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026		U-1238		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 003	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 004	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 005	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 006	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N202088 003	6149938	Jul 23, 2018	DP U-1243			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N022580 001	>A> 7056890	Jun 14, 2020	DP U-1262		NC	Jul 17, 2015
	>A> 7553818	Jun 14, 2020	U-1262			
	>A> 7659256	Jun 14, 2020	DP U-1262			
	>A> 7674776	Jun 14, 2020	DP U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N022580 002	>A> 7056890	Jun 14, 2020	DP U-1262		NC	Jul 17, 2015
	>A> 7553818	Jun 14, 2020	U-1262			
	>A> 7659256	Jun 14, 2020	DP U-1262			
	>A> 7674776	Jun 14, 2020	DP U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N022580 003	>A> 7056890	Jun 14, 2020	DP U-1262		NC	Jul 17, 2015
	>A> 7553818	Jun 14, 2020	U-1262			
	>A> 7659256	Jun 14, 2020	DP U-1262			
	>A> 7674776	Jun 14, 2020	DP U-1262			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N022580 004	>A> 7056890	Jun 14, 2020	DP U-1262		NC	Jul 17, 2015
	>A> 7553818	Jun 14, 2020	U-1262			
	>A> 7659256	Jun 14, 2020	DP U-1262			
	>A> 7674776	Jun 14, 2020	DP U-1262			
<u>PIOGLITAZONE HYDROCHLORIDE - PIOGLITAZONE HYDROCHLORIDE</u>						
A076801 001					>A> PC	Feb 13, 2013
<u>PIOGLITAZONE HYDROCHLORIDE - PIOGLITAZONE HYDROCHLORIDE</u>						
A076801 002					>A> PC	Feb 13, 2013
<u>PIOGLITAZONE HYDROCHLORIDE - PIOGLITAZONE HYDROCHLORIDE</u>						
A076801 003					>A> PC	Feb 13, 2013
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 001	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 002	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 003	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 004	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 001	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 002	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 003	8133883	Apr 14, 2023	DP U-282			
<u>PREDNISOLONE ACETATE - FLO-PRED</u>						
N022067 001	7799331	Oct 11, 2028	DP U-139			
	7799331	Oct 11, 2028	DP U-1068			
<u>PREDNISOLONE ACETATE - FLO-PRED</u>						
N022067 002	7799331	Oct 11, 2028	DP U-139			
	7799331	Oct 11, 2028	DP U-1068			
<u>PREDNISONE - RAYOS</u>						
N202020 001	>A> 6488960	Mar 14, 2020	DP U-1267			
	>A> 6677326	Mar 14, 2020	DP U-1268			
<u>PREDNISONE - RAYOS</u>						
N202020 002	>A> 6488960	Mar 14, 2020	DP U-1267			
	>A> 6677326	Mar 14, 2020	DP U-1268			
<u>PREDNISONE - RAYOS</u>						
N202020 003	>A> 8168218	Jan 07, 2028	DP U-1269			
<u>PREGABALIN - LYRICA</u>						
N021446 001	6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	RE41920	Dec 30, 2018	U-1250			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE	
PREGABALIN - LYRICA								
N021446 002	6001876	Dec	30, 2018	U-819	Y	I-651	Jun	20, 2015
	6001876	Dec	30, 2018	U-55	Y			
	RE41920	Dec	30, 2018	U-1250				
PREGABALIN - LYRICA								
N021446 003	6001876	Dec	30, 2018	U-819	Y	I-651	Jun	20, 2015
	6001876	Dec	30, 2018	U-55	Y			
	RE41920	Dec	30, 2018	U-1250				
PREGABALIN - LYRICA								
N021446 004	6001876	Dec	30, 2018	U-819	Y	I-651	Jun	20, 2015
	6001876	Dec	30, 2018	U-55	Y			
	RE41920	Dec	30, 2018	U-1250				
PREGABALIN - LYRICA								
N021446 005	6001876	Dec	30, 2018	U-819	Y	I-651	Jun	20, 2015
	6001876	Dec	30, 2018	U-55	Y			
	RE41920	Dec	30, 2018	U-1250				
PREGABALIN - LYRICA								
N021446 006	6001876	Dec	30, 2018	U-819	Y	I-651	Jun	20, 2015
	6001876	Dec	30, 2018	U-55	Y			
	RE41920	Dec	30, 2018	U-1250				
PREGABALIN - LYRICA								
N021446 007	6001876	Dec	30, 2018	U-819	Y	I-651	Jun	20, 2015
	6001876	Dec	30, 2018	U-55	Y			
	RE41920	Dec	30, 2018	U-1250				
PREGABALIN - LYRICA								
N021446 008	6001876	Dec	30, 2018	U-819	Y	I-651	Jun	20, 2015
	6001876	Dec	30, 2018	U-55	Y			
	RE41920	Dec	30, 2018	U-1250				
PREGABALIN - LYRICA								
N022488 001	6001876	Dec	30, 2018	U-819	Y			
	6001876	Dec	30, 2018	U-55	Y			
	RE41920	Dec	30, 2018	U-1250				
PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL								
N021438 001	6500454	Oct	04, 2021	DP				
PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL								
N021438 002	6500454	Oct	04, 2021	DP				
RALTEGRAVIR POTASSIUM - ISENTRESS								
N022145 001						M-114	Mar	28, 2015
RALTEGRAVIR POTASSIUM - ISENTRESS								
N203045 001	7169780	Oct	03, 2023	DS DP		M-114	Mar	28, 2015
	7217713	Oct	21, 2022	U-257				
	7435734	Oct	21, 2022	U-257				
	7754731	Mar	11, 2029	DS DP U-257				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N203045 002	7169780	Oct 03, 2023	DS DP		M-114	Mar 28, 2015
	7217713	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-257			
	7754731	Mar 11, 2029	DS DP U-257			
<u>REGADENOSON - LEXISCAN</u>						
N022161 001	8106029	Jun 22, 2019	U-1042			
	8106183	Feb 02, 2027	DS			
	8133879	Jun 22, 2019	DP			
	8183226	Jun 22, 2019	U-116			
<u>REPAGLINIDE - PRANDIN</u>						
N020741 001	>A> 6677358	Jun 12, 2018	DS DP U-1265			
<u>REPAGLINIDE - PRANDIN</u>						
N020741 002	>A> 6677358	Jun 12, 2018	DS DP U-1265			
<u>REPAGLINIDE - PRANDIN</u>						
N020741 003	>A> 6677358	Jun 12, 2018	DS DP U-1265			
<u>RETAPAMULIN - ALTABAX</u>						
N022055 001	RE43390	Apr 12, 2021	DS DP U-805			
<u>RIFAXIMIN - XIFAXAN</u>						
N021361 001	8158644	Jun 19, 2024	DP			
	8158781	Jun 19, 2024	DS			
	8193196	Sep 02, 2027	DS DP			
<u>RIFAXIMIN - XIFAXAN</u>						
N022554 001	8158644	Jun 19, 2024	DP			
	8158781	Jun 19, 2024	DS			
	8193196	Sep 02, 2027	DS DP			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N202022 001	8080551	Apr 11, 2023	DS DP			
	8101629	Aug 09, 2022	DP			
<u>RISEDRONATE SODIUM - ATELVIA</u>						
N022560 001	>A> 8246989	Jan 16, 2026	DP			
<u>RIZATRIPTAN BENZOATE - MAXALT</u>						
N020864 001	5602162	Jan 28, 2012		Y		
	5602162*PED	Jul 28, 2012				
<u>RIZATRIPTAN BENZOATE - MAXALT</u>						
N020864 002	5602162	Jan 28, 2012		Y		
	5602162*PED	Jul 28, 2012				
<u>RIZATRIPTAN BENZOATE - MAXALT-MLT</u>						
N020865 001	5602162	Jan 28, 2012	U-240	Y		
	5602162*PED	Jul 28, 2012				
<u>RIZATRIPTAN BENZOATE - MAXALT-MLT</u>						
N020865 002	5602162	Jan 28, 2012	U-240	Y		
	5602162*PED	Jul 28, 2012				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ROMIDEPSIN - ISTODAX</u>						
N022393 001	4977138	Aug 22, 2013	DS DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 001	>A> 8246979	Sep 01, 2027	DP U-1273		I-647	Apr 02, 2015
	>A> 8246979	Sep 01, 2027	DP U-1272		I-646	Apr 02, 2015
	>A> 8246980	Nov 27, 2025	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 002	>A> 8246979	Sep 01, 2027	DP U-1273		I-647	Apr 02, 2015
	>A> 8246979	Sep 01, 2027	DP U-1272		I-646	Apr 02, 2015
	>A> 8246980	Nov 27, 2025	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 003	>A> 8246979	Sep 01, 2027	DP U-1273		I-647	Apr 02, 2015
	>A> 8246979	Sep 01, 2027	DP U-1272		I-646	Apr 02, 2015
	>A> 8246980	Nov 27, 2025	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 004	6699498	Nov 27, 2020	DP		I-647	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-646	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
	>A> 8246979	Sep 01, 2027	DP U-1273			
	>A> 8246979	Sep 01, 2027	DP U-1272			
	>A> 8246980	Nov 27, 2025	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 005	6699498	Nov 27, 2020	DP		I-647	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-646	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
	>A> 8246979	Sep 01, 2027	DP U-1273			
	>A> 8246979	Sep 01, 2027	DP U-1272			
	>A> 8246980	Nov 27, 2025	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 006	6699498	Nov 27, 2020	DP		I-647	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-646	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
	>A> 8246979	Sep 01, 2027	DP U-1273			
	>A> 8246979	Sep 01, 2027	DP U-1272			
	>A> 8246980	Nov 27, 2025	DP			
<u>RUFINAMIDE - BANZEL</u>						
N201367 001	6740669	Nov 14, 2022	DS DP			
<u>SILDENAFIL CITRATE - REVATIO</u>						
N021845 001	5250534	Mar 27, 2012	DS DP		I-598	May 07, 2012
	5250534*PED	Sep 27, 2012			>A> M-61	Aug 30, 2015
					>A> PED	Mar 01, 2016
					PED	Nov 07, 2012
<u>SILDENAFIL CITRATE - REVATIO</u>						
N022473 001	5250534	Mar 27, 2012	DS DP		>A> M-61	Aug 30, 2015
	5250534*PED	Sep 27, 2012			NDF	Nov 20, 2012
					>A> PED	Mar 01, 2016
					PED	May 20, 2013

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SILDENAFIL CITRATE - REVATIO</u>						
N203109	001				>A> NDF >A> PED	Aug 30, 2015 Mar 01, 2016
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N020895	001	5250534	Mar 27, 2012			
		5250534*PED	Sep 27, 2012			
		6469012	Oct 22, 2019	U-155		
		6469012*PED	Apr 22, 2020			
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N020895	002	5250534	Mar 27, 2012			
		5250534*PED	Sep 27, 2012			
		6469012	Oct 22, 2019	U-155		
		6469012*PED	Apr 22, 2020			
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N020895	003	5250534	Mar 27, 2012			
		5250534*PED	Sep 27, 2012			
		6469012	Oct 22, 2019	U-155		
		6469012*PED	Apr 22, 2020			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N202343	001	8168637	Jun 26, 2022	DP U-1188		
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N202343	002	8168637	Jun 26, 2022	DP U-1188		
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N202343	003	8168637	Jun 26, 2022	DP U-1188		
<u>SODIUM NITRITE - SODIUM NITRITE</u>						
N203922	001				ODE	Jan 14, 2018
<u>SODIUM THIOSULFATE - SODIUM THIOSULFATE</u>						
N203923	001				ODE	Jan 14, 2018
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N022239	001	>A> 7776007	Nov 22, 2026	DP		
		8118771	Aug 10, 2023	DP		
		>A> 8241243	Dec 25, 2025	DP		
		>A> 8241244	Nov 21, 2022	DP		
<u>TAFLUPROST - ZIOPTAN</u>						
N202514	001	5886035	Dec 18, 2017	DS DP U-778	NCE	Feb 10, 2017
<u>TALIGLUCERASE ALFA - ELELYSO</u>						
N022458	001	>A> 8227230	Feb 24, 2024	DS DP	NCE	May 01, 2017
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533	001	>A> 6071970	Jun 06, 2017	U-1276	>A> I-656	Aug 28, 2015
		>A> 6071970	Jun 06, 2017	U-1178		
		>A> 7994364	Jun 27, 2025	DS DP U-1276		
		>A> 7994364	Jun 27, 2025	DS DP U-1178		
		8114383	Oct 10, 2024	DP		
		>A> RE39593	Aug 05, 2022	DS DP U-1276		
		>A> RE39593	Aug 05, 2022	DS DP U-1178		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N200533 002	>A> 6071970	Jun 06, 2017	U-1276		>A> I-656	Aug 28, 2015
	>A> 6071970	Jun 06, 2017	U-1178			
	>A> 7994364	Jun 27, 2025	DS DP U-1276			
	>A> 7994364	Jun 27, 2025	DS DP U-1178			
	8114383	Oct 10, 2024	DP			
	>A> RE39593	Aug 05, 2022	DS DP U-1276			
	>A> RE39593	Aug 05, 2022	DS DP U-1178			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N200533 003	>A> 6071970	Jun 06, 2017	U-1276		>A> I-656	Aug 28, 2015
	>A> 6071970	Jun 06, 2017	U-1178			
	>A> 7994364	Jun 27, 2025	DS DP U-1276			
	>A> 7994364	Jun 27, 2025	DS DP U-1178			
	8114383	Oct 10, 2024	DP			
	>A> RE39593	Aug 05, 2022	DS DP U-1276			
	>A> RE39593	Aug 05, 2022	DS DP U-1178			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N200533 004	>A> 6071970	Jun 06, 2017	U-1276		>A> I-656	Aug 28, 2015
	>A> 6071970	Jun 06, 2017	U-1178			
	>A> 7994364	Jun 27, 2025	DS DP U-1276			
	>A> 7994364	Jun 27, 2025	DS DP U-1178			
	8114383	Oct 10, 2024	DP			
	>A> RE39593	Aug 05, 2022	DS DP U-1276			
	>A> RE39593	Aug 05, 2022	DS DP U-1178			
TAPENTADOL HYDROCHLORIDE - NUCYNTA ER						
N200533 005	>A> 6071970	Jun 06, 2017	U-1276		>A> I-656	Aug 28, 2015
	>A> 6071970	Jun 06, 2017	U-1178			
	>A> 7994364	Jun 27, 2025	DS DP U-1276			
	>A> 7994364	Jun 27, 2025	DS DP U-1178			
	8114383	Oct 10, 2024	DP			
	>A> RE39593	Aug 05, 2022	DS DP U-1276			
	>A> RE39593	Aug 05, 2022	DS DP U-1178			
TAZAROTENE - FABIOR						
N202428 001					NDF	May 11, 2015
TECHNETIUM TC-99M SULFUR COLLOID KIT - AN-SULFUR COLLOID						
N017858 001					>A> ODE	Aug 13, 2019
TELAVANCIN HYDROCHLORIDE - VIBATIV						
N022110 001	8101575	May 01, 2021	DP			
	8158580	May 01, 2021	DP			
TELAVANCIN HYDROCHLORIDE - VIBATIV						
N022110 002	8101575	May 01, 2021	DP			
	8158580	May 01, 2021	DP			
TELBIVUDINE - TYZEKA						
N022154 001	7858594	Sep 11, 2023	DS DP U-999			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TEMSIROLIMUS - TORISEL</u>						
N022088 001	5362718	Apr 18, 2014	DS DP		M-92	Jul 09, 2013
	5362718*PED	Oct 18, 2014			M-91	Apr 26, 2013
	8026276	Jan 20, 2026	DP		>A> M-61	May 30, 2015
	8026276*PED	Jul 20, 2026			ODE	May 30, 2014
					>A> PED	Nov 30, 2015
					PED	Nov 30, 2014
					PED	Jan 09, 2014
					PED	Oct 26, 2013
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N021356 001	>A> 5922695	Jul 25, 2017	DS U-999		>A> NPP	Aug 16, 2015
	>A> 5922695	Jul 25, 2017	DS U-256		NPP	Jan 18, 2015
	>A> 5922695	Jul 25, 2017	DS U-250		PED	Jul 18, 2015
	>A> 5922695	Jul 25, 2017	DS U-248			
	>A> 5922695	Jul 25, 2017	DS U-1275			
	>A> 5977089	Jul 25, 2017	DS DP U-999			
	>A> 5977089	Jul 25, 2017	DS DP U-256			
	>A> 5977089	Jul 25, 2017	DS DP U-250			
	>A> 5977089	Jul 25, 2017	DS DP U-248			
	>A> 5977089	Jul 25, 2017	DS DP U-1275			
	>A> 6043230	Jul 25, 2017	U-999			
	>A> 6043230	Jul 25, 2017	U-256			
	>A> 6043230	Jul 25, 2017	U-250			
	>A> 6043230	Jul 25, 2017	U-248			
	>A> 6043230	Jul 25, 2017	U-1275			
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N021356 002	>A> 5922695	Jul 25, 2017	DS U-248		M-95	Oct 01, 2013
	>A> 5922695	Jul 25, 2017	DS U-250		>A> NPP	Aug 16, 2015
	>A> 5922695	Jul 25, 2017	DS U-256		NPP	Jan 18, 2015
	>A> 5922695	Jul 25, 2017	DS U-999		NPP	Mar 24, 2013
	>A> 5922695	Jul 25, 2017	DS U-1275		ODE	Mar 24, 2017
	5922695*PED	Jan 25, 2018			PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-248		PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP U-250		PED	Apr 01, 2014
	5935946	Jul 25, 2017	DS DP U-256		PED	Sep 24, 2013
	5935946	Jul 25, 2017	DS DP U-999			
	5935946*PED	Jan 25, 2018				
	>A> 5977089	Jul 25, 2017	DS DP U-248			
	>A> 5977089	Jul 25, 2017	DS DP U-250			
	>A> 5977089	Jul 25, 2017	DS DP U-256			
	>A> 5977089	Jul 25, 2017	DS DP U-999			
	>A> 5977089	Jul 25, 2017	DS DP U-1275			
	5977089*PED	Jan 25, 2018				
	>A> 6043230	Jul 25, 2017	U-1275			
	>A> 6043230	Jul 25, 2017	U-248			
	>A> 6043230	Jul 25, 2017	U-250			
	>A> 6043230	Jul 25, 2017	U-256			
	>A> 6043230	Jul 25, 2017	U-999			
	6043230*PED	Jan 25, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TENOFVIR DISOPROXIL FUMARATE - VIREAD						
N021356 003	>A> 5922695	Jul 25, 2017	DS U-248		M-95	Oct 01, 2013
	>A> 5922695	Jul 25, 2017	DS U-250		>A> NPP	Aug 16, 2015
	>A> 5922695	Jul 25, 2017	DS U-256		NPP	Jan 18, 2015
	>A> 5922695	Jul 25, 2017	DS U-999		NPP	Mar 24, 2013
	>A> 5922695	Jul 25, 2017	DS U-1275		ODE	Mar 24, 2017
	5922695*PED	Jan 25, 2018			PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-248		PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP U-250		PED	Apr 01, 2014
	5935946	Jul 25, 2017	DS DP U-256		PED	Sep 24, 2013
	5935946	Jul 25, 2017	DS DP U-999			
	5935946*PED	Jan 25, 2018				
	>A> 5977089	Jul 25, 2017	DS DP U-248			
	>A> 5977089	Jul 25, 2017	DS DP U-250			
	>A> 5977089	Jul 25, 2017	DS DP U-256			
	>A> 5977089	Jul 25, 2017	DS DP U-999			
	>A> 5977089	Jul 25, 2017	DS DP U-1275			
	5977089*PED	Jan 25, 2018				
	>A> 6043230	Jul 25, 2017	U-1275			
	>A> 6043230	Jul 25, 2017	U-248			
	>A> 6043230	Jul 25, 2017	U-250			
	>A> 6043230	Jul 25, 2017	U-256			
	>A> 6043230	Jul 25, 2017	U-999			
	6043230*PED	Jan 25, 2018				
TENOFVIR DISOPROXIL FUMARATE - VIREAD						
N021356 004	>A> 5922695	Jul 25, 2017	DS U-248		M-95	Oct 01, 2013
	>A> 5922695	Jul 25, 2017	DS U-250		>A> NPP	Aug 16, 2015
	>A> 5922695	Jul 25, 2017	DS U-256		NPP	Jan 18, 2015
	>A> 5922695	Jul 25, 2017	DS U-999		NPP	Mar 24, 2013
	>A> 5922695	Jul 25, 2017	DS U-1275		ODE	Mar 24, 2017
	5922695*PED	Jan 25, 2018			PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-248		PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP U-250		PED	Apr 01, 2014
	5935946	Jul 25, 2017	DS DP U-256		PED	Sep 24, 2013
	5935946	Jul 25, 2017	DS DP U-999			
	5935946*PED	Jan 25, 2018				
	>A> 5977089	Jul 25, 2017	DS DP U-248			
	>A> 5977089	Jul 25, 2017	DS DP U-250			
	>A> 5977089	Jul 25, 2017	DS DP U-256			
	>A> 5977089	Jul 25, 2017	DS DP U-999			
	>A> 5977089	Jul 25, 2017	DS DP U-1275			
	5977089*PED	Jan 25, 2018				
	>A> 6043230	Jul 25, 2017	U-1275			
	>A> 6043230	Jul 25, 2017	U-248			
	>A> 6043230	Jul 25, 2017	U-250			
	>A> 6043230	Jul 25, 2017	U-256			
	>A> 6043230	Jul 25, 2017	U-999			
	6043230*PED	Jan 25, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N022577 001	>A> 5922695	Jul 25, 2017	DS U-248		M-95	Oct 01, 2013
	>A> 5922695	Jul 25, 2017	DS U-250		>A> NPP	Aug 16, 2015
	>A> 5922695	Jul 25, 2017	DS U-256		NPP	Mar 24, 2013
	>A> 5922695	Jul 25, 2017	DS U-999		NDF	Jan 18, 2015
	>A> 5922695	Jul 25, 2017	DS U-1275		ODE	Mar 24, 2017
	5922695*PED	Jan 25, 2018			PED	Sep 24, 2017
	5935946	Jul 25, 2017	DP U-248	Y	PED	Jul 18, 2015
	5935946	Jul 25, 2017	DP U-250	Y	PED	Apr 01, 2014
	5935946	Jul 25, 2017	DP U-256	Y	PED	Sep 24, 2013
	5935946	Jul 25, 2017	DP U-999	Y		
	5935946*PED	Jan 25, 2018				
	>A> 5977089	Jul 25, 2017	DS DP U-248			
	>A> 5977089	Jul 25, 2017	DS DP U-250			
	>A> 5977089	Jul 25, 2017	DS DP U-256			
	>A> 5977089	Jul 25, 2017	DS DP U-999			
	>A> 5977089	Jul 25, 2017	DS DP U-1275			
	5977089*PED	Jan 25, 2018				
	>A> 6043230	Jul 25, 2017	U-1275			
	>A> 6043230	Jul 25, 2017	U-248			
	>A> 6043230	Jul 25, 2017	U-250			
	>A> 6043230	Jul 25, 2017	U-256			
	>A> 6043230	Jul 25, 2017	U-999			
	6043230*PED	Jan 25, 2018				
<u>TESAMORELIN ACETATE - EGRIFTA</u>						
N022505 002					NCE	Nov 10, 2015
<u>TESTOSTERONE - TESTIM</u>						
N021454 001	8178518	Apr 21, 2023	DP			
<u>TESTOSTERONE - TESTOSTERONE</u>						
N202763 001					NP	Feb 14, 2015
<u>THALIDOMIDE - THALOMID</u>						
N020785 001	8143283	Mar 01, 2013	U-1236			
	8204763	Aug 28, 2018	U-1249			
<u>THALIDOMIDE - THALOMID</u>						
N020785 002	8143283	Mar 01, 2013	U-1236			
	8204763	Aug 28, 2018	U-1249			
<u>THALIDOMIDE - THALOMID</u>						
N020785 003	8143283	Mar 01, 2013	U-1236			
	8204763	Aug 28, 2018	U-1249			
<u>THALIDOMIDE - THALOMID</u>						
N020785 004	8143283	Mar 01, 2013	U-1236			
	8204763	Aug 28, 2018	U-1249			
<u>TIZANIDINE HYDROCHLORIDE - ZANAFLEX</u>						
N021447 001	6455557	Nov 28, 2021		Y		
<u>TIZANIDINE HYDROCHLORIDE - ZANAFLEX</u>						
N021447 002	6455557	Nov 28, 2021		Y		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TIZANIDINE HYDROCHLORIDE - ZANAFLEX</u>						
N021447 003	6455557	Nov 28, 2021		Y		
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 001					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 002					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 004					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 005					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020844 001					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020844 002					NPP	Jul 15, 2014
<u>TOPOTECAN HYDROCHLORIDE - HYCAMTIN</u>						
N020981 001	8158645	Dec 10, 2024	DP			
<u>TOPOTECAN HYDROCHLORIDE - HYCAMTIN</u>						
N020981 002	8158645	Dec 10, 2024	DP			
<u>TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE</u>						
A091607 001					PC	Jun 27, 2012
<u>TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE</u>						
A091607 002					PC	Jun 27, 2012
<u>TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE</u>						
A091607 003					PC	Jun 27, 2012
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N022411 001	8133893	Mar 13, 2029	DS DP			
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N022411 002	8133893	Mar 13, 2029	DS DP			
<u>TRIAMCINOLONE ACETONIDE - TRIESENCE</u>						
N022048 001	8128960	Dec 17, 2029	DP			
	8211880	Mar 10, 2029			U-1258	
	8211880	Mar 10, 2029			U-1257	
<u>TRYPAN BLUE - MEMBRANEBLUE</u>						
N022278 001					ODE	Feb 20, 2016
<u>VEMURAFENIB - ZELBORAF</u>						
N202429 001	8143271	Jun 21, 2026	DS DP			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 001	8193195	Jun 05, 2022			U-839	
	8236804	Jun 05, 2022			U-839	
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 002	8193195	Jun 05, 2022			U-839	
	8236804	Jun 05, 2022			U-839	

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 8 - August 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 003	8193195	Jun 05, 2022	U-839			
	8236804	Jun 05, 2022	U-839			
<u>VINCRIStINE SULFATE - MARQIBO KIT</u>						
N202497 001	>A> 5543152	Jun 20, 2014	DP		>A> NP	Aug 09, 2015
	>A> 5741516	Jun 20, 2014	DP			
	>A> 5814335	Jun 20, 2014	DP			
	>A> 6723338	Mar 31, 2020	U-1271			
	>A> 7247316	Sep 25, 2020	DP			
	>A> 7887836	Mar 31, 2020	U-1271			
<u>VISMODEGIB - ERIVEDGE</u>						
N203388 001	>A> 7888364	Nov 11, 2028	DS DP		NCE	Jan 30, 2017
<u>VORINOSTAT - ZOLINZA</u>						
N021991 001	8093295	May 16, 2026	DP			
	8101663	Mar 04, 2023	U-892			
<u>ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE</u>						
A077560 001					PC	Aug 29, 2012
<u>ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE</u>						
A077560 002					PC	Aug 29, 2012
<u>ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE</u>						
A077560 003					PC	Aug 29, 2012
<u>ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE</u>						
A077560 004					PC	Aug 29, 2012
<u>ZOLPIDEM TARTRATE - INTERMEZZO</u>						
N022328 001	>A> 8242131	Aug 20, 2029	U-1266			
	>A> 8252809	Feb 16, 2025	DP			
<u>ZOLPIDEM TARTRATE - INTERMEZZO</u>						
N022328 002	>A> 8242131	Aug 20, 2029	U-1266			
	>A> 8252809	Feb 16, 2025	DP			

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 31st Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of patent terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>